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ABSTRACT OF DISSERTATION 
 
 
SYNTHESIS AND STABILITY STUDIES OF PRODRUGS AND CODRUGS OF 
NALTREXONE AND 6-β-NALTREXOL   
 
The present study was divided between two different drug delivery goals, each 
involving naltrexone (NTX) or its active metabolite, 6-β-naltrexol (NTXOL).  First, 
amino acid esters of NTX and NTXOL were prepared in order to test their 
candidacy for microneedle-enhanced transdermal delivery.  Second, a 3-O-(-)-
cytisine-naltrexone (CYT-NTX) codrug was prepared for screening as a potential 
oral delivery form of NTX and (-)-cytisine (CYT).  The amino acid prodrugs were 
intended for the treatment of alcohol abuse, while the codrug was designed as a 
single agent for the treatment of alcoholism and tobacco-dependency co-
morbidities.  One hypothesis of this work was that prodrugs of NTX or NTXOL 
can be designed that possess superior skin transport properties through 
microneedle-treated skin compared to parent NTX or NTXOL.  Nine amino acid 
ester prodrugs were prepared, and only three 6-O amino acid ester prodrugs of 
NTXOL were stable enough at skin pH (pH 5.0) to move forward to studies in 
50% human plasma.  6-O-β-Ala-NTXOL, the lead compound, exhibited the most 
rapid bioconversion to NTXOL in human plasma (t1/2 = 2.2 ± 0.1 h); however, this 
in vitro stability value indicates that the prodrug may require hepatic enzyme-
mediated hydrolysis for sufficiently rapid bioconversion to NTXOL in vivo.   A 
second hypothesis of this work was that a CYT-NTX codrug could be designed 
with appropriate stability characteristics for oral delivery.  CYT-NTX was found to 
be stable over the time course of 24 h in buffer systems of pH 1.5, 5.0, 7.4 and 
9.0, and in 80% rat plasma, 80% human plasma, simulated gastric fluid and 
simulated intestinal fluid.  Six (3 rats/group) Sprague-Dawley male rats were 
dosed i.v. with 1 mg/kg CYT-NTX codrug, or 10 mg/kg, p.o.  Oral administration 
of a 10 mg/kg dose of CYT-NTX codrug resulted in rapid absorption and 
distribution (5 min) of CYT-NTX codrug, and NTX was released from codrug with 
a peak plasma concentration of 6.8 ± 0.9 nmol/L reached within 65 minutes. 
Plasma CYT was not detected; however, NTX delivery was achieved with a 
fraction absorbed value of 13%.  Thus, CYT-NTX may hold promise as a 
potential oral codrug for further optimization and development.  
 Keywords:  naltrexone, amino acid prodrugs, codrugs, (-)-cytisine, microneedles  
                                
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                               
 
 
 
 
 
 
   
__Joshua A. Eldridge________________________ 
Signature of Student 
                                                                        
    4-29-13________________________________ 
Date  
  
 
 
 
 
 
SYNTHESIS AND STABILITY STUDIES OF PRODRUGS AND CODRUGS OF 
NALTREXONE AND 6-β-NALTREXOL   
 
 
By 
Joshua A. Eldridge 
 
 
 
 
 
 
 
 
___Peter A. Crooks_____________________ 
                      Director of Dissertation 
 
___Jim Pauly__________________________ 
                               Director of Graduate Studies 
 
____4-29-13___________________________ 
                                                          Date 
 
 
 
  
 
 
 
DEDICATION 
This work is dedicated to my wife, parents, family and friends.  Thank you for 
your patience and support.   
 
 
 
 
 
 
 
 
 
 
iii 
 
ACKNOWLEDGEMENTS 
The following dissertation arose through a combination of collaboration and 
personal effort.  Without the expertise and guidance of Drs. Peter Crooks and 
Audra Stinchcomb, and the resources they worked hard to secure over many 
years of research, this dissertation would not have been possible.  Synthesis 
advice was also provided by Dr. Greg Elliott, formerly of the University of 
Kentucky, and I am likewise thankful to him for the use of his resources (LC-MS, 
Biotage microwave reaction equipment, and a solvent drying system).  Drs. 
Andrew J. Morris, Philip Breen, Zaineb Albayati and Manjula Sunkara were 
indispensible in the development of Chapter 7 of this dissertation.  Special thanks 
are given within the introductory comments of Chapter 7 to emphasize the 
division of labor that culminated in the final write-up.   
I am further thankful to the members of my committee for helping me stay on the 
right track throughout the course of this doctoral work.  These members include 
Drs. Peter Crooks, Audra Stinchcomb, Abeer Al-Ghananeem, Susan Barron and 
Jim Pauly.  Likewise, gratitude is warranted for the members of Peter Crooks’ 
and Audra Stinchcomb’s research groups (both past and present) who were 
involved directly or indirectly in the procurement of data and knowledge that lead 
to the end product presented within these pages.  Especially of note are the 
following:  Mikolaj Milewski, my collaborator and dear friend, who participated 
directly in this work and was always there to help me figure out problems with 
analytical assays; Dr. Guangrong Zheng, who was a constant source of great 
information regarding synthetic problems; John Culver, who was a true comrade 
iv 
 
when it came time to fix laboratory equipment that did not wish to cooperate 
(especially Old Betsy, the 300 MHz NMR); Dana Hammell, who ordered so many 
reagents and vital pieces of lab equipment for me that she must have a list the 
size of Texas; Ujjwal Chakraborty and Harpreet Dhooper, who combined forces 
with me on HPLC method development work that proved to be anything but 
trivial; and Ashish, Sonny, Razi and many other post-docs who helped to keep 
me from making silly mistakes along the way. 
Final thanks are to be paid to my wife, my family and my friends, who were all 
instrumental in providing me with the support and understanding that completion 
of this scientific endeavor required.  Thanks to all of you for listening to me talk 
jargon or whine; whichever was required following lab work on a particular day…  
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
TABLE OF CONTENTS 
 
Acknowledgements                  iii 
List of Tables                          viii 
List of Schemes                  ix 
List of Figures                  xi 
Chapter 1: Goals of the study and literature review            1 
1.1 Hypotheses                  1 
1.2 Overall Aims                  1 
1.3 Methodology to be utilized in this study              2 
1.4 Alcohol and tobacco abuse prevalence and treatment limitations          3 
1.5 Rationale for the transdermal delivery approach              
to dose NTX/NTXOL                8 
1.6 Rationale for oral delivery of a secondary carbamate           
codrug of NTX and (-)-cystisine             10  
1.7 Prodrugs and Codrugs (What are they?)            13 
1.8 Amino acid prodrugs               18 
1.9 PTD prodrug design to treat alcoholism            80 
1.10 MNTD prodrug design to treat alcoholism           85 
1.11 Codrugs                87 
1.12 Microneedle-enhanced transdermal delivery (MNTD)          95 
1.13 Concluding Remarks            104 
Chapter 2 Synthesis of 3-O-NTX amino acid esters         106 
2.1 Synthetic design considerations           106 
vi 
 
2.2 Synthesis of trifunctional amino acid ester prodrugs        108 
2.3 Synthesis of bifunctional amino acid ester prodrugs (R=alkyl)       114 
2.4 Future Directions             116 
2.5 Experimental Section            117 
Chapter 3 Synthesis of 6-O-NTXOL amino acid esters        149 
3.1 Synthetic Design Considerations           149 
3.2 Synthesis of trifunctional amino acid ester prodrugs of NTXOL      150 
3.3 Synthesis of amino acid esters of NTXOL by solid phase strategies      154 
3.4 Synthesis of bifunctional amino acid esters by multiple protective             
group strategies             159 
3.5 Experimental Section            170 
Chapter 4 Synthesis of 14-O-amino acid esters and miscellaneous                
prodrugs of NTX            223 
Chapter 5 Synthesis of Codrugs of Naltrexone with Bupropion                             
and (-)-Cytisine            245 
5.1 (-)-Cytisine-NTX (CYT-NTX) carbamate as a codrug for oral delivery      245 
5.2 Synthesis of CYT-NTX carbamate          245 
5.3 Attempted syntheses of BUP-NTX carbonate         247 
5.3.1  Attempt to prepare N-PNP-BUP carbamate        249 
5.3.2 Attempts to prepare BUP-NTX via 3-O-PNP-NTX carbonate      250 
5.4 Experimental Section            251 
Chapter 6 In vitro stability studies of the prodrugs         271 
6.1 Introduction              271 
6.2 Kinetics of hydrolysis in aqueous solutions (non-enzymatic)       274 
vii 
 
6.3 Kinetics of hydrolysis in human plasma and/or rat plasma       276 
6.4 Kinetics of hydrolysis in SGF and SIF          278 
6.5 Standard Curves and Data Analysis          278 
6.6 HPLC Analysis             281 
6.7 Discussion              283 
Chapter 7 Pharmacokinetic Analysis of CYT-NTX in male                                
Sprague-Dawley Rats           296 
7.1 Animals              296 
7.2 Objectives              297 
7.3 Methods              298 
7.4 CYT-NTX dose preparations           298 
7.5 Analyte Sample Preparation           298 
7.6 LC-MS/MS Analysis             299 
7.7 Plasma Pharmacokinetics            301 
7.8 Results              303 
7.9 Pharmacokinetic Properties           304 
7.10 Discussion              304 
7.11 Bioavailability of CYT-NTX and fraction of NTX absorbed       307 
7.12 Conclusions              309 
Chapter 8 Summary             319 
References               325 
Vita                340 
 
viii 
 
LIST OF TABLES 
 
Table 1.1 Viscosity of amino acids (35°C).  Adapted from                              
(Lark, Patyar et al. 2007).             87 
Table 2.1 3-O-NTX amino acid dihydrochlorides material recovery.       124 
Table 3.1 Phenol loading on HMPR-PNP solid phase synthesis resin.      182 
Table 3.2 6-O-Leu-NTXOL ester hydrogenolysis test.         183 
Table 3.3 6-O-NTXOL amino acid esters final material recovery.       184 
Table 6.1 Standard curve data for the analytes.  (No standard                       
curves generated for plasma, SGF and SIF studies of                       
CYT-NTX since AUCcodrug/AUCIS was robust throughout                        
a stability experiment (p > 0.05)).          288 
Table 6.2 Stability of amino acid ester prodrugs of NTX and NTXOL.                 
Data are reported as t1/2(avg) ± SD as determined from two               
(n=2) or three (n=3) independent experiments.         289 
Table 6.3 Stability of CYT-NTX.             290 
Table 7.1 Optimal ion source settings for each MRM transition.       312 
Table 7.2 Two-compartmental pharmacokinetic parameters of NTX after 
administration to male rats of 1.0 mg/kg  (1.79 x 103 nmol.kg) CYT-
NTX codrug i.v. or 10.0 mg/kg (1.7932 x 104 nmol/kg ) p.o.  Data are        
represented as mean ± SEM, n =3 of CYT-NTX codrug for each       
route (p.o. and i.v.).            313 
 
ix 
 
LIST OF SCHEMES 
 
Scheme 2.1 BOC method to form 3-O-NTX amino acid ester prodrugs.      125 
Scheme 2.2 Cbz method to form 3-O-NTX amino acid ester prodrugs.      126 
Scheme 2.3 First attempted debenzylations of 3-O-Boc-Thr(Bzl)-NTX.      127 
Scheme 2.4 Synthesis of 3-O-NTX amino acid dihydrochlorides.       128 
Scheme 3.1 Synthesis of 6-O-Asp-NTXOL by the Fmoc/OBn route.       185 
Scheme 3.2 Hydroxymethyl polystyrene resin solid phase synthesis        
approach to 6-O-amino acid esters of NTXOL.        186 
Scheme 3.3 SASRIN resin solid phase synthesis approach to                              
6-O-amino acid esters of NTXOL.          187 
Scheme 3.4 Synthesis of 3-O-TBDMS-NTXOL ether synthon.       188 
Scheme 3.5 Synthesis of 6-O-amino acid esters of NTXOL by                            
the Fmoc/Oallyl route.            189 
Scheme 3.6 Allyloxybenzene model deallylation with homogenous          
palladium catalyst and NMBA allyl scavenger.       190 
Scheme 3.7 Allyloxybenzene model deallylation with PdCl2 and                  
alternative heterogenous palladium catalysts using                          
NMBA allyl scavenger.           191 
Scheme 3.8 Synthesis of 6-O-amino acid esters of NTXOL by                            
the Fmoc/Oallyl global deblocking route.         192 
Scheme 3.9 Synthesis of 6-O-amino acid esters of NTXOL by                            
the Boc/Oallyl route.            193 
x 
 
Scheme 3.10 Synthesis of 6-O-amino acid esters of NTXOL by the                   
Bis-coupling route.           194 
Scheme 3.11 Synthesis of 6-O-β-Ala-NTX by the Cbz/Obn route.                195 
Scheme 4.1 Synthesis of 3-O-allyl-14-O-Fmoc-β-Ala-NTXOL.       231 
Scheme 4.2 Synthesis of keto-protected NTX synthons.        232 
Scheme 4.3: Synthesis of 6-(1-oxa-4-azaspiro-glycinyl)-NTX.       233 
Scheme 4.4 Synthesis of 6-NH-Val-tBu-NTX.         234 
Scheme 5.1 One-pot synthesis of CYT-NTX via microwave chemistry.      257 
Scheme 5.2 Attempted synthesis of N-PNP-BUP carbamate synthon.      258 
Scheme 5.3 Attempted synthesis of BUP-NTX via 3-O-PNP-NTX carbonate.  259 
 
 
 
 
 
 
 
 
 
 
 
 
 
xi 
 
LIST OF FIGURES 
 
Figure 1.1 Structure of Naltrexone (NTX).              7 
Figure 1.2 Structure of 6-β-Naltrexol (NTXOL).              8 
Figure1.3. Structure of (-)-cytisine (CYT).            11 
Figure 1.4 (A) A bipartate conjugate of NTX and β-alanine.                                 
(B) A tripartate codrug of NTX and (-)-cytisine.          17 
Figure 1.5 Structures of the most successful amino acid                                      
ester prodrugs of ACV (R = H).            19 
Figure 1.6 Structures of model benzyl alcohols and their L-tyrosinyl ether 
conjugates/ synthesis of the conjugates.                                    
Adapted from (Yang and Mitra 2001).           31 
Figure 1.7 Structures of danazol and its amino acid ester conjugates.       
Adapted from (Simmons, Portmann et al. 1995).          33 
Figure 1.8 Rational design of N-lysyl-2-(4-amino-3-methylphenyl)-5-
fluorobenzothiazole.  Adapted from                                             
(Bradshaw, Bibby et al. 2002, Bradshaw, Chua et al. 2002, 
Hutchinson, Jennings et al. 2002).            35 
Figure 1.9 Structures of 5-aminosalicylic acid prodrugs and their           
mechanism of drug delivery.  Adapted from (Pellicciari, Garzon-
Aburbeh et al. 1993).              39 
Figure 1.10 Brain delivery of AZT from IAZT prodrug.   
Adapted from (Lupia, Ferencz et al. 1993).          41 
xii 
 
Figure 1.11 Amino acid ester prodrugs of propofol.  Adapted from (Trapani, 
Latrofa et al. 1998, Altomare, Trapani et al. 2003).         43 
Figure 1.12 Bioconversion of famciclovir to penciclovir.         46 
Figure 1.13 Generation of Penciclovir from amino acid/alkyl ester and                
di-amino acid ester prodrugs.                                                   
Adapted from (Kim, Lee et al. 1996).           48 
Figure 1.14 Generation of floxuridine and an amino acid from amino acid       
esters of floxuridine.  Adapted from (Vig, Lorenzi et al. 2003).        50 
Figure 1.15 Structures of most promising BDCRB amino acid prodrugs.  Adapted 
from (Lorenzi, Landowski et al. 2005, Song, Vig et al. 2005).        52 
Figure 1.16 Structure of dacarbazine.                                                                  56 
Figure 1.17 mode of DNA alkylation by 1-aryl-3,3-dimethyltriazenes.              
Adapted from (Perry, Carvalho et al. 2009).          57 
Figure 1.18 Bioconversion of aminoacyl-1-aryl-3,3-triazene and 3-[α-
(acylamino)acyl]-1-aryl-3-methyltriazene prodrugs to 
monomethyltrazene alkylating agents.  Adapted from                                    
(Carvalho, Iley et al. 1998) and (Perry, Carvalho et al. 2009).        59 
Figure 1.19 Generation of benzocaine from amino acid amide prodrugs.    
Adapted from (Slojkowska, Krasuska et al. 1982).         62 
Figure 1.20 Generation of quercetin from quercetin prodrugs in                          
1:1 PBS/CH3CN.  Adapted from (Biasutto, Marotta et al. 2007).      66 
xiii 
 
Figure 1.21 Generation of metronidazole from amino acid ester prodrugs      
under physiological conditions.  Adapted from                   
(Bundgaard, Larsen et al. 1984).            68 
Figure 1.22 Generation of sulfonamides from                                                              
N-methyl-N-aminoacylsulfonamide carriers.  Adapted from      
(Larsen, Bundgaard et al. 1988).            74 
Figure 1.23 Synthesis of amino acid esters of saquinavir and indinavir.     
Adapted from (Gaucher, Rouquayrol et al. 2004).         76 
Figure 1.24 Synthesis of tyrosinyl derivative carbonates and carbamates of 
saquinavir, indinavir, and nelfinavir with spacer linkers                    
nCH2 = 1-4.  Adapted from (Gaucher, Rouquayrol et al. 2004).        77 
Figure 1.25 Straight-chain and branched-chain alkyl esters of NTX for PTD.  
Adapted from (Stinchcomb, Swaan et al. 2002, Pillai, Hamad et al. 
2004, Vaddi, Hamad et al. 2005).            80 
Figure 1.26 Novel Pegylated 3-O-carboxylate and 3-O-carbamate prodrugs of 
NTX.  Adapted from (Yerramreddy, Milewski et al. 2010).        86 
Figure 1.27 Marketed Codrugs.  Adapted from (Baltzer, Binderup et al. 1980, 
Peppercorn 1984, Crooks, Dhooper et al. 2011).          88 
Figure 1.28 PTD codrugs for alcohol abuse or alcohol-tobacco co-abuse.  
Adapted from (Hammell, Hamad et al. 2004, Hamad, Kiptoo et al. 
2006, Kiptoo, Hamad et al. 2006, Kiptoo, Paudel et al. 2008).        92 
Figure 1.29 Structure of Calcein.              98 
Figure 2.1 Mechanism of carbodiimide coupling (PG = protecting group).        129 
xiv 
 
Figure 2.1 Mechanism of carbodiimide coupling (continued).        130 
Figure 2.1 Mechanism of carbodiimide coupling (continued).        131 
Figure 2.1 Mechanism of carbodiimide coupling (continued).        132 
Figure 2.2 ESI-MS of 3-O-BOC-Asp(OBzl)-NTX.         133 
Figure 2.3 ESI-MS of 3-O-BOC-Lys(Z)-NTX.          134 
Figure 2.4 ESI-MS of 3-O-BOC-Thr(Bzl)-NTX.          135 
Figure 2.5 LC-UV/ESI-MS of 3-O-BOC-Thr(Bzl)-NTX after 48 h       
hydrogenolysis @ 50 psi H2 with Pd-C.  Mass spectrum             
extracted from r.t.= 13.43 min.          136 
Figure 2.6 LC-UV/ESI-MS of 3-O-BOC-Thr(Bzl)-NTX                                                   
after 48 h hydrogenolysis @ 50 psi H2 with Pd-C.  Mass         
spectrum extracted from the peak at r.t.= 10.21 min.        137 
Figure 2.7 Total Ion Count (ESI-MS Positive Scan Mode).        138 
Figure 2.8 Stability of 3-O-NTX amino acid dihydrochlorides R=alkyl  
in pH 5.0 acetate buffer (32 °C)                   139 
Figure 2.9 1H NMR spectra of the 3-O-Val-NTX dihydrochloride prodrug 
and  NTX•HCl               140 
Figure 2.10 13C NMR spectrum of 3-O-Val-NTX dihydrochloride prodrug.      141 
Figure 2.11 LC-UV/ESI-MS of 3-O-Val-NTX prodrug.         142 
Figure 2.12 1H NMR spectra of the 3-O-Leu-NTX dihydrochloride prodrug 
and NTX•HCl                143 
Figure 2.13 13C NMR spectrum of 3-O-Leu-NTX dihydrochloride prodrug.      144 
Figure 2.14 LC-UV/ESI-MS of 3-O-Leu-NTX prodrug.         145 
xv 
 
Figure 2.15 1H NMR spectra of the 3-O-Ala-NTX dihydrochloride prodrug 
 and NTX•HCl                146 
Figure 2.16 13C NMR spectrum of 3-O-Ala-NTX dihydrochloride prodrug.      147 
Figure 2.17 LC-UV ESI-MS 3-O-Ala-NTX prodrug.         148 
Figure 3.1 1H NMR spectrum of 3-OBn-6-O-Fmoc-Asp(OBzl)-NTXOL.      196 
Figure 3.2 1H NMR spectrum of 3-OBn-6-O-Asp(OBzl)-NTXOL.       197 
Figure 3.3 ESI-MS of 3-OBn-6-O-Asp(OBzl)-NTXOL  
hydrogenolysis products            198 
Figure 3.3 (cont.) ESI-MS of 3-OBn-6-O-Asp(OBzl)-NTXOL  
hydrogenolysis products.             199 
Figure 3.4 1H NMR spectrum of 3-OBn-6-O-Asp(OBzl)-NTXOL  
hydrogenolysis products.              200 
Figure 3.5 LC-UV/ESI-MS of 3,6-O-Bis-Fmoc-β-Ala-NTXOL  
deblocking test.            201 
Figure 3.6 6-O-Leu-NTXOL ester hydrogenolysis test.        202 
Figure 3.6 (cont.) 6-O-Leu-NTXOL ester hydrogenolysis test.       203 
Figure 3.7 LC-UV/ESI-MS of 3-OBn-6-O-Cbz-β-Ala-NTXOL  
hydrogenolysis.  Conditions:  10 mol% Pd Black / EtOAc /  
H2 @ 50 psi / 4 days.               204 
Figure 3.8 LC-UV/ESI-MS of 3-OBn-6O-Cbz-β-Ala-NTXOL 
 hydrogenolysis.  Conditions:  Pd Black 3 x wt%  /  
EtOAC/ THF wash / 24 h / H2 @ 50 psi.           205 
Figure 3.9 1H NMR spectrum of 6-O-β-Ala-NTXOL.        206 
xvi 
 
Figure 3.10 13C NMR spectrum of 6-O-β-Ala-NTXOL.               207 
Figure 3.11 LC-UV/ESI-MS of 6-O-β-Ala-NTXOL.         208 
Figure 3.12 1H NMR spectrum of 6-O-Ile-NTXOL.         209 
Figure 3.13 13C NMR spectrum of 6-O-Ile-NTXOL.         210 
Figure 3.14  X-Ray crystal structure of 6-O-Ile-NTXOL.       211 
Figure 3.15 LC-UV/ESI-MS of 6-O-Ile-NTXOL.          212 
Figure 3.16 1H NMR spectrum of 6-O-Leu-NTXOL.         213 
Figure 3.17 13C NMR spectrum of 6-O-Leu-NTXOL.         214 
Figure 3.18 LC-UV/ESI-MS of 6-O-Leu-NTXOL.         215 
Figure 3.19 1H NMR spectrum of 6-O-Val-NTXOL.          216 
Figure 3.20 13C NMR spectrum of 6-O-Val-NTXOL.         217 
Figure 3.21 LC-UV/ESI-MS of 6-O-Val-NTXOL.         218 
Figure 3.22 13C NMR spectrum of 6-O-Ala-NTXOL.         219 
Figure 3.23 LC-UV/ESI-MS of 6-O-Ala-NTXOL.                   220 
Figure 3.24 13C NMR spectrum of 6-O-Pro-NTXOL.        221 
Figure 3.25 LC-UV/ESI-MS of 6-O-Pro-NTXOL.        222 
Figure 4.1 1H NMR spectrum of 3-O-allyl-14-O-Fmoc-β-Ala-NTX.       235 
Figure 4.2 13C NMR spectrum of 3-O-allyl-14-O-Fmoc-β-Ala-NTX.        236 
Figure 4.3 MALDI-TOFMS of 3-O-allyl-14-O-Fmoc-β-Ala-NTX.         237 
Figure 4.4 1H NMR spectrum of 3-O-allyl-6-O,14-O-bis-Fmoc-β-Ala-NTX.      238 
Figure 4.5 13C NMR spectrum of 3-O-allyl-6-O,14-O-bis-Fmoc-β-Ala-NTX.      239 
Figure 4.6 MALDI-TOFMS of 3-O-allyl-6-O,14-O-bis-Fmoc-β-Ala-NTX.      240 
Figure 4.7 ESI-MS of 6-NH-Val-tBu-NTX.          241 
 
xvii 
 
Figure 4.8: Comparison of 13C NMR spectral data  
obtained from Scheme 4.2.            242 
Figure 4.8: Comparison of 13C NMR spectral data  
obtained from Scheme 4.2 (continued).         243 
Figure 4.8: Comparison of 13C NMR spectral data  
obtained from Scheme 4.2 (continued).         244 
Figure 5.1 Codrug structures.            260 
Figure 5.2 ESI-MS of 3-O-(-)-cytisine naltrexone (CYT-NTX) carbamate.      261 
Figure 5.3 (A) HPLC chromatogram of CYT, CYT-NTX, NTXOL and NTX.        
(B) Clean chromatogram of CYT-NTX after solvent washes with     
THF and MeOH. (C) 1H NMR spectrum of CYT-NTX after solvent 
washes with THF and MeOH (solvent peaks:                                
MeOH δ 1.22, 3.5ppm; DCM δ 5.3 ppm; CDCl3 δ 7.26 ppm ).      262 
Figure 5.4 (A) 13C NMR spectrum of CYT-NTX (expanded view).                                
(B) 13C NMR spectrum of CYT-NTX with overnight acquisition              
time and no peak expansion (CDCl3 triplet δ 77.2 ppm                        
is cut off to emphasize product peaks).          263 
Figure 5.5 GC-MS of the N-PNP-BUP-carbamate synthesis.        264 
Figure 5.6 EI-MS of Bupropion.            265 
Figure 5.7 EI-MS of p-nitrophenol.           266 
Figure 5.8 EI-MS of 3-tert-butyl-5-(3-chloro-phenyl)-4-methyl-                  
oxazolidin-2-one.            267 
Figure 5.9 EI-MS of p-nitrophenol Gemini carbonate.         268 
xviii 
 
Figure 5.10 ESI-MS of BUP and NTX (failed reflux in THF).        269 
Figure 5.11 ESI-MS of NTX-NTX Gemini prodrug, the major product  
from microwave chemistry.          270 
Figure 6.1 HPLC chromatogram of salicylamide, NTXOL and                              
6-O-Ile-NTXOL (gradient elution).           291 
Figure 6.2 HPLC chromatogram of salicylamide, NTXOL and                              
6-O-Val-NTXOL (gradient elution).          292 
Figure 6.3 HPLC chromatogram of salicylamide, NTXOL and 
6-O-β-Ala-NTXOL (gradient elution).        293 
Figure 6.4 (A) HPLC chromatogram of (-)-cytisine, CYT-NTX, NTX and 
                 N-1-naphthylacetamide (isocratic elution).  (B) Representative      
HPLC Chromatograms of CYT-NTX in buffers at t = 24 hours. 
Broad peak at r.t.= 16.0 – 16.7 min (pH 1.5) is  
present in blank buffer.             294 
Figure 6.5 HPLC chromatogram of (-)-cytisine, salicylamide, NTX and 
CYT-NTX (gradient elution).           295 
Figure 7.1 Plot of mean plasma concentration vs. time of the CYT-NTX         
codrug and NTX released from the codrug after a single oral            
dose of 1.79 x 104 nmol/kg.                                                                        
Results are the mean of 3 rats ± SEM.          314 
 
xix 
 
Figure 7.2 Plot of mean plasma concentration vs. time of the CYT-NTX         
codrug and NTX released from the codrug after a single intravenous 
dose of 1.79 x 103 nmol/kg.  
Results are the mean of 3 rats ± SEM.             315 
Figure 7.3 Plot of mean plasma concentration vs. time of NTX released            
from CYT-NTX codrug after oral and i.v. administration.                
Results are the mean of 3 rats ± SEM.         316 
Figure 7.4A LC-MS/MS chromatogram of (-)-cytisine, salicylamide, NTX            
and the CYT-NTX codrug.           317 
Figure 7.4B LC-MS/MS extracted ion chromatograms of (-)-cytisine,     
salicylamide, NTX and the CYT-NTX codrug.        318 
1 
 
Chapter 1 
Goals of the study and literature review 
1.1 Hypotheses 
This study involved two central hypotheses.  One hypothesis of this work was 
that prodrugs of NTX or NTXOL can be designed that possess superior skin 
transport properties through microneedle-treated skin compared to parent NTX or 
NTXOL.  A second hypothesis of this work was that a CYT-NTX codrug could be 
designed with appropriate stability characteristics for oral delivery.    
1.2 Overall Aims 
There exists an ongoing need for new medications that can provide efficacy in 
the treatment of alcohol abuse and nicotine addiction with minimal side effects.  
This project has been designed to address two specific populations of drug-
addicted individuals.  The first target population is people who abuse alcohol, but 
who do not smoke cigarettes as well.  The second target population is the group 
of individuals who smoke cigarettes and abuse alcohol simultaneously.  For 
those who abuse alcohol but do not smoke, poorly bioavailable naltrexone (NTX) 
is often a medication that is prescribed.  To circumvent the poor bioavailability 
and gastrointestinal side effects of NTX, it has been envisioned that highly water 
soluble prodrugs of NTX or its active metabolite 6-β-naltrexol (NTXOL) could 
possibly serve as dosage forms for microneedle-enhanced transdermal delivery 
(MNTD).  Otherwise, for the second population of drug-dependent individuals 
who abuse alcohol and smoke cigarettes, a dual therapeutic strategy is indicated 
2 
 
since consumption of either drug serves as a cue for abuse of the other 
(comorbidity).  In the case of patients belonging to population two, it has been 
envisioned that an oral codrug of NTX conjugated to (-)-cytisine, a smoking 
cessation agent, could be a plausible therapeutic agent to approach the 
treatment of both addictions with a single drug molecule (i.e. a codrug).  Within 
the following dissertation, the design, synthesis, and stability characterization of a 
number of amino acid ester prodrugs of NTX and NTXOL is described.  Also, the 
design, synthesis, stability, and pharmacokinetic evaluation of a codrug of NTX 
conjugated with (-)-cytisine is described.    
1.3 Methodology to be utilized in this study 
 To develop the chemistry to afford amino acid ester prodrugs of NTX and 
NTXOL.  
 To investigate amino acid ester prodrug chemical stability at pH 5.0 and 
pH 7.4 to assess MNTD candidacy. 
 To investigate amino acid ester prodrug enzymatic stability in 50% human 
plasma. 
 To prepare a codrug of (-)-cytisine and NTX (CYT-NTX) in which (-)-
cytisine and NTX are covalently linked by a secondary carbamate linker. 
 To evaluate oral delivery candidacy of the CYT-NTX codrug by 
investigating its simple chemical stability over the pH range 1.2 – 9.0 and 
its enzymatic stability in simulated gastric and intestinal fluids using an 
HPLC-UV assay. 
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 To evaluate the enzymatic stability of CYT-NTX in 80% rat and 80% 
human plasma using an HPLC-UV assay. 
 To investigate the hydrolytic profile and pharmacokinetics of the CYT-NTX 
codrug in the live Sprague-Dawley rat using LC-MS/MS. 
 
1.4  Alcohol and tobacco abuse prevalence and treatment limitations 
Abuse of alcohol and/or tobacco are worldwide problems with enormous 
societal and medical impact.  In the United States, alcohol abuse is the third 
leading cause of preventable death, while tobacco use is the first.  The scope of 
the American alcohol and tobacco abuse problem is perhaps best understood by 
inspection of the annual statistics published by the Substance Abuse and Mental 
Health Services Administration (SAMHSA 2011).  The following data are quoted 
directly from the reference. 
Alcohol Use 
“In 2011, 133.4 million (51.8%) American citizens aged 12 years or older 
reported themselves to be drinkers of alcohol, which is similar to the number 
reported in 2010.  A large percentage, 22.6% (58.3 million), of these individuals 
reported binge pattern drinking which is characterized by having five or more 
drinks on the same day on at least one day in the 30 days prior to the survey.  
Heavy drinking, as defined by at least five days of binge drinking in the 30 days 
prior to the study, was characteristic of 15.9 million people surveyed (6.2%).  
Among young adults aged 18 to 25 in 2011, the rate of binge drinking was 39.8 
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percent. The rate of heavy drinking was 12.1 percent, which was lower than the 
rate in 2010 (13.5 percent).”   
Tobacco Use 
“In 2011, an estimated 68.2 million Americans aged 12 or older were current 
(past month) users of a tobacco product. This represents 26.5 percent of the 
population in that age range. Also, 56.8 million persons (22.1 percent of the 
population) were current cigarette smokers; 12.9 million (5.0 percent) smoked 
cigars; 8.2 million (3.2 percent) used smokeless tobacco; and 2.1 million (0.8 
percent) smoked tobacco in pipes.” 
Alcohol Abuse Treatment 
Currently, alcohol abuse is approached therapeutically with pharmaceuticals, 
psychotherapy and group counseling efforts.  Medical programs often involve 
inpatient treatment during drug detoxification periods, with concomitant use of 
pharmaceutical regimens. Subsequently, outpatient group therapies are also 
often employed, with or without personal psychotherapy.  Regardless of the 
effectiveness of such approaches for some individuals, often only limited success 
is realized.  The limitations of these approaches could be related to the low 
number of available medicines indicated for alcohol addiction management. For 
instance, only four pharmaceutical options are currently FDA-indicated: NTX 
(ReVia®), NTX depot (Vivitrol®), acamprosate (Campral®), and disulfiram 
(Antabuse®).  Likewise, each option has its own share of problems that often lead 
to poor patient compliance and/or poor effectiveness in the management of 
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alcohol addiction.  Acamprosate has undesirable adverse-effects, including 
diarrhea and suicidality, and the therapy requires a large dosing regimen and pill 
burden (2 x 333 mg tablets 3 x daily) (Forest Pharmaceuticals, St. Louis, MO. 
2004).  Disulfiram is hepatotoxic, and requires patient compliance to take the 
drug, since nausea occurs if the patient drinks after drug administration 
(Bjoernsson, Nordlinder et al. 2006).  Additionally, oral NTX delivery carries the 
burden of dose-dependent hepatotoxicity along with variable, poor bioavailability 
(5-40%) and gastrointestinal adverse-effects (Verebey 1981, Verebey and Mule 
1986, Volpicelli, Rhines et al. 1997).  The problems involved with oral 
administration of NTX have been addressed by the invention of Vivitrol®, a once-
per month IM depot injection of NTX that does not exhibit the fluctuating plasma 
concentrations associated with daily oral dosing of NTX (Garbutt 2006, 
Swainston, Plosker et al. 2006).  However, in emergency situations where pain 
management by opioid administration may be beneficial, Vivitrol® has the 
disadvantage that larger doses of agonist must be administered to a patient to 
overcome µ-receptor blockade.  Another disadvantage of the depot form is the 
possibility of adverse reactions at the injection site (Covyeou, Atto et al. 2011).  
Clearly, oral and depot delivery forms of NTX cannot meet the needs of all 
alcoholic patients who could benefit from the use of the drug in their cessation 
and abstinence programs.    
Tobacco abuse treatment 
Tobacco abuse is facilitated by nicotine dependence.  Indeed, some research 
has suggested that nicotine is akin to heroin or alcohol in its addiction potential, 
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but these claims have also been critiqued (Frenk and Dar 2011).  Nonetheless, it 
is clear that the smoking process exposes the smoker to numerous toxic and 
carcinogenic chemicals that ultimately lead to chronic disorders such as COPD, 
emphysema and/or lung cancers (Rodgman, Smith et al. 2000, Starek and 
Podolak 2009).  Smokeless tobacco has proven to be no better than smoked 
tobacco, because it also results in various cancers (Zhou, Michaud et al. , Roy, 
Chatterjee et al. 2011). 
Since tobacco abuse is a pervasive health problem, numerous therapy 
regimens have emerged to aid nicotine addicts in their efforts to quit smoking or 
using smokeless tobacco products.  For instance, psychotherapy is available for 
smokers who seek help to quit smoking.  Nicotine replacement therapies are also 
available which include patches, lozenges, gums, nasal sprays and electronic 
cigarettes.  Also, non-nicotine pharmaceuticals such as bupropion hydrochloride 
(Wellbutrin®, Zyban®) and varenicline tartrate (Chantix®) have shown promise in 
certain patient populations.  However, all of these treatment options are met with 
high relapse rates and other unsavory limitations that render them sub-optimal as 
front line therapies for tobacco abuse (Dwoskin, Smith et al. 2009, Keating and 
Lyseng-Williamson 2010).  In particular, none of these approaches address the 
co-abuse problem of simultaneous nicotinism and alcoholism.   Therefore, within 
this body of work, we sought to explore a codrug design to approach the 
development of a dual therapeutic which could lead to management of tobacco 
abuse and alcoholism simultaneously.   
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Naltrexone 
NTX (Fig. 1.1) is a long-acting synthetic competitive µ-/κ-, and to a lesser 
extent δ-opioid receptor antagonist used primarily in the management of alcohol 
and opioid dependence (Verebey 1981, Volpicelli, Rhines et al. 1997).  Blockade 
of the aforementioned receptors prevents activation of the critical dopamine 
reward system and attenuates the desire for drug self-administration in opioid-
dependent people. The mode of action of NTX in the treatment of alcohol 
dependence seems to involve blockade of endogenous opioid receptor binding 
that normally accompanies alcohol consumption (Jung and Namkoong 2006, 
Unterwald 2008).   In this respect, alcoholic patients taking NTX are reported to 
have as much as a 50% reduction in the number of drinks they consume per day.   
 
 
Figure 1.1 Structure of Naltrexone (NTX). 
 
 
NTXOL 
NTXOL (Fig. 1.2) is the major active metabolite of NTX that is present in 
higher concentration than NTX in blood samples following oral dosing in man, 
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and NTXOL could contribute significantly to the duration of the therapeutic effects 
of NTX (Verebey, Volavka et al. 1976, Volpicelli 1995).   
 
 
Figure 1.2 Structure of 6-β-Naltrexol (NTXOL). 
 
1.5 Rationale for the transdermal delivery approach to dose NTX/NTXOL 
Formulation of a drug into a transdermal delivery system is desirous when the 
effective dose of the drug is fairly low and the drug has side effects or extensive 
first pass metabolism or extraction via the oral route.  As mentioned above, NTX 
exhibits variable interpatient bioavailabilty and extensive first pass side effects 
when dosed per os.  Inasmuch, formulation of a transdermal NTX dosage form 
could potentially solve the problems associated with oral NTX therapy.  
Transdermal delivery of NTXOL could also be of potential clinical utility since 
NTX is extensively converted to NTXOL via first pass metabolism when the FDA-
approved hydrochloride salt is given orally.  Unfortunately, previous work in this 
area has demonstrated that neither NTX nor NTXOL can be delivered in 
therapeutically-relevant levels by traditional passive transdermal delivery (PTD) 
techniques (Paudel, Nalluri et al. 2005).  Therefore, several NTX prodrugs with 
enhanced lipophilicity have been prepared and assayed for their potential as 
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PTD candidates (Stinchcomb, Swaan et al. 2002, Pillai, Hamad et al. 2004, 
Hammell, Stolarczyk et al. 2005, Vaddi, Hamad et al. 2005, Valiveti, Hammell et 
al. 2005). Straight-chain and branched-chain 3-O-NTX carboxylate and 
carbonate ester prodrugs were investigated in these studies.  Although superior 
flux values were observed in the straight-chain 3-O-NTX ester series of prodrugs, 
plasma levels that would be adequate for therapeutic outcomes in man were not 
achieved.   
Microneedle-enhanced transdermal delivery (MNTD) methods have been 
developed in recent years which have allowed expansion of the pool of 
molecules that can be delivered transdermally.  Notably, the hydrochloride salt of 
NTX has been shown to be transdermally available in man in the lower levels of 
the therapeutic window when aqueous microchannels are first created to breech 
the barrier properties of the stratum corneum (SC) (Wermeling, Banks et al. 
2008).  Otherwise, a clear increase in the microneedle enhanced delivery of NTX 
or NTXOL as a function of increased water solubility due to ionic charge has 
been demonstrated (Banks, Pinninti et al. 2008).  Nonetheless, to make NTX or 
NTXOL transdermally useful for alcoholic patients, further enhancements to 
these molecular skeletons is still necessary.  Therefore, in keeping with the 
prodrug approach, it was envisioned in this body of work that amino acid ester 
prodrugs of NTX and NTXOL could be prepared that would impart additional 
charge at skin-relevant pH (~ pH 5.0).  The goal of this part of the study was to 
prepare a prodrug with adequate solubility and stability at pH 5.0, which would 
also rapidly afford parent drug at pH 7.4 or in human plasma.  A successful 
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MNTD prodrug could serve as a potential clinical addition to the currently limited 
pool of pharmaceuticals used to treat alcohol abuse, and its advantages would 
be as follows: 
 Painless patient self-application 
 Steady-state profiles of drug delivery (zero order) 
 Avoidance of first pass effects  
 Reduced gastrointestinal adverse-effects and hepatotoxicity  
 Improved patient compliance 
 Lower effective dose compared to oral formulations  
The syntheses of amino acid ester prodrugs of NTX and NTXOL are summarized 
in Chapters 2-4, and their stability data are summarized in Chapter 6. 
 
1.6 Rationale for oral delivery of a secondary carbamate codrug of NTX and 
(-)-cystisine   
(-)-cytisine (CYT) 
CYT (Fig. 1.3) is a natural product isolated from Cytisus laborinum which is 
marketed in Europe as a smoking cessation agent under the trade name Tabex 
(Etter 2006, Zatonski, Cedzynska et al. 2006).  It is currently unavailable in the 
USA, and varenicline (Chantix®) is the synthetic analogue of CYT that has 
achieved FDA approval.  Nonetheless, CYT has a long-standing record of 
efficacy in the treatment of nicotine addiction in Europe, and it could be far 
cheaper to produce and utilize than bupropion or varenicilne (Etter, Lukas et al. 
2008).  CYT is a selective partial agonist of human α4β2 nicotinic acetylcholine 
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receptors (Lukas 2007) and a full agonist of α7 receptors (LeSage, Shelley et al. 
2009).  In addition to its known efficacy in smoking cessation treatments (Hajek, 
McRobbie et al. 2013), CYT has also shown anti-depressant activity in male 
C57BL/6J mice (Mineur, Somenzi et al. 2007).  In contrast, currently FDA-
approved varenicline carries a black box warning for adverse effects that include 
depression and suicidality. 
 
 
Figure 1.3 Structure of (-)-cytisine (CYT). 
 
Codrug design is often undertaken to afford dual drug delivery from a single 
molecule.  It is a type of prodrug strategy that has been widely investigated by 
many routes of administration (Crooks, Dhooper et al. 2011).   The particular 
formulation and delivery method assigned to a given codrug generally depends 
on the target area for the two released agents and the stability profile of the 
codrug.  It is known that the hydrolytic stability of carbamates over a large pH 
range is dependent upon the substitution of the carbamate, where secondary 
carbamates tend to show many orders of magnitude higher stability than primary 
carbamates (Hegarty and Frost 1972).  One would expect that enzymatic 
systems could increase the rate of hydrolyses dramatically in the case of 
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carbamate esters; however, this need not be the case.  The particular molecule 
in question must always be assayed individually.   
Indeed, primary carbamates need not always degrade faster than secondary 
carbamates either.  Recently, primary carbamate codrugs of opioids and 
ketamine or norketamine have been patented (Holtman, Crooks et al. 2009).  
Additionally, secondary carbamate codrugs of nornicotine and opioids have also 
been patented and prepared (Holtman, Crooks et al. 2009).  However, these 
compounds proved to be stable over a pH 1.3 – 7.4 range, and they also did not 
degrade to parent drugs in simulated gastric fluid (SGF), in simulated intestinal 
fluid (SIF), in 80% rat plasma, or in rat brain homogenate (Chakraborty 2011). 
Previously, the synthesis of secondary carbamates of bupropion (BUP) and NTX 
or BUP and NTXOL were attempted, and it was found that N-acylated derivatives 
of the bupropion core moiety could not be isolated (Hamad, Kiptoo et al. 2006).  
Follow up efforts within the present body of work also failed to afford the desired 
secondary carbamate of bupropion and NTX (Chapter 5).  
In order to continue pursuit of a potential co-therapeutic for alcohol and 
tobacco abuse, design efforts were switched toward alternative molecules that 
have been shown to be efficacious in the treatment of nicotine addiction, while 
maintaining NTX as the alcohol abuse agent.  Since the secondary amine of 
bupropion is sterically hindered, we decided to pursue chemistry to afford a 
conjugate of (-)-cytisine (CYT) and NTX.  The structure of CYT (Fig. 1.3) affords 
a sterically accessible secondary amine for acylation reactions, and synthesis of 
the CYT-NTX codrug proved to be facile with microwave chemistry (Chapter 5). 
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Overall, by switching attention to the study of CYT-NTX, three themes of the 
original BUP-NTX codrug work were maintained.  First, the formulation stability 
advantages of a secondary carbamate were preserved in the CYT-NTX codrug 
structure.  Second, The NTX moiety remained as the key FDA-approved alcohol 
abuse agent.  Finally, the codrug thus designed should have potential as a co-
therapeutic for alcohol and tobacco abuse since CYT is used commercially in 
Europe as a smoking cessation agent.  One critical deviation of the CYT-NTX 
work was a change of course from the MNTD approach to oral delivery; a data-
driven decision which was made during stability analyses. 
During the course of the present study, it was found that CYT-NTX is stable 
over the pH 1.5 – 9.0 range.  Stability studies in 80% human plasma, 80% rat 
plasma, SGF, and SIF also showed that the codrug was stable under a variety of 
physiologically-relevant conditions (Chapter 6).  However, in vivo analysis of the 
codrug demonstrated that oral delivery in the live rat resulted in systemic 
hydrolysis of CYT-NTX to afford NTX more efficiently than intravenous delivery 
(Chapter 7), indicating that first-pass metabolism was a likely mechanism for 
increased systemic delivery of NTX.  CYT was unfortunately not detected.   
 
1.7 Prodrugs and Codrugs (What are they?) 
Oftentimes in drug design and development, there are situations in which a 
given drug lacks optimal physiochemical properties or in vivo performance.  For 
instance, the drug may have poor bioavailability if given as an oral delivery form.  
The latter situation can be subdivided into several undesirable physiochemical 
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features that ultimately cause the low systemic exposure.  These include poor 
aqueous solubility, inadequate absorption or permeation, extensive first pass 
metabolism and extraction, and/or general instability in the variable pH 
environment of the gut or in the presence of the various gut enzymes.  Otherwise 
the performance of a therapeutic agent may be limited by poor site activity or 
transport, or by general formulation difficulties.  In many cases, these types of 
problems can be solved by converting the potential drug molecule into a delivery 
form called a prodrug.  Various types of prodrugs have recently been widely 
reviewed (Yang, Aloysius et al. 2011, Imai 2012, Li, Dong et al. 2012, 
Wexselblatt and Gibson 2012, Zhang, Qu et al. 2012), and numerous books have 
been published on the subject (Higuchi and Stella 1975, Roche 1977, Bundgaard 
1985, Reeves, Speller et al. 1989, Stella, Borchardt et al. 2007).    
A prodrug can be a composite of the therapeutic agent of interest and a 
promoiety, such that exposure to physiological conditions results in release of the 
drug molecule and the promoiety as separate molecules.  Otherwise, a 
compound can be a bioprecursor that has to undergo biotransformation in vivo to 
become pharmacologically active.  In the latter case, no promoiety exists.  Within 
this body of work, the use of a promoiety strategy was employed. 
The critical defining features of a properly designed prodrug which contains a 
promoiety are as follows.  First, the prodrug must possess a promoiety that is 
conjugated to the parent drug by a biologically labile linker.  Second, the linker 
must cleave under physiological conditions to release the parent drug and the 
promoiety.  Generally speaking, the promoiety needs to be a pharmacologically 
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inert or harmless endogenous chemical species so it does not present toxicity 
issues when it is generated following hydrolysis.  The prodrug cleavage event 
that delivers the parent drug and promoiety may be facilitated by simple chemical 
means under various physiologically-relevant pH conditions or by enzymatically-
accelerated processes, and the usual mode of conversion is a hydrolytic event.  
A third important feature of a properly designed prodrug of this class is that the 
prodrug must not have any biological activity of its own (i.e. it must not be a new 
drug entity).   
  An important deviation from these critical criteria is the case in which a 
prodrug is actually a codrug.  In that case, there is no true promoiety, because 
the prodrug species is specifically designed to release more than one therapeutic 
agent, or more than one molar equivalent of the same therapeutic agent following 
systemic hydrolysis.  Therefore, codrugs may be comprised of two different drugs 
conjugated by a hydrolyzable linker moiety in a one-to-one molar ratio, or they 
may be comprised of two molar equivalents of the same drug conjugated 
similarly.  Otherwise, some codrugs are designed in molar ratios other than one-
to-one, depending on the particular design.  Codrugs have also been widely 
reviewed (Bryskier 1997, Bryskier 2005, Al-Ghananeem and Crooks 2007, 
Cynkowski, Cynkowska et al. 2008, Lau, White et al. 2008, Strasinger, Scheff et 
al. 2008, Das, Dhanawat et al. 2010, Das, Dhanawat et al. 2010, Crooks, 
Dhooper et al. 2011) 
Within this dissertation, prodrugs and codrugs will both be covered, so it is 
important to understand their differences now.  Figure 1.4(A) shows a bipartate 
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conjugate of NTX and β-alanine with an ester linker.  Figure 1.4 (B) depicts a 
tripartate codrug of NTX in which the co-therapeutic entity is (-)-cytisine, and the 
linker is a secondary carbamate.   
 
In Fig 1.4 (A), the ester linker can theoretically be cleaved by enzyme-
assisted or simple chemical hydrolysis.  The same can be said of the secondary 
carbamate in Fig. 1.4 (B).  The defining difference is that in (A), hydrolytic 
cleavage of the ester results in the release of two separate chemical species, 
NTX and β-alanine, while in (B), hydrolytic cleavage of the secondary carbamate 
linker leads to the release of (-)-cytisine, NTX and a molar equivalent of carbonic 
acid or carbon dioxide, depending on pH.  Thus, bipartate prodrugs cleave into 
two parts while tripartate prodrugs cleave into three parts.  
The bonds that are cleaved by a molar equivalent of water are shown in 
Figure 1.4 as indicated by the wavy lines, and the resultant cleavage products 
are identified as well.  In the codrug, there are two possible cleavage points that 
are plausible, although it is far more likely that the carbon-oxygen bond of the 
NTX side of the carbamate linker is cleaved since the phenolate leaving group 
that would emerge is resonance stabilized and a far better leaving group than a 
nucleophilic secondary amine.   
There is currently a rich body of literature surrounding the idea of amino acid 
conjugation to drugs, especially in the recent prodrugs literature.  The resultant 
prodrug design affords bipartate prodrugs with improved physiochemical 
properties that solve one or more of the typical drug performance problems 
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mentioned above.  Indeed, the recent surge in prodrug design that is aimed at 
the development of amino acid prodrugs of various drug molecules is in keeping 
with the bulk of the work presented in this dissertation, and a thorough review is 
presented.  Amino acids as promoieties in prodrug design are also the subject of 
an excellent, recent review (Vig, Huttunen et al. 2012).  
 
 
 
Figure 1.4 (A) A bipartate conjugate of NTX and β-alanine. (B) A tripartate 
codrug of NTX and (-)-cytisine. 
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1.8  Amino acid prodrugs 
Throughout recent decades, a hot area of drug delivery research has focused 
on the development of amino acid prodrugs for various active transporter-
targeted delivery goals.  In this section, a review of many of these research 
efforts and their various delivery contexts is presented (i.e. oral, intraocular, and 
intranasal).  Indeed, L-Valine ester prodrugs of the antiviral nucleoside analogues 
acyclovir (ACV) and ganciclovir (GCV) have been developed and have 
progressed to the market.  Of these two, the richest body of literature exists for 
ACV, and Figure 1.5 illustrates the best prodrug structures that have been 
prepared and assayed along with their references.  
  
Valacylovir 
One of the most extensively studied amino acid prodrugs is the antiviral agent 
valacyclovir (Valtrex®), an FDA-approved L-valine ester prodrug of acyclovir.  As 
with many amino acid prodrugs, D- and L- forms of the prodrug have been 
prepared and assayed (Beauchamp, Orr et al. 1992).  For the purpose of this 
review, VACV denotes specifically the L-isomer of valacyclovir as shown in 
Figure 1.5, unless stated otherwise.  
Acyclovir (ACV) is an antiherpetic drug which suffers from poor bioavailability 
of 15-21% (Blum 1983).  Varicella zoster (VSZ) and human cytomegalovirus 
(HCMV) belong to the herpes family along with herpes simplex virus types 1 and 
2 (HSV-1 and HSV-2), and VSV and HCMV have been shown to be less 
sensitive to acyclovir treatment (O'Brien and Campoli-Richards 1989).   
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Figure 1.5 Structures of the most successful amino acid ester 
prodrugs of ACV (R = H). 
 
In order to approach an improved oral drug delivery profile of acyclovir to 
avoid the need for parenteral administration to treat VSV and HCMV, 
Beauchamp et al. synthesized and bioassayed 18 amino acid ester prodrugs of 
ACV (Beauchamp, Orr et al. 1992).  In this work, D-, L-, and racemic forms of 
amino acid esters of acyclovir were tested for stability, bioavailability and antiviral 
activity against HSV-1.  The L-Val prodrug, valacyclovir (VACV) was found to be 
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the best candidate.  Indeed, the findings of this work ultimately led to clinical trials 
and the eventual market approval of VACV (Valtrex®) by the FDA.  Valtrex® has 
since reached blockbuster status. 
To assay bioavailabilities of the prodrugs, Long Evans rats were dosed by 
oral gavage using solutions of the amino acid ester prodrugs (Beauchamp, Orr et 
al. 1992).  The amount of ACV present in urine filtrates was analyzed by HPLC 
over a 40 hour time course.  ACV is known to be excreted virtually unchanged 
following oral dosing (Krasny, Page et al. 1981).   
None of the amino acid esters were detected in urine, indicating a probable 
100% hydrolytic conversion of the prodrugs to parent acyclovir in the biophase.  
Also, VACV demonstrated the best oral bioavailability (63%).  Of all the prodrugs 
tested, D-forms of the promoieties afforded less enhancement in bioavailability 
compared to their L-isomers, which suggested the involvement of a 
stereospecific transport system.  It is interesting to note that most of the prodrugs 
tested improved bioavailability of ACV compared to parent ACV. 
A significant solubility enhancement in water at room temperature was also 
afforded by VACV.  An approximate 134-fold increase in solubility was observed 
(174 mg/mL VACV compared to 1.3 mg/mL ACV), which also favored improved 
oral dosing.  The aqueous stability of VACV was also acceptable for oral delivery 
(t1/2 = 95 h @ pH 6, 13 h @ pH 7.4, and 9.5 h @ pH 9.5).   
In a much later body of work, the stability of VACV was investigated in buffer, 
in dog gastrointestinal fluids, and in the gastrointestinal fluids of man (Granero 
and Amidon 2006).  At acidic pH (below pH 4), VACV was adequately stable (t1/2 
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= 1386 h in human gastric fluid (pH 1.22), 111.77 h in dog gastric fluid, and 39.60 
h (pH 4.11) in phosphate buffer).  The results in dog and human intestinal fluids, 
and in buffers which mimic GI pH gradients suggest that VACV is stable enough 
to be dosed orally, but some hydrolysis in the gut lumen is to be expected, which 
limits bioavailability.  Nonetheless, the approximate 54.5% bioavailability of 
VACV in man represents a 3-5-fold increase in bioavailability over orally 
administered ACV, and  VACV is 99% converted to ACV by first pass 
metabolism.   
In terms of antiviral activity against HSV-1 SC 16 strain in Vero Cells, VACV 
again showed the best activity; IC50VACV = 0.84 µM compared to 10.5 µM for the 
3-aminopropionate ester.  ACV demonstrated the highest IC50 value (0.1 µM), 
indicating that the antiviral activity of VACV required a hydrolytic event, and the 
observed plaque reduction in Vero Cells was most likely due to regenerated ACV 
(Beauchamp, Orr et al. 1992).  
In a separate study of amino acid ester prodrugs of ACV, similar antiviral 
activities against various HSV-1 and HSV-2 strains were observed in infected 
primary rabbit kidney cells (Colla, Busson et al. 1983). The prodrugs were 
synthesized as hydrochloride salts, and the observed IC50 = 0.04 – 0.5 µg/mL 
values for Gly, L-Ala, and β-Ala prodrugs of ACV compared to 0.04 – 0.1 µg/mL 
values for ACV also suggested that the antiviral activity of the prodrugs was due 
to parent ACV.  Here, the goal was to design a water soluble prodrug of ACV that 
could be formulated as an IM injectable dosage form, or as an eye drop 
formulation for the treatment of ocular HSV-1 keratitis.  It was found that HSV-1 
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induced epithelial and stromal keratitis and irititis were suppressed in rabbits 
when the Gly prodrug of ACV (GACV) was formulated into a 1% eye drop 
solution in pH 5.7 isotonic borate buffer.  ACV could not be dissolved in a 
sufficient quantity to prepare a 1% eye drop.  Importantly, GACV was stable for 6 
days at room temperature in the borate buffer as compared to pH 7.4.  These 
data suggest that eye drops containing an amino acid ester prodrug of ACV can 
be prepared and administered to treat ocular HSV-1 infections.  The structure of 
GACV is given in Figure 1.5. 
Given these encouraging results, it is no surprise that significant research 
efforts have been applied to establish the utility of active transporters as targets 
for enhanced drug absorption.  Indeed, several studies have provided evidence 
for the human peptide transporter (hPEPT-1) as the critical absorption enhancer 
of VACV following oral administration (Balimane, Tamai et al. 1998, Han, Oh et 
al. 1998, Smith and Lee 1998).  Further amino acid prodrug designs to target 
hPEPT-1 are covered under specific prodrugs later in this review.  
  
Amino acid esters of acyclovir for ocular drug delivery 
Ocular drug delivery can also benefit from an amino acid prodrug approach.  
Evidence of a rabbit corneal oligopeptide transport system has been obtained 
(Anand and Mitra 2002).  Threefold enhancement of corneal permeation of VACV 
was observed compared to ACV.  Moreover, known substrates of a peptide 
transporter (glycylsarcosine, glycylproline, captopril, and others) inhibited the 
transport of VACV, and the transport of VACV was pH/concentration-dependent 
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and saturable.  Also, Ouabain, a Na+/K+ ATPase inhibitor, significantly decreased 
the permeability of VACV across rabbit cornea.  Taken together, these data 
suggest the role of an active oligopeptide transport system in the corneal 
permeation of VACV.  On the other hand, ACV corneal transport is limited by 
passive diffusion and poor lipophilicity among other physiochemical shortcomings 
(Anand and Mitra 2002). 
In addition to an active oligopeptide transport system on the rabbit cornea, an 
Na+-dependent cationic and neutral amino acid transporter (B0,+) has been 
identified (Jain-Vakkalagadda, Pal et al. 2004).  L-Arg transport across rabbit 
cornea was concentration-dependent, saturable, and involved a single carrier 
system.  Inhibition of L-Arg permeation by ouabain or sodium and chloride free 
buffers suggested the involvement of an active carrier transport process.  Neutral 
amino acids L-Phe, L-Cys, and Gly significantly inhibited the transport of [3H]-L-
Arg, as did L-Arg itself, suggesting substrate recognition of neutral and cationic 
amino acids.  L-Glu, an anionic amino acid did not inhibit the transport of L-Arg 
while 2-aminobicyclo[2,2,1]heptane-2-carboxylic acid (BCH) did.  BCH is a 
known specific inhibitor of the B0,+ system, and this further suggests that 
transport of L-Arg is enhanced by B0,+ carrier-mediated processes.   The amino 
acid transporter was further characterized by reverse transcription-polymerase 
chain reaction (RT-PCR) utilizing total RNA from rabbit cornea, human cornea, 
and rabbit corneal epithelium samples. 
In this same work, three amino acid prodrugs of acyclovir were prepared (γ-
Glu-ACV, Phe-ACV, and Gly-ACV).  Inhibition studies in Dulbecco’s phosphate 
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buffered saline (PBS) at a concentration of 1mM prodrug demonstrated that only 
γ-Glu-ACV (EACV) and Phe-ACV (FACV) had a significant inhibition of [3H]-L-
Arg.  The Gly-ACV prodrug did not inhibit the transport, although the amino acid 
Gly was found to be an inhibitor in the same study.  Obviously, there is no 
guarantee of substrate recognition by a given transporter in prodrug design if one 
simply prepares a conjugate of a drug and a known transporter substrate.  All 
prodrugs must be tested in a biological context to unveil their utility in clinical 
applications.     
A Na+-independent large neutral amino acid transporter (LAT1) has also been 
identified in human and rabbit cornea (Jain-Vakkalagadda, Dey et al. 2003) 
which is responsible for the transport of L-forms of Leu, Ile, Val, Phe, Tyr, Trp, 
Met, and His.  Using RT-PCR and various inhibition studies, the authors 
investigated [3H]-L-Phe transport across rabbit cornea and uptake in SIRC rabbit 
corneal cells.  Uptake was concentration-dependent and saturable.  Transport 
was saturable, sodium buffer-independent, energy-independent, and significantly 
inhibited in the presence of L-Phe, L-Tyr, L-Leu, L-Ile, and L-dopa.  Gly and L-Ala 
had a negligible effect on transport.  Also, D-forms of Leu, Phe, and Met are 
known substrates of LAT1, and D-Phe and D-Leu inhibited [3H]-L-Phe uptake in 
SIRC cells.  No amino acid esters of ACV were assayed in this study. 
An Na+-dependant neutral amino acid transporter (ASCT1), has also been 
characterized in rabbit primary corneal epithelial cell culture and rabbit cornea 
using the same type of inhibition studies and RT-PCR techniques (Katragadda, 
Talluri et al. 2005).  [3H]-L-Ala uptake in rabbit primary corneal epithelial culture 
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and [3H]-L-Ala transport across rabbit cornea were found to be saturable, 
sodium-dependent, energy and pH- independent, and inhibited in the presence of 
L-Ser, L-Thr, L-Cys, and L-Glu.  The transporter was not inhibited in the 
presence of BCH or α-methylaminoisobutyric acid, which sets it apart as the ASC 
system, rather than the A system which is known to be inhibited by those 
species.  
In  follow up efforts to exploit the B0,+ amino acid transporter as an ocular 
bioavailability enhancer, Anand et al. synthesized and assayed the transcorneal 
flux of L-γ-Glu-ACV (EACV) and L-Tyr-ACV (YACV) (Anand, Katragadda et al. 
2004).  In PBS buffers held at pH 5.0, 6.0, and 7.4, half lives of the two prodrugs 
covered a large rang (5.5 – 654.5 h).  Maximum stability for both prodrugs was 
observed at pH 5.0.  In cornea, YACV was much more labile to hydrolysis than 
EACV; however, EACV was converted to ACV more rapidly in aqueous humor 
and in the Iris-cilliary body.   
Noncompetitive inhibition of [3H]-L-Arg was observed in the presence of 1mM 
EACV but not in the presence of an equivalent concentration of YACV.  
Accordingly, EACV and ACV had similar transport while YACV transport was 
significantly less than either EACV or ACV.  The affinity of EACV for the B0,+ 
transporter was low (2.66 ± 0.28 mM), which accounts for a similar transport 
profile to ACV.  Further experiments revealed that EACV transport was pH-
independent, Na+-dependent, and energy-dependent.  These data suggest the 
involvement of B0,+ in the transport of EACV.  However, in this case the delivery 
was not sufficient to constitute an advantage in corneal dosing with EACV over 
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ACV.  Still, the antiviral activities of both prodrugs against HSV-1, HSV-2, HCMV, 
and VZV were quite similar to commercial VACV and ACV, so these prodrugs 
could still be good oral delivery candidates since hPEPT-1 was not targeted in 
these delivery efforts. 
L-serine-succinate (SSACV), L-cysteine (CACV), L-alanine (AACV), and L-
serine (SACV) prodrugs have also been assayed as potential ocular drug 
delivery candidates (Suresh, Zhu et al. 2010).  The drug target for these 
candidates was the Na+-dependent neutral amino acid transporter (ASCT1) 
where ASC refers to the Alanine-, Serine-, and Cysteine-preferring nature of the 
nutrient transporter.  Additionally, these prodrugs were also tested for their 
affinity at the other known corneal nutrient transporters.  A 51% inhibition of 
transcorneal flux of SACV was observed in the presence of 5 mM arginine and a 
38% inhibition was noted in the presence of BCH.  CACV transport was 
uninhibited by alanine or gly-sar.  AACV transport was unaffected by alanine, gly-
sar, or BCH, and the prodrug was found to be unstable in transport medium.  On 
the other hand, [3H]-L-Alanine transport was significantly inhibited in the 
presence of 10 mM SSACV, and the uptake of [3H]-L-Alanine into rPCEC cells 
was likewise inhibited in the presence of SSACV.  Taken together, these results 
indicate that CACV and SACV are not substrates for ASCT1, while AACV was 
too unstable, and its permeability data were statistically identical to parent ACV.  
Inhibition of [3H]-L-Alanine in the presence of SSACV indicates that SSACV is 
the only substrate for ASCT1 in this series of prodrugs, and it is likely that the 
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free carboxylate is necessary for transporter recognition.  In every case, the 
prodrugs were converted to ACV in ocular tissues. 
Permeability of the prodrugs was best for SACV; however, despite recognition 
by ASCT1, SSACV showed permeability no better than CACV, and both SSACV 
and CACV were less permeable than ACV control.  SACV proved to be a 
substrate for multiple nutrient transporters.  SACV also showed the best antiviral 
activity against HSV-1 and VZV (HSV-1 EC50 (SACV/ACV) = (6.3/7.1)µM, VZV 
EC50 (SACV/ACV) = (1.7/2) µM).  AACV and CACV had similar acitivities against 
HSV-1 compared to ACV.  Otherwise, antiviral activity data suggest that none of 
the prodrugs was as effective against HSV-2 as ACV, and only SACV was similar 
in affinity for VZV compared to control.  SSACV, the only ASCT1 substrate, 
demonstrated poor affinity for HSV-1 and HSV-2 compared to ACV, and a nearly 
4-fold lower affinity for VZV.  Overall, SACV was the best prodrug discovered in 
this series of compounds.  
A recent study was conducted to assess the pharmacokinetics of amino acid 
ester prodrugs of acyclovir (ACV) following oral administration (Katragadda, Jain 
et al. 2008).  The prodrugs studied were AACV, SACV, L-isoleucinyl-ACV 
(IACV), EACV, and VACV.   
  The in vitro enzymatic stability data that were obtained in this study are very 
interesting.  AACV was observed to be too unstable in liver homogenate to 
measure residual prodrug, while EACV showed the longest half life (223 ± 8.8 h).  
VACV was rapidly hydrolyzed in intestinal and liver homogenate with half lives of 
0.6 ± 0.02 h and 0.07 ± 0.004 h respectively.  On the other hand, the rat plasma 
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half life of VACV was 226 ± 67 h.  These data suggest that systemic exposure to 
ACV from VACV occurs via a combination of intestinal and hepatic metabolism.  
Interestingly, the plasma half lives of all of the acyclovir amino acid ester 
prodrugs except AACV were found to be rather long, ranging from a low of 4.8 ± 
0.7 h for AACV to a maximum of 226 ± 67 h for VACV.  Overall, the study 
suggests that the in vitro stability of amino acid ester prodrugs of acyclovir is 
highly dependent upon the tissue used in the stability studies.  
A number of transporter affinity studies were carried out in this work; 
however, the pharmacokinetics data best speak to the ability of these prodrugs to 
act as bioavailability enhancers in the live Sprague-Dawley rat.  In that regard, 
SACV and VACV showed the best bioavailability enhancements compared to 
control, as determined by AUCInf(T).  An approximately 7.2-fold increase was 
observed for SACV, and a roughly 5-fold increase was observed for VACV.  The 
Cmax for SACV (39 ± 2 µM) was also significantly higher than that of VACV (22 ± 
0.3 µM), the commercial prodrug.  Cmax for ACV was fifteen times less than 
SACV.  These data, and data from the previous study, suggest that SACV should 
be strongly considered as a candidate for further study in oral and ocular 
treatment of HSV infections. 
 
Amino acid ester prodrugs of acyclovir for intranasal drug delivery 
ACV cannot be delivered by nasal drug delivery without a prodrug approach 
(Shao and Mitra 1994).  L-Phe and L-Tyr are absorbed nasally by an active 
transport process (Tengamnuay and Mitra 1988).  As a natural parallel to oral 
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and ocular drug delivery efforts involving amino acid prodrugs of acyclovir which 
target nutrient transporters, the nasal drug delivery route has also been 
investigated (Yang, Gao et al. 2001).  Utilizing L-amino acids, Phe-ACV, Lys-
ACV, and β-Asp-ACV were synthesized and assayed for stability and nasal 
uptake compared to parent ACV.  The animal model used in this work was the 
adult male Sprague-Dawley rat.  Stability studies were conducted in phosphate 
buffers held at pH 3.0, 5.0 and 7.4 containing a minimal amount of acetonitrile for 
complete prodrug dissolution.  Samples of rat nasal washings and rat plasma 
were utilized as the enzymatic hydrolysis media.   
The prodrugs were very stable with measured degradation values of less than 
10 – 15% in one week at pH 3.0 or pH 5.0 and 25 °C, with the exception of Phe-
ACV which had a half life of 136.6 ± 3.7 h at pH 5.0 and 25 °C.  A significant rate 
enhancement in prodrug hydrolysis to roughly t1/2 = 4 hours was observed in 
buffer held at pH 7.4 and 37 °C for Lys-ACV and Phe-ACV (approximately four 
times faster than β-Asp-ACV).   β-Asp-ACV showed no significant increase in 
hydrolysis rate in rat nasal washings but demonstrated nearly 1/13th the apparent 
buffer stability in rat plasma which indicates that the β-Asp-ACV prodrug could 
likely be a good nasal delivery candidate for ACV with sustained stability at the 
nasal mucosa absorption barrier (t1/2 = 16.6 ± 0.3 h) and rapid systemic 
hydrolysis  (t1/2 = 77.5 min) to ACV following absorption.  Stability of the Phe-ACV 
and Lys-ACV prodrugs in nasal washings suggested that these prodrugs would 
not be the best candidates for intranasal drug delivery (t1/2 = 0.80 h and 2.93 h 
respectively).  Furthermore, the nasal absoprtion of Phe-ACV and Lys-ACV were 
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found to be immeasurable, which certainly excludes these compounds as nasal 
delivery candidates.  On the other hand, 8% absoprtion of  β-Asp-ACV at a 
concentration of 100 µM was observed over 90 minutes perfusion.  As would be 
expected, the transport of β-Asp-ACV appears to be carrier-mediated in that 2 
mM L-asparagine significantly inhibited the nasal uptake of the prodrug. 
 
Model L-tyrosine derivatives for intranasal drug delivery 
In order to explore the carrier-mediated drug delivery of L-tyrosine derivatives 
and their nasal absorption, Yang  et al. (Yang and Mitra 2001) prepared three 
model L-tyrosine-linked benzyl alcohol conjugates with a variable R-substitution 
in the 4-position (Figure 1.6).  The ether linkage utilized in this model compound 
design evades systemic cleavage by hydrolytic enzymes so the nasal absorption 
data need not be convoluted by concurrent metabolism during barrier transport.   
From this work, it can be appreciated in general that an active transport 
system does exist on the nasal mucosa that can significantly increase the 
bioavailability of L-tyrosine-linked model test compounds.  For instance, when R 
= COOH versus R = NO2 an expected increase in nasal absorption was seen for 
the parent benzylic alcohols.  In this case, the nitro compound absorbed while 
the carboxylic acid did not.  This was due to the ionic nature of the carboxylate in 
the isotonic phosphate buffer vehicle which was held at pH 7.4.  Also, the nitro 
compound showed  a linear correlation between initial drug concentration and 
absorption rate which was maintained over a concentration range of two orders 
of magnitude.   
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Figure 1.6 Structures of model benzyl alcohols and their L-tyrosinyl ether 
conjugates/ synthesis of the conjugates.  Adapted from (Yang and Mitra 
2001). 
 
The latter suggests a passive permeation mechanism of absorption.  On the 
other hand, each of the L-tryosinyl conjugates, along with L-tyrosine, exhibited 
Michaelis-Menten kinetics, and a clear dependance of the apparent first order 
rate constant on initial drug concentration was observed.  Also, each of the 
conjugates showed higher affinity for the carrier system than L-tyrosine, and they 
were transport-inhibited in the presence of L-tyrosine.  The nitro and fluoro 
dervatives in particular showed an order of magnitude increase in transporter 
affinity.  These affinity data also correlated positively with the absorption rate 
data in which the nitro conjugate showed the best affinity and fastest absorption 
rate.  Importantly, the impermable parent 4-carboxylic benzyl alcohol moiety did 
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not inhibit absorption rate enhancement of the carboxylate conjugate model 
compound, which further suggests the presence of an active transport system 
that recognizes the L-tyrosine moiety as a substrate.  These data provide good 
evidence that amino acid ester prodrugs may be a suitable drug design strategy 
for intranasal drug delivery.   
 
Amino Acid esters of Danazol for oral drug delivery  
Danazol (D) (Figure 1.7) is an oral therapeutic approved for the treatment of 
endometriosis.  It is also used in fibrocystic breast disease and angioedema.  
Several dosage strengths of the drug are avaiable in capsule form.  As may be 
expected, the neutral nature of danazol, and its sterol core structure impart little 
water solubility to the compound (5 mg/mL), and its solubility is not variable as a 
function of pH (Simmons, Portmann et al. 1995).  Inasmuch, dose doubling of D 
does not result in a compensatory doubling of systemic drug concentration due to 
the bioavailability limitations of poor aqueous solubility.  At best, approximately 
35 – 45% increases in blood levels have been noted.  Therefore, the amino acid 
ester prodrug approach has been applied to D with some very interesting results.   
A study by Simmons et al. (Simmons, Portmann et al. 1995) has 
demonstrated that L-Lysine, Glycine, and sarcosine conjugates of D (DL, DG, 
and DS respectively) (Figure 1.7) improve systemic exporsure to D.  Also, 
whithin this study, significant differences were observed in enzymatic activities 
between different species and different biological fluids.  For instance, upon rat 
intraduodenal bolus dosing of prodrug, DL and DS were completley hydrolyzed to 
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D, while DG could be measured in portal plasma in a ratio of 2:1 D:DG.  In 
contrast, DL did not hydrolyze at all in rat liver perfusion studies while DG could 
be measured along with D and DS was not present (i.e. hydrolyzed completely).  
In rat intestinal fluid, DG did not hydrolyze at all while DL hydrolyzed rapidly and 
DS hydrolyzed slowly.   
 
 
 
Figure 1.7 Structures of danazol and its amino acid ester conjugates. 
Adapted from (Simmons, Portmann et al. 1995). 
  
In human gastric and intestinal fluids, DG was not a substrate for esterase 
enzymes.  DS hydrolyzed slowly in human intestinal fluid, similar to its behavior 
in rat intestinal fluid, and DL hydrolyzed rapidly in human intestinal fluid just like 
its behavior in rat intestinal fluid.  
Porcine liver esterase rapidly cleaved the DG and DS prodrugs, but did not 
hydrolyze DL at all, and a completely opposite rate enhancement effect was 
observed in porcine pancreatin.   
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Comparing rat, human and dog plasma, DL hydrolyzed slowly in dog plasma 
and not at all in rat and human media.  The other two prodrugs were not 
substrates for esterase activity in human and dog media, but they were rapidly 
converted to D in rat plasma. 
These data demonstrate a very important point in prodrug design.  The 
different biological fluids that the prodrug will encounter in transport to its target 
represent variegated barriers whose specific effects on the prodrug must be 
individually studied.  It is not possible a priori to determine what the specificity of 
a prodrug will be for the enzymatic mileau of a particular biological matrix, and 
interspecies differences must also be considered.  In this case, each of the 
prodrugs tested increased systemic exposure to parent D by the oral route as 
compared to control; however, their manner of doing so must clearly abide by 
different mechanisms.     
 
Amino acid amide prodrugs of antitumor benzothiazoles 
2-(4-aminophenyl)benzothiazoles (Figure 1.8) have been shown to possess 
potent activity against numerous cancer cell lines, and they also exhibit  activity 
against a unique subset of human cancer cell lines that are part of the National 
Cancer Institute’s in vitro anticancer drug screen (Bradshaw, Wrigley et al. 1998, 
Bradshaw, Chua et al. 2002).    
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Figure 1.8 Rational design of N-lysyl-2-(4-amino-3-methylphenyl)-5-
fluorobenzothiazole.  Adapted from (Bradshaw, Bibby et al. 2002, 
Bradshaw, Chua et al. 2002, Hutchinson, Jennings et al. 2002). 
 
Compund I has been pursued as an anticancer agent due to its activity 
against breast MCF-7, MDA-468 and other sensitive cell lines; however, its utility 
has been truncated by problems associated with its hydroxy metabolites.  In 
particular the C-6 oxidation product of compound I causes sensitive cells to not 
36 
 
sequester the therapeutic parent compound I, and the C-6 metabolite is itself 
inactive as an antitumor agent (Kashiyama, Hutchinson et al. 1999).   
In efforts to circumvent these untoward characteristics of the hydroxy 
metabolites, flourine isosteric replacement of the hydrogen atoms on the 
benzothiazole core has been investigated.  As a result, compound 2 was found to 
be the best compound for further drug development due to its performance 
against human breast and ovarian tumor xenografts in nude mice.  Also, 
compound 2 exhibits superior performance in blocking the C-6 oxidation on the 
benzothiazole core which in the case of compound I effectively thwarts CYP1A1 
induction and suicide inhibition.  Respectively, the latter two events result in the 
formation of active metabolites and the tumor growth-inhibiting CYP1A1-
benzothiazole covalent binding complex (Hutchinson, Chua et al. 2001).      
In order to develop a clinical candidate with adequate water solubility for 
parenteral administration, Bradshaw et al. (Bradshaw, Chua et al. 2002) 
synthesized a series of amino acid amide prodrugs of 2-(4-amino-3-
methylphenyl)-5-fluorobenzothiazole (compound 2) along with other homologous 
isosteres of the fluorobenzothiazole class.  Though promising results were 
obtained with L-alanyl and L-lysyl promoieties when they were conjugated to 
many of the fluoro-isostere positional isomers, the N-lysyl-5-F dihydrochloride 
prodrug (5-FBL) of compound 2 (Figure 1.8) has emerged as the most promising 
candidate for clinical development (Bradshaw, Wrigley et al. 1998, Bradshaw, 
Bibby et al. 2002, Hutchinson, Jennings et al. 2002).    
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In terms of pH-dependent stability, at pH 4.5 and 25 °C, 5-FBL was stable for 
45 days.  At pH 7.4 and 25 °C, 5-FBL exhibited  t90 = 45 days.  These data 
suggest that 5-FBL is best stored in mildly acidic solution as a dosage form with 
acceptable shelf life.  Furthermore, 5-FBL showed 136.4-fold better solubility at 
pH 5.0 than at pH 7.4, as expected of an amine-containing compound 
(Hutchinson, Jennings et al. 2002).  In general, the stability of 5-FBL is as should 
be expected for an amide prodrug.   
In the presence of senstitive cancer cell lines, 5-FBL was converted to parent 
compound 2 in detectable amounts within 24 hours, and levels of compond 2 
significantly increased over seven days of the experiment.  Furthermre, 5-FBL 
was observed to be stable for greater than seven days at 37 °C  in cell culture 
medium not containing cells, indicating that conversion of prodrug 5-FBL to 
active compound 2 was facilitated by cellular metabolic machinery.  Western Blot 
analysis of CYP1A1 induction in lysates of MCF-7 (sensitive) cells exposed to 5-
FBL compared to those untreated with 5-FBL revealed selective induction of 
CYP1A1, which is required for anticancer activity.  Insensitive HCT 116 cells did 
not present evidence of CYP1A1 induction when treated with 5-FBL or parent 
compound 2.  Maximum CYP1A1 induction occurred at 1 µM 5-FBL 
concentration (Bradshaw, Chua et al. 2002).  
In a further study, the pharmacokinetics of 5-FBL in mice and dogs were 
determined (Bradshaw, Bibby et al. 2002).  The t1/2β values indicate that in mice 
and both male and female dogs, 5-FBL is rapidly converted to parent compound 
2 (2, 17, and 30 minutes respectively).  However, these data were obtained at a 
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dose level of 32.2 mg/kg i.v. in mice and 14.3 mg/kg in the dogs.  Significant 
gastrointestinal toxicity was observed in the dogs at the 14.3 mg/kg dose level, 
and 4 mg/kg was found to be a more suitable dose with an associated peak 
plasma concentration of compound 2 of 0.9 µM.  The latter exposure level is 
within the range of efficacy in terms of sensitive breast cancer cell in vitro data.   
 
Amino acid prodrugs of 5-aminosalacylic acid for colonic delivery       
  Figure 1.9 shows the structures of the compounds which are relevant for the 
following discussion.  Lialda® (mesalamine) is the trade name for 5-
aminosalicylic acid (5-ASA) which is an effective clinical agent for the treatment 
of inflammatory bowel diseases such as Crohn’s Disease and ulcerative colitis.  
In order to effectively deliver 5-ASA to the colon, the azo prodrug (actually a 
codrug type of prodrug) sulfasalazine (Azulfidine®, SASP) has been designed.  
70% of SASP is available to the distal intestine and colon upon oral dosing of 
SASP (Das, Chowdhury et al. 1979), and aza reductase enzymes that are 
present in the colonic region of the gut readily cleave the azo bond to liberate 5-
ASA and sulfapyridine (SP).  The prodrug approach is necessary in this case in 
order to prevent rapid pre-colonic absorption and acetylation of 5-ASA, both of 
which eliminate the drug from its desired target location.  Though SASP is 
efficient in its delivery of 5-ASA, the SP moiety is known to cause hypersensitivity 
reactions in the majority of patients who receive therapy with SASP (Das, 
Eastwood et al. 1973, Taffet and Das 1983, Peppercorn 1984).   
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Figure 1.9 Structures of 5-aminosalicylic acid prodrugs and their 
mechanism of drug delivery.  Adapted from (Pellicciari, Garzon-Aburbeh et 
al. 1993). 
 
The amino acid prodrug approach has been utilized to afford amino acid 
amide prodrugs of 5-ASA for potential colonic delivery (Pellicciari, Garzon-
Aburbeh et al. 1993).  L-Glutamate and L-Aspartate moieties were conjugated to 
5-ASA at the aryl amine moiety to prepare 5-(N-L-Glutamylamino)salicylic acid 
(5-GS) and 5-(N-L-Aspartylamino)salicylic acid (5-AS) as their disodium salts.  In 
vitro experiments revealed that 5-GS did not cleave to release 5-ASA in human 
gastric juice, human feces suspension, human pancreatic juice, or bovine 
protease hydrolysis media; however, porcine peptidases cleaved the prodrug 
following first order kinetics, resulting in the liberation of 5-ASA (t1/2 = 81 
minutes).       
40 
 
Subsequently, 5-GS and 5-AS were orally dosed in colostomized and 
noncolostomized male Fisher rats and compared to 5-ASA and SASP to assess 
the effectiveness of brush border aminopeptidase-assisted release of 5-ASA 
from prodrug.  The largest level of urinary recovery of 5-ASA and its metabolite, 
5-N-acetyl-ASA was observed with oral dosing of 5-ASA, which substantiates 
early absorption in the first tract of the small intestine when 5-ASA is 
administered as parent drug.  In contrast, the amino acid amide prodrugs 
exhibited lower urinary recovery levels of 5-ASA and the N-acetyl metabolite 
compared to oral dosing with 5-ASA, and fecal levels for 5-ASA and metabolite 
were far greater with orally dosed prodrug than with orally dosed 5-ASA.  In all 
cases, there were no significant differences in recovery levels between the 
colostomized and noncolostomized rats.  Collectively, these data suggest that an 
amino acid amide prodrug design can be advantageous for the delivery of 5-ASA 
to the proximal part of the ascending colon, which is a key area for the treatment 
of Crohn’s Disease and ulcerative colitis.  The activating enzymes in this case 
appear to be brush border aminopeptidases. 
 
5’-Isoleucinyl-zidovudine for brain delivery  
Zidovudine (AZT) is an antiviral agent used to treat HIV infection.  However, 
AZT does not penetrate the blood brain barrier to an extent that is therapeutically 
relevant to treat brain infection of HIV-1.  In order to improve brain delivery of 
AZT, the 5’-Isoleucinyl ester of zidovudine (IAZT, Figure 1.10) has been 
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prepared.  Promising pharmacokinetic results have been observed in rabbits 
dosed by intravenous infusion (Lupia, Ferencz et al. 1993).  
 
 
 
Figure 1.10 Brain delivery of AZT from IAZT prodrug.  Adapted from 
(Lupia, Ferencz et al. 1993). 
 
 In the live rabbit, IAZT was rapidly converted to parent AZT (90% in 5 
minutes) while in vitro plasma hydrolysis samples showed slower rates of 
conversion (22.5% in 5 minutes).  Within 120 minutes, significantly higher levels 
of AZT were obtained from animals treated with IAZT compared to animals 
treated with AZT.  However, at 120 minutes, IAZT could still be detected.  The 
AUC for IAZT was approximately 1.5 times higher than that for AZT based on 
extrapolation to infinity for data points covering the time course to 120 minutes.  
Furthermore, a mean brain/CSF ratio of 0.64 corresponding to AZT from IAZT 
was observed, which is approximately twice the value observed following AZT 
dosing (0.32).   IAZT was found to be completely hydrolyzed by plasma 
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esterases within 240 minutes, and by hepatic microsomes within 60 minutes.  
These data suggest that IAZT is a potential therapeutic agent for improved brain 
delivery of AZT. 
 
Amino acid prodrugs of propofol for IV dosing   
 Propofol (PF) has become a staple in surgical anesthesia; however, a 
quick look at the molecule (Figure 1.11) reveals that it is quite lipophilic in nature 
and very water insoluble.  To circumvent the solubility problems associated with 
PF, formulation design has been employed (Diprivan® 1% w/v oil/water 
emulsion).  Also, the prodrug approach has resulted in an FDA-approved drug 
delivery system as well (Lusdera®, Fospropofol disodium).  However, it has also 
been shown that the amino acid ester prodrug approach is likely to be a useful 
strategy for improved water solubility and IV delivery of PF (Trapani, Latrofa et al. 
1998, Altomare, Trapani et al. 2003).   
Figure 1.11 summarizes the amino acid ester prodrug structures as 
synthesized and tested by Trapani, Latrofa, Altomare and others.  In every case 
racemic precursors were used to install the promoieties except for the L-prolinyl 
prodrug which was enantiopure.  Compounds 1 – 8 were studied separately from 
compounds 9 – 12.   
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Figure 1.11 Amino acid ester prodrugs of propofol.  Adapted from (Trapani, 
Latrofa et al. 1998, Altomare, Trapani et al. 2003). 
   
Solubility studies in pH 7.4 phosphate buffer revealed that compound 8 had 
the greatest solubility (mg/mL) out of compounds 1-8; however, approximately 
0.6 mg/mL is not highly soluble either.  Hydrochloride salts of compounds 2 – 7 
had better solubility than their free bases in phosphate buffer, with the exception 
of compound 5 in which no significant solubility difference was observed between 
the hydrochloride and free base at pH 7.4.  The hydrochloride of compound 4 
was significantly more soluble than the free base of compound 8, but none of the 
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materials (compounds 1 – 8) achieved even 1.0 mg/mL solubility regardless of 
ionic charge.  Comparatively, the promoieties depicted in compounds 1 – 8 
afforded an approximately 4.8-fold increase in solubility over propofol at best, 
and some prodrugs were far less soluble than propofol itself.  Compound 3 had 
the worst solubility.  
Amino acid esters 9 – 12 were prepared as hydrochloride salts only and 
tested for solubility in deionized water at room temperature (pH not reported).  It 
is worth noting that this solubility testing procedure is in no way equivalent to that 
which was done on compounds 1 – 8 in which a controlled pH of 7.4 was 
maintained.  IV injectable prodrugs should be assayed for solubility at pH 7.4.  
Nonetheless, the data are interesting.   Ironically, compounds 9 and 11 exhibited 
log orders greater solubility (mmol/mL) as compared to the other isomers of 11.  
As expected, all of the amino acid ester hydrochloride prodrugs in the series of 
compounds 9 – 12 afforded at least 50-fold greater solubility than propofol in DI 
water.  However, as a general critique, this may not be the case at all at pH 7.4.   
In terms of stability, compounds 2, 4 and 5 were far too stable at pH 7.4 in 
buffer and in biological media to be considered viable prodrugs of propofol.  This 
was true regardless of free base or salt form.  Compounds 3 and 6 – 8 were not 
tested due to poor solubility.   
Compounds 9 and 10 had half lives of 6 and 7 hours respectively in pH 7.4 
buffer with large rates of acceleration in 50% rat plasma ( 17 and 2.5 minutes 
respectively).  Similarly, in porcine liver esterase media, compound 9 hydrolyzed 
with a half life of 17 minutes, and compound 10 hydrolyzed with a half life of 13 
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minutes.  These data provide clear evidence that compounds 9 and 10 are 
suitable prodrugs to consider as potential intravenous delivery systems of 
propofol.  From this series of prodrugs, the L-prolinyl ester arises as the best 
candidate for further development given its greatly enhanced water solubility 
compared to propofol and its rapid conversion to propofol in biological media. 
One important feature of compounds 2-12 must be addressed.  In the 
definition of prodrugs, there is a requisite criterion that no prodrug can have 
pharmacological activity of its own.  Within these studies, it was shown that the 
prodrugs do in fact have pharmacological activity at GABAA receptors in that 
many of them are able to reduce the binding of [3S]tert-
butylbicyclophosphorothionate ([3S]TBPS) in a dose-dependent manner like 
propofol despite clear evidence of slow hydrolysis of most of the esters.  Those 
esters are therefore behaving as analogues of propofol in the case where 
hydrolysis to propofol is too slow for prodrug behavior.  Even the L-prolinyl 
prodrug exhibited some analogue activity in addition to its propofol drug delivery 
mechanism of action.  Therefore, by definition, these agents are more 
appropriately viewed as analogues of propofol rather than prodrugs.  
 
Amino acid esters of Penciclovir 
Penciclovir (PCV), like acyclovir, is an acylnucleoside derivative of guanine 
that has potent and selective antiviral activity toward various herpes viruses in 
man.  HSV-1, HSV-2, Epstein-Barr virus, and varicella-zoster viruses have each 
shown inhibited replication in the presence of PCV, both in cell cultures and in 
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animals (Harnden, Jarvest et al. 1987, Kim, Lee et al. 1996).  Due to its poor oral 
bioavailability, which is akin to acyclovir, PCV is generally dosed as a topical 
formulation that is designed to treat cold sores of the HSV-1 variety.  In the 
united states, PCV is supplied as a sodium salt in a 1% topical cream under the 
trade name Denavir®, and several strengths of the PCV prodrug famciclovir 
(FCV) are also available as oral delivery forms.  In either case, PCV is available 
only by prescription.  Systemic exposure to PCV following oral dosing of FCV 
requires two key steps (Figure 1.12).  The terminal acetyl groups must be 
cleaved hydrolytically to afford the free hydroxyl groups of PCV, and the 6-
position of the 6-deoxyguanine core structure of FCV must undergo oxidative 
bioconversion by xanthine oxidase to afford the true guanine skeleton of PCV. 
 
 
 
Figure 1.12 Bioconversion of famciclovir to penciclovir. 
 
Notwithstanding the fact that famciclovir is orally well absorbed and 
extensively bioconverted to the desired PCV drug molecule, the bioconversion is 
not complete, and 60% PCV along with 5% 6-deoxy-PCV is observed in urine 
samples (Harnden, Jarvest et al. 1989, Vere, Sutton et al. 1989, Pue and Benet 
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1993).  The 6-deoxy-PCV species represents a loss of PCV bioavailability, and it 
is of probable toxicological importance in that a similar 6-deoxy-ACV species has 
shown a chronic toxicity profile in animal models that is less favorable than the 6-
oxy ACV compound (Beauchamp, Orr et al. 1992).   
In order to investigate the utility of the PCV scaffold in a prodrug approach 
that does not require oxidation by xanthine oxidase at the 6-position of the 
guanine core structure, the amino acid ester approach was utilized on PCV itself 
(Kim, Lee et al. 1996).  Again, it was expected that prodrugs of this structural 
design would be targets for the PEPT-1 and PEPT-2 transporters in the gut 
which are responsible for the increased absorption of VACV and VGCV by active 
transport.   
Figure 1.13 illustrates the prodrug design and the intended outcome of 
prodrug exposure to physiological conditions.  In this work, two forms of prodrug 
were assayed.  In one design, the hydroxyl groups were substituted differently 
such that a simple alkyl ester was formed by acylation on one of the available 
hydroxyl groups while the other hydroxyl group was converted to an amino acid 
ester.   In the second prodrug design, both available hydroxyl groups on PCV 
were substituted as amino acid esters using the same amino acid promoiety on 
both sides.   
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Figure 1.13 Generation of Penciclovir from amino acid/alkyl ester and di-
amino acid ester prodrugs.  Adapted from (Kim, Lee et al. 1996). 
 
Since the PCV molecule is symmetric about the carbon connecting the free 
hydroxyl groups, this chemistry was easily achieved with traditional coupling 
methods to afford the desired compounds; however, unexpected racemization of 
the α-carbon was encountered in the Cbz-approach for reasons that are not very 
clear.  Each of the prodrugs was found to be highly water soluble and to have a 
stability profile that was suitable for oral delivery at physiologically-relevant pH 
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values (pH 1.0, 6.0, 7.4, and 8.0).  The oral bioavailability of the prodrugs was 
compared to that of PCV in ICR mice following 48 hours of urine collection, and it 
was observed that O-acetyl-O-L-valylpenciclovir achieved the highest systemic 
exposure of PCV with a fourfold increase over PCV.  Importantly, the 
bioavailability of PCV from the O-acetyl-O-L-valylpenciclovir prodrug was not 
significantly different than that observed for the FDA-approved FCV, which bodes 
well for the amino acid ester approach in the case of PCV.  The other prodrugs 
also afforded improved bioavailability of PCV as compared to the parent 
compound; however, none of them showed delivery comparable to that of FCV.  
In vitro anti-HSV-1 activity assays were less encouraging with EC50 values for 
prodrugs spanning a range of fourfold less than PCV to more than tenfold less; 
however, the authors note that partial hydrolysis in the test system could have 
been the problem.  Overall, the L-valinyl promoiety theme for acylnucleoside 
antiviral medications is also applicable to PCV. 
 
Amino acid esters of floxuridine 
Floxuridine (FU) is a fluorinated nucleoside anticancer drug derived from a 
pyrimidine scaffold that is used in the treatment of colorectal and metastatic 
cancers (Kemeny, Huang et al. 1999).  Like other nucleoside anticancer agents, 
FU exhibits considerable oral bioavailability problems.  Therefore, it is dosed as 
an intravenous infusion.   
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Figure 1.14 Generation of floxuridine and an amino acid from amino acid 
esters of floxuridine.  Adapted from (Vig, Lorenzi et al. 2003). 
 
In terms of prodrug design, FU has two available and nonequivalent hydroxyl 
functional groups which can be exploited as acylation handles (Figure 1.14).  
Accordingly, in a recent publication, both of these positions were derivatized into 
amino acid esters to determine the rate of prodrug hydrolysis in Caco-2 cell 
homogenates (Vig, Lorenzi et al. 2003).  First, the effect of amino acid promoiety 
structure on hydrolysis rate was assayed using phenylalanine (Phe), valine (Val), 
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and proline (Pro).  Second, D- and L-forms of Phe and Val were prepared and 
assayed to determine the effect of stereochemistry on hydrolysis rate.  Finally, 
the authors determined the effect of esterification site on hydrolysis rate using 3’-
monesters, 5’-monoesters, and 3’,5’-diester prodrugs of FU.  In all cases, the rate 
of prodrug hydrolysis in Caco-2 cell homogenates was compared to a pH 7.4 
phosphate buffer to appreciate the rate acceleration afforded by enzymatic 
catalysis in the Caco-2 biological medium.   
The structure of the promoiety had a big impact on hydrolysis rate in buffer.  
At pH 7.4, monoesters of Pro hydrolyzed approximately fourteen times faster 
than monoesters of Val and nearly ten times faster than monoesters of Phe.  
However, in buffer there was no significant effect of stereochemistry or site of 
esterification on the rate of hydrolysis, as expected.     
The enzymatic environment of Caco-2 cell homogenates unveiled a 
significant effect on the rate of prodrug hydrolysis from all three of the variables 
tested, which is right in line with what should be observed.  L-Val monoesters 
exhibited the longest half lives compared to L-Phe and L-Pro, and the L-forms of 
the promoieties imparted eleven to seventy-five times faster rates of hydrolysis 
over D-forms, depending on the site of esterification.  There was no particular 
advantage to be realized by 3’,5’-diester prodrug strategy, as these compounds 
were generally less stable in buffer than their monoester counterparts.  Overall, it 
was found that the 5’-Valyl ester prodrug of FU is comparable in stability to the 
two commercial antiviral prodrugs VACV and VGCV which were tested under the 
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same conditions.  Again, the L-Valyl promoiety is of probable utility in the design 
of an amino acid ester prodrug of FU.  
 
 
 
 
Figure 1.15 Structures of most promising BDCRB amino acid prodrugs.  
Adapted from (Lorenzi, Landowski et al. 2005, Song, Vig et al. 2005). 
 
 
2-Bromo-5,6-dichloro-1-(β-D-ribofuranasyl)-benzimidazole (BDCRB, Figure 1.15) 
is a member of a class of compounds designed to target human cytomegalovirus 
(HCMV) replication.  This particular ribonucleoside suffers from poor oral 
bioavailability due to hydrophilicity and metabolic instability of the N-glycosidic 
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bond.  Accordingly, the compound is rapidly destroyed upon IV administration by 
N-glycosidic bond cleavage.  Through analogues synthesis and testing, it has 
been demonstrated that this bond can be stabilized in vivo when the 2-Bromo 
substitutent is replaced by an isopropyl amino group (maribavir).  Also, two of the 
enzymes responsible for the catalytic cleavage of the N-glycoside have been 
identified as 8-oxoguanine DNA glycosylase (OGG1) and N-methylpurine DNA 
glycosylase (MPG) (Lorenzi, Landowski et al. 2006).  ―Bioevasion‖ prodrug 
design has therefore been a key focus with this compound (Lorenzi, Landowski 
et al. 2005).   
Since hPEPT1 has been shown to increase absorption of amino acid ester 
prodrugs via facilitated diffusion, recent work was aimed at investigating amino 
acid promoiety derivitization at the 5’-hydroxy position of the ribose sugar moiety 
of BDCRB to determine if enhanced hPEPT1 substrate affinity could be achieved 
(Song, Vig et al. 2005).  In a follow up study, stabilization of the glycosidic bond 
in vivo by amino acid ester prodrug design was also investigated (Lorenzi, 
Landowski et al. 2005).    
With regard to hPEPT1, the prodrugs were assayed for their ability to inhibit 
[3H]Gly-Sar uptake in HeLa cells that overexpress hPEPT1, and it was found that 
amino acid promoieties with aromatic, aliphatic, and acidic side chains showed 
the best affinity for hPEPT1 compared to BDCRB and VACV.  The lysinyl and 
prolinyl prodrugs had worse affinity for the hPEPT1 transporter than BDCRB 
alone or VACV.  Of the D-amino acid forms that were tested, none of them 
showed enhanced affinity compared to BDCRB itself (which is oddly a good 
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substarte for hPEPT1), and the best prodrug in this series was actually p-ethoxy-
L-Phe-BDCRB (Fig. 1.15).  The latter material possesses a non-standard amino 
acid promoiety, so it could possibly have toxicity issues associated with its 
clinical use.  The second best affinity for hPEPT1 was observed with L-Ile-
BDCRB (Fig. 1.15). 
In later experiments, the in vitro and in vivo stabilities of the amino acid ester 
prodrugs were assayed, and the hPEPT1 affinity studies were expanded to 
functional Caco-2 uptake studies (Lorenzi, Landowski et al. 2005).  In the 
presence of human OGG1 (hOGG1) and murine MPG (mMPG), the glycosidic 
bond of all the BDCRB amino acid esters was significantly more stable than that 
of parent BDCRB.  With the exception of the L-lys and L-Pro prodrugs, the amino 
acid esters were not substrates for the DNA repair enzymes. 
In the enzymatic milieu of mouse liver and intestine homogenates, the 
prodrugs showed N-glycoside metabolic stability that was rate-limited by 
hydrolytic conversion of prodrugs to BDCRB.  Therefore, further evidence was 
observed to suggest a protective role of amino acid ester derivatization on the 
parent drug.   
Functional Caco-2 uptake studies were also conducted to give meaning to the 
original observations made in hPEPT1 affinity assays. The L-Ile prodrug 
performed the best.  However, none of the prodrugs performed as good as 
BDCRB itself, which is oddly enough a good substrate for hPEPT1. 
Tests for antiviral activity and cytotoxicity, when combined with the Caco-2 
cellular uptake studies, hOGG1 and mMPG stability studies, and liver and 
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intestinal homogenate stability studies led to the discovery that the most 
promising ―bioevasive prodrug‖ for pharmacokinetic analysis was L-Asp-BDCRB 
(Fig 1.15).  When dosed in mice by oral gavage, and compared to BDCRB, the 
L-aspartyl prodrug exhibited five-fold enhancement in half-life, which confirmed a 
bioevasive mechanism of N-glycoside protection.  Both the Cmax and AUC of 
BDCRB following dosing with the L-aspartyl prodrug increased by a factor of 
approximately 1.5 as compared to dosing with the parent drug.  Overall, these 
data suggest the potential for increased bioavailability and prolonged delivery of 
BDCRB via the L-Asp-BDCRB prodrug.  It is also worth noting that the free 
carboxylate side chain of aspartic acid is situated in perfect position for a 
kinetically-favored 5-membered cyclization on the ester bond of this prodrug.  
The latter can lead to kinetic instability of the prodrug in various pH environments 
in the body; however, in the case of L-Asp-BDCRB, this appears to be a non-
issue.  To make a direct correlation to the work detailed in this dissertation, the 
aspartic acid prodrug of NTXOL coupled at the 6-OH position was extremely 
unstable (see Chapter 3), and it could not be isolated in pure form.  Clearly, the 
stability of amino acid esters depends just as greatly on the drug moiety as it 
does the promoiety.  These disparate stability profiles are of particular interest to 
medicinal chemists who will design amino acid ester prodrugs of other promising 
drug molecules in the future. 
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Amino acid amide prodrugs of 1-aryl-3,3-dimethyltriazene antitumor agents  
Dacarbazine (Figure 1.16) is an anticancer drug that is typically employed for the 
treatment of malignant melanoma.  It is supplied by IV injection under the 
supervision of a physician.  In the United States, dacarbazine is available as the 
generic, or under the trade name DTIC-Dome®.  The mode of action of 
dacarbazine involves a biotransformation process which dealkylates the 3-N,N-
dimethyltriazene moiety to the monomethyltriazene.  The latter is an alkylating 
agent that can methylate DNA and RNA.  Referring to Figure 1.17, 1-Aryl-3,3-
dimethyltriazenes (1) also possess antitumor activity due to their ability to 
alkylate DNA (Carvalho, Iley et al. 1998, Perry, Carvalho et al. 2009).  Upon 
presentation to cytochrome P450 enzymes, phase I metabolism at the 3-methyl 
position of the triazene moiety results in the formation of a hydroxymethyltriazene 
intermediate (2) that is unstable under aqueous physiological conditions.  
Following the loss of the hydroxyl proton, a molar equivalent of formaldehyde is 
liberated from the molecule with the resultant formation of a molar equivalent of 
the 3-desmethyl triazene (3).   
 
 
Figure 1.16 Structure of dacarbazine. 
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Figure 1.17 Mode of DNA alkylation by 1-aryl-3,3-dimethyltriazenes.  
Adapted from (Perry, Carvalho et al. 2009). 
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Subsequent protonation of the 1-nitrogen of the triazene moiety sets up the 
elimination of an aniline leaving group, and the remaining methanediazonium ion 
alkylates DNA following nucleophilic attack on the methyl group by DNA.  
Nitrogen gas that is liberated in the alkylation step ensures that the reaction is 
entropically driven to completion.   
For the following discussion, refer to Figure 1.18. The CYP450 
biotransformation is not always efficient.  Indeed, dacarbazine is known to suffer 
from poor metabolic conversion of less than 20%. Therefore, along with the 
investigation of new derivatives that lack the imidazole core, prodrug strategies 
have been employed on triazenes in order to afford functional 
monomethyltriazene alkylating agents.  With regard to amino acid promoieties, 
aminoacyltriazenes have shown promise as a means to avoid the oxidation step 
that normally affords the functional therapeutic agents in vivo (Carvalho, Iley et 
al. 1998). 
Kinetics studies of the aminoacyltriazene prodrugs in isotonic phosphate 
buffer (pH 7.7) revealed hydrolysis rates on the order of 26 – 180 minutes when 
the amino acid moiety was not derivatized as an N-acetamide.  Acetylation of the 
amino functional group of alanine in the compound R,R’ = CH3, X = CN led to a 
3.4-fold increase in stability compared to the free amine.  In terms of 80% human 
plasma hydrolysis (pH 7.7), when R = CH3 and X = Br or CH3, the free amine 
prodrugs had 3 – 4 times greater stability than in buffer, suggesting that plasma 
protein binding protected these compounds from enzymatic hydrolysis.   
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Figure 1.18  Bioconversion of aminoacyl-1-aryl-3,3-triazene and 3-[α-
(acylamino)acyl]-1-aryl-3-methyltriazene prodrugs to monomethyltriazene 
alkylating agents.  Adapted from (Carvalho, Iley et al. 1998) and (Perry, 
Carvalho et al. 2009). 
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In the case of the free amine compound R,X = CH3, the magnitude of 
hydrolytic protection was definitely found to depend on the concentration of 
human serum albumin spiked to working isotonic phosphate buffer solutions, 
which supports a plasma protein binding mode of hydrolytic protection.  For the 
most part, the differences in phosphate buffer hydrolysis and plasma hydrolysis 
within this series of compounds were not extreme (i.e. the prodrugs were not 
good substrates for plasma esterases).  However, the free amine compound 
where X = CN and the promoiety was β-alanine showed a 3.4 –fold fatser rate of 
80% human plasma hydrolysis as compared to phosphate buffer, and the N-
acetyl compound where R,R’ = CH3 and X = CN was 15.1 times more stable in 
phosphate buffer than in 80% human plasma.  Therefore, within this series of 
potential antitumor prodrugs, β-alanine and N-acetylalanine proved to be the best 
promoieties, and the N-acetylalanine prodrug had the best bioconversion of all 
prodrugs tested (t1/2 = 41 minutes in human plasma compared to 53 minutes for 
the β-alanine prodrug).  This preliminary work showed that an acylated amino 
acid promoiety was a better substrate for hydrolytic plasma enzymes than the 
natural free amino acid congeners tested.  
 To note some interesting parallels to these findings, the reader is referred to 
Chapter 6 of this dissertation, in which β-alanine was found to be the best 
promoiety to use in order to prepare a prodrug of NTXOL.  Within the NTXOL 
prodrugs series, there was also evidence of possible plasma protein binding that 
protected the valanyl and isoleucinyl prodrugs from enzymatic hydrolysis.  Again, 
it is not possible to determine a priori which molecular features will ultimately 
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result in the best prodrug-like behavior under physiological conditions.  
Therefore, a structure-reactivity study is always called for in prodrug design. 
Following the observation that N-acylation of the amino acid promoiety can 
afford better plasma enzyme targeting, more 3-[α-(acylamino)acyl]-1-aryl-3-
methyltriazenes were also assayed (Perry, Carvalho et al. 2009).  The goal was 
to investigate the utility of these potential prodrugs as compounds that are more 
formulation stable, but still adequately unstable in human plasma to be 
considered prodrugs.   Each of the N-acylated compounds showed kinetics in 
human plasma 3-15 times faster than in buffer, which is in contrast to the free 
amino acid materials from the previous study.  Apparently, the N-acylated 
compounds were substrates for esterase enzymes while the free amino 
compounds were not.  With regard to simple chemical hydrolytic stability in pH 
7.7 buffer, where the X substituent was electron withdrawing (i.e. –CN) the rate 
of hydrolysis was accelerated, and where the R-group of the N-acyl amino acid 
carrier was bulky (i.e. valine), the reaction rate was up to greater than ten times 
slower.  The substitution R’ of the N-acyl moiety contributed significant, but small 
reaction rate effects.  In most cases, the rate enhancement obtained by plasma 
enzymes was good enough to impart prodrug-like character to the compounds, 
regardless of substitution; however, where R,R’,X = CH3, the compound was too 
stable to be a useful prodrug. 
The triazene moiety is an interesting functional group.  When it is acylated, as 
in amino acid prodrugs, an amide is generated.  Normally, amides have very 
different stability characteristics as prodrugs than do esters; however, it has been 
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adequately shown that amino acid amide and N-acyl amino acid amide prodrugs 
of triazenes exhibit stability characteristics that are more characteristic of amino 
acid ester prodrugs (Carvalho, Iley et al. 1993), (Carvalho, Iley et al. 1998), (Iley, 
Ruecroft et al. 1989).  Overall, these compounds show the promise of a 
potentially bright future as possible therapeutic agents in the war on cancer. 
 
Amino acid ester prodrugs of benzocaine 
 
 
 
Figure 1.19 Generation of benzocaine from amino acid amide prodrugs.  
Adapted from (Slojkowska, Krasuska et al. 1982). 
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Benzocaine (Figure 1.19) is a local anesthetic medication that is used in 
multiple over the counter medications in the United States.  As one might expect 
from the structure, benzocaine is very water insoluble.  The water insolubility of 
benzocaine limits its delivery to certain tissues, so an amino acid amide prodrug 
strategy has been investigated to determine if prodrugs of benzocaine may be 
designed as water soluble agents (Slojkowska, Krasuska et al. 1982).  In this 
study, the authors prepared a number of prodrugs using the promoieties glycine, 
alanine, valine, leucine, dimethylglycine, dimethylalanine, and γ-methylglutamic 
acid.  Each prodrug was assayed for hydrolytic rate in the presence of specific rat 
tissues, gastric and duodenal juices, pronase and other purified enzymes, and 
human serum.  As would be expected, the rates of hydrolysis were found to vary 
widely depending on the specific tissue or biological fluid employed due to the 
different expression of enzymes between these various biological media.  
However, important insights can be gleaned from a study this thorough, as most 
prodrug analyses are done with buffer and plasma samples alone. 
Adult male albino rats were sacrificed to obtain homogenates of various 
tissues, and a summary of the results follows.  In rat kidney the leucine prodrug 
hydrolyzed the fastest with approximately 1.3 – 22 times the rate of any other 
prodrug; however, this trend did not hold in liver where the prodrugs were mostly 
similar in their rates of hydrolysis.  Significant, but not dramatic, differences in 
hydrolysis rates were noted in other tissues (i.e. brain, heart, lung, stomach, 
small intestine, spleen, and duodenum) and in plasma, but the differences in rate 
were not higher than a factor of about 2 in most cases.  Indeed, for all the 
64 
 
prodrugs, the rate of hydrolysis in kidney was much enhanced compared to the 
other tissues (1.72±0.02 – 38.17±0.98 nmol/min per mg of protein). 
The prodrugs were fairly stable in duodenal juice.  There was no degradation 
of any prodrug in gastric juice or in the presence of pepsin, trypsin, and 
chymotrypsin.  However, pronase hydrolyzed the prodrugs remarkably faster 
than any of the tissue homogenates (340±50 – 19,900± 800 nmol/min per mg 
protein).  In this case, the valine and alanine prodrugs were the best substrates 
for pronase.  Alanylbenzocaine also showed the fastest rate of conversion to 
parent benzocaine in human serum while valylbenzocaine was only one third as 
rapid in conversion to the parent drug.  The leucine, valine, alanine, and γ-
methlyglutamic acid prdrugs all showed similar rates of hydrolysis in rat muscle 
homogenates which could be of potential therapeutic value (21 – 67 pmol/min 
per mg of protein).  Leucinylbenzocaine exhibited the fastest muscular tissue 
release of benzocaine.  Dimethylglycylbenzocaine was not a very good substrate 
for the enzymatic conditions in any case other than pronase, but 
dimethylalanylbenzocaine was the best substrate for enzymatic conversion in the 
lungs.  Again, the theme is noted that structure means everything in prodrugs 
design, and that it is not possible to determine without thorough study which 
promoieties will result in the best prodrugs between different parent drugs and 
different target sites of delivery. 
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Amino acid esters of Quercetin 
Quercetin is one of a number of plant polyphenols implicated in an antioxidant 
protective role against cellular reactive oxygen and reactive nitrogen oxide 
species.  One major problem with polyphenols is their poor bioavailability which 
results from phase II metabolism by enterocytic transferases.  In order to 
maintain intestinal absorption and solubility while simultaneously exploring the 
ability of prodrugs to avoid phase II conversion, amino acid esters of quercetin 
have been prepared and assayed (Biasutto, Marotta et al. 2007).  Referring to 
Firgure 1.20, the 3’-position of quercetin was selected for amino acid ester 
derivitization; however, the authors note that some 4’-substitution was 
unavoidable, and the two acylated products could not be separated.  
Nonetheless, stability studies were conducted on the compounds in order to find 
suitable substrates for MDCK-1, MDCK-2, and Caco-2 transport studies.   
As might be expected, the unprotected amino acid ester salts were too 
unstable for transport studies at pH values that would support cell function 
(except for where X = -Ph-).  This was observed regardless of the substitution on 
the remaining phenolic hydroxyl groups of quercetin (R = H or COCH3).  Also, the 
Boc-protected amino acid esters of quercetin that had unacylated phenol groups 
were rapidly degraded in buffer.  These compounds all showed hydrolysis half 
lives on the order of (0.07 – 119) x 10-2 s!  Only Boc-protected amino acid esters 
with fully acylated phenols on quercetin proved to be stable enough for the 
transport studies, as would be expected for phenolic amino acid esters that are 
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known to be unstable (see Chapter 6 on amino acid esters of 3-O-NTX for 
further evidence of instability of phenolic esters).   
 
 
 
Figure 1.20 Generation of quercetin from quercetin prodrugs in 1:1 
PBS/CH3CN.  Adapted from (Biasutto, Marotta et al. 2007). 
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  Of the compounds found to be stable enough for cellular transport studies, 
only those with R = COCH3 and X = -CH(CH3)-, -(CH2)3-, or –(CH2)5- were more 
soluble in Hank’s salt buffer than quercetin itself, so these prodrugs were 
examined for phase II conversions in cellular media.  The fully acetylated 3’-O-
Boc-alanyl quercetin prodrug was found to contain 4.2% more quercetin on the 
basolateral side of Caco-2 monolayers compared to 1.0% that was observed 
following transport of quercetin itself.  The Boc-γ-aminobutryic acid prodrug and 
the X = -(CH2)5- homologue (both fully acetylated) showed less phase II 
protection in Caco-2 cells in terms of basolateral quercetin observed after 6 
hours (2.6 & 2.5% respectively).  Quercetin sulfate and quercetin methylsulfate 
were significantly reduced in every case.  In MDCK-1 and MDCK-2 cells, the 
basolateral concentrations of quercetin from apically loaded prodrugs were 
generally less than that observed from apically loaded quercetin; however, 
significant concentrations of diacetylated and monoacetylated quercetins were 
found in the basolateral compartment after 6 hours, and it is to be assumed that 
the prodrug intermediates would further degrade to quercetin over time.  Indeed, 
they may represent slow-release forms of the parent drug in these cell lines.  
Also, in the MDCK-1 and MDCK-2 cell lines where mono- and diacetylated 
quercetins were observed, no phase II quercetin sulfate and quercetin 
methylsulfate was detected.  Overall, these data suggest that esterification of 
polyphenols with Boc-amino acids and acetate blocking groups can lead to 
improved bioavailability by protecting phenols from phase II conjugation during 
enterocytic translocation. 
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Amino acid esters of metronidazole 
Metronidazole is an antimicrobial agent that is often used to treat anaerobic 
bacterial infections.  The drug is marketed in the United States under numerous 
trade names (i.e. Flagyl®) and as generic as well.  In terms of formulations, the 
drug is supplied orally, as a lotion, as a vaginal gel, and in intravenous 
applications.  It is dosed either as free base or as the hydrochloride salt, 
depending on the particular delivery form.   
  
 
Figure 1.21 Generation of metronidazole from amino acid ester prodrugs 
under physiological conditions.  Adapted from (Bundgaard, Larsen et al. 
1984). 
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In the early days of amino acid ester prodrug design, Bundgaard and others 
looked at metronidazole as a potential drug for prodrug development, because 
intravenous delivery of the drug was hampered by poor aqueous solubility 
(roughly 1% w/v @ 25°C).  Indeed, parenteral injection of the compound was not 
possible at the time, and only large volume infusions were available (Bundgaard, 
Larsen et al. 1984).  Referring to Figure 1.21, it can be seen that Bundgaard et 
al. chose to use amino acid residues, with the exception of glycine, that are not 
members of the 20 endogenous examples.  To a large extent, this was done for 
basic structure-reactivity analysis, and to avoid protecting group chemistry.  At 
the time, little work had been done with amino acid prodrugs, and this is one of 
the pioneer works in the area. 
The results obtained are very interesting.  All of the compounds were 
hydrochloride end products with solubilities > 20% w/v at 20°C; however, the 
N,N-dimethylglycinate prodrug had the best combination of solubility (> 50% w/v 
@ 20°C) and pH 7.4 stability (250 min) with a rapid hydrolytic conversion to 
metronidazole in 80% human plasma (12 min).  For the remainder of the 
prodrugs, these values varied by a large degree.   
For instance, removal of the protonated amino group away from the ester 
carbonyl by one methylene unit, as in the dimethylaminopropionate prodrug, 
actually resulted in one fifth the pH 7.4 stability, but a nearly 4-fold increase in 
plasma stability as compared to the dimethylglycinate prodrug.  In buffer alone, 
this is a bit counterintuitive.  At pH 7.4, the dimethylamino moiety in both the 
dimethylglycinate and the dimethylaminopropionate (pKa ~ 9) prodrugs is 
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protonated like other amino acids, and one would expect a methylene spacer to 
diminish the electron withdrawing effect at the carbonyl of the ester, which would 
impart greater stability.  Indeed, the pH 7.4 stability data of the primary amine 
prodrugs, glycinate and aminopropionate, were 115 min and 315 min 
respectively, accounting for a 2.7-fold increase in stability by comparison.  One 
could posit a sterics argument here and suggest that the greater degrees of 
freedom obtained from moving the bulky methyl groups away from the center of 
nucleophilic attack in dimethylaminopropionate afforded accelerated access to 
the electrophilic carbon as compared to the dimethylglycinate prodrug.  No 
matter the case, this is another example of why prodrugs have to be carefully 
assayed for their behavior under physiological conditions in order to find the best 
balance of stability and physiochemical properties. 
The other prodrugs were either too stable in plasma or too unstable in buffer 
to be considered for further study.  However, the 4-morpholinoacetate prodrug 
could be considered a promising candidate with only 2.5-fold greater stability 
than the dimethylglycinate prodrug in 80% human plasma (t1/2 = 30 min vs. 12 
min) and approximately 7.5-fold greater stability at pH 7.4.  Nonetheless, 
metronidazole dimethylglycinate (MDMG) was found to be the best prodrug in 
this work. 
MDMG hydrolysis kinetics studies in 80% plasma samples prepared from 
dog, rat, mouse, rabbit, and guinea pig revealed large differences in interspecies 
hydrolysis rates (t1/2 = 1.9 min – 25 min) which is to be expected given the 
difference in genetics between these species.  More importantly, this suggests 
71 
 
that a prodrug intended for human use should be assayed for hydrolysis kinetics 
in human plasma. 
In a follow up cross-over study using two beagle dogs, metronidazole and 
MDMG were administered by IV injection in order to examine the in vivo prodrug 
behavior of MDMG as an injectable dosage form (Bundgaard, Larsen et al. 
1984).  The half-lives of MDMG in the two dogs were 3 and 7 minutes compared 
to 25 minutes in 80% dog plasma.  MDMG was quantitatively converted to 
metronidazole within 37 minutes, and the metabolism and elimination profiles for 
metronidazole were similar whether dosed as parent drug or as prodrug.  These 
data taken together suggest that MDMG could be a potential intravenous prodrug 
of metronidazole with greater than 50-fold increased solubility over parent drug. 
In vitro antimicrobial activities of metronidazole esters containing glycine (R = 
CH2NH2), phenyalanine (R = CH-(CH2Ph)-NH2), leucine (R = CH-(CH2 (CH3)2)-
NH2), and glycine-glycine (R = CH2NHCOCH2NH2) spacers bound to a dextran 
carrier moiety have been conducted using Trichomonas vaginalis in Kupferberg 
medium (Vermeersch, Remon et al. 1990).  The phenylalanyl metronidazole 
ester (M-Phe) and the leucinyl metronidazole ester (M-Leu) were found to exhibit 
similar behaviors to parent drug in terms of end point viability (in hours) of T. 
vaginalis at drug concentrations equivalent to 1-30 µg/mL metronidazole.  
However, it is interesting to note that 4 hours was the end point of viability for all 
of the prodrugs and metronidazole at 30 µg/mL concentration, but the M-Gly and 
M-GlyGly prodrugs showed twice the time to inhibit cell growth at 10 and 20 
µg/mL concentrations.  Since the half lives of the prodrugs were very similar, it is 
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tempting to assume that the cell growth was stopped by evolved metronidazole; 
however, the M-GlyGly ester degraded at roughly twice the rate of the other 
prodrugs with the evolution of a diketopiperazine (as expected).  These data are 
also complicated by the fact that several kinetic phenomena are involved in the 
end result.  For instance, the diffusion of metronidazole into the trichomonad cells 
is one variable.  Increase in the number of viable cells that can absorb drug over 
time is also a variable.  Diffusion of prodrug into the cells is yet a third variable.  
Cellular-level hydrolysis of the prodrugs supplies another variable. Culture 
medium level hydrolysis of the prodrugs over time is a fourth variable (pH ~ 6).  
Finally, whether or not the diketopiperazine of the GlyGly moiety is also cytotoxic 
is a variable too.  Clearly, one must proceed with caution in the interpretation of 
these data.  It appears as though the two most lipophilic prodrugs may have 
permeated the cells in a similar fashion to metronidazole, while the M-Gly and M-
GlyGly compounds did not.  However, it cannot be concluded that the prodrugs 
were actually converted to free metronidazole inside the cells in the manner that 
this study was done, and the authors note that the mode of action of 
metronidazole is mainly due to an enzymatic reduction of the nitro group and the 
access of the nitro group to electron transport proteins in the microbial cell.  
Since this blocking strategy only serves to enhance water solubility for improved 
metronidazole delivery, and the nitro group is free, it is just as likely that the 
prodrugs have intrinsic antimicrobial activity as it is that the end points of viability 
were caused by metronidazole itself.  Clearly, a more thorough investigation 
would be needed to sort out the shortcomings of this experimental design. 
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Amino acid prodrugs of sulfonamides  
Prodrugs of carbonic anhydrase inhibitors (CAIs) were examined several 
decades ago before the advent of ophthalmic solutions like Trusopt® 
(dorzolamide, FDA approved in 1994) and Azopt® (brinzolamide, FDA approved 
in 1998).  The CAIs originally were dosed in an oral or parenteral fashion, and 
they showed little utility in topical eye delivery for the treatment of glaucoma.  As 
part of a program to investigate the potential of amino acid conjugated 
sulfonamides as prodrugs, the model compound N-methyl-p-toluenesulfonamide 
was exploited as a sulfonamide material for in vitro stability studies (Larsen, 
Bundgaard et al. 1988).  
The substituted sulfonamide amine moiety as depicted in Figure 1.22 is a 
dual prodrug design.  The aminoacyl portion is degraded by simple chemical or 
enzyme-assisted hydrolysis to liberate the N-methylsulfonamide and a molar 
equivalent of the amino acid promoeity.  Then the N-methylsulfonamide is 
expected to undergo demethylation in the biophase to release the parent 
sulfonamide (Maren 1956, Duffel, Ing et al. 1986).   
The aminoacyl carrier instills hydrophilicity to the molecule that increases 
aqueous solubility in the ionized form.  Otherwise, when unionized, lipophilicity of 
the compound is improved over the primary amine form.  The methyl group also 
increases lipophilicity.  These physiochemical properties in unison were thought 
to be a reasonable approach to improve permeation of the cornea for intraocular 
delivery which would in turn have possible therapeutic use in the treatment of 
glaucoma. 
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Figure 1.22 Generation of sulfonamides from N-methyl-N-
aminoacylsulfonamide carriers.  Adapted from (Larsen, Bundgaard et al. 
1988). 
 
The diethylglycine prodrug had a half-life at pH 4.0 of 4.3 days and 3.2 hours 
at pH 7.4.  80% human plasma enzymes cleaved the prodrug 3.2-fold faster than 
pH 7.4 buffer (t1/2 = 1.0 h), indicating that the compound was a substrate for 
esterase enzymes.  The 4-morpholinoacetate prodrug was much more stable, 
and unlikely to be a good prodrug candidate owing to its 6.8 hour half-life in 80% 
human plasma.  Of course, since these prodrugs were intended for intraocular 
delivery, hydrolysis rates in aqueous humor would be of particular interest as 
well, and these values were not obtained in the study.  Apparently, there was 
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also no follow up animal work to determine if these prodrugs actually improve 
corneal permeation over parent drug, and the authors note that the stability 
characteristics of these compounds, much like other amino acid-based prodrugs, 
warrant the possible need to use polymeric matrices or ophthalmic rods in order 
to achieve a formulation with a good shelf-life. 
   
Amino acid prodrugs of saquinavir, indinavir, and nelfinavir  
 Saquinavir (Saq), indinavir (Ind), and nelfinavir (Nelf) are HIV protease 
inhibitors that are used in combination with HIV reverse transcriptase inhibitors.  
Saquinavir currently comes in two dosage forms.  Invirase® is the mesylate salt, 
and it is supplied as a capsule or tablet and in different strengths depending on 
the prescription.  Ritonavir (Norvir®) is often added to Invirase to improve its 
bioavailability.  Another formulation of saquinavir (Fortovase®) has been 
discontinued.  Indinavir (Crixivan®) is indinavir sulfate, and it comes as a capsule 
form in various strengths.  Viracept® (nelfinavir mesylate) comes in several 
approved dosage forms (powder and tablet) of various strengths, and it is also 
taken orally.  Any of the three drugs can be used in HAART (highly active 
retroviral therapy) as a means to battle HIV infection and AIDS.  However, these 
compounds suffer from some pharmacokinetic shortcomings that limit their utility 
for absolute management of the HIV virus.  For instance, viral replication has 
been observed to continue in the presence of these therapies, and the 
polytherapy regimens that include them, because poor penetration into the CNS 
and the lymphatic system allows a ―sanctuary‖ reservoir for the HIV virus to be 
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established.  Otherwise, resistance issues associated with the HIV virus also 
come into play.  These problems are summarized in the references listed below.  
It has been suggested that a prodrug approach may afford a solution to the 
CNS permeation problem.  To approach this hypothesis, amino acid prodrugs 
have been synthesized and evaluated for their chemical stability, antiviral activity, 
Caco-2 cell transport, and P-gp transport. (Farese-Di, Rouquayrol et al. 2000, 
Rouquayrol, Gaucher et al. 2002, Gaucher, Rouquayrol et al. 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.23 Synthesis of amino acid esters of saquinavir and indinavir.  
Adapted from (Gaucher, Rouquayrol et al. 2004). 
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Figure 1.24 Synthesis of tyrosinyl derivative carbonates and 
carbamates of saquinavir, indinavir, and nelfinavir with spacer linkers nCH2 
= 1-4.  Adapted from (Gaucher, Rouquayrol et al. 2004). 
 
The amino acid esters (Fig. 1.23) hydrolysis studies were conducted in buffer 
at pH 7.3 and 37 °C.  The Phe and Leu esters had the shortest half-lives ( t1/2 ≤ 
4h) while Val esters exhibited up to 68h half-lives.  In regard to esters containing 
the tyrosine derivative side chains (Figure 1.24), half-life values ranged from 1.5 
– 60h.  The n=1 homologues were far more labile to hydrolysis than were n=4 
longer chain homologues.  The carbamate prodrugs with tyrosine derivative side 
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chains were very stable with half lives longer than 7 days (Gaucher, Rouquayrol 
et al. 2004)!  The tyrosinyl side chain design in this work was intended to target 
the amino acid transporter system of the blood brain barrier, which is known to 
actively transport tyrosine and tyrosinyl compounds (Walker, Nicholls et al. 
1994).   
Transport of the prodrugs in the apical-to-basolateral (AP to BL) and 
basolateral-to-apical (BL to AP) directions was carried out to determine the best 
candidates for active transport in the small intestine.  The AP to BL transport 
relies on substrate recognition by hPEPT1 while the BL to AP transport relies on 
P-gp substrate recognition.  A proper prodrug candidate should increase the 
transport of parent drug in the AP to BL direction, either by better carrier-
mediated transport via hPEPT1, by worse transport by P-gp, or by a combination 
of the two transport events (Rouquayrol, Gaucher et al. 2002).  
Using Caco-2 cell monolayers 14-27 days post-seeding, the parent drugs 
were found to favor BL to AP transport approximately 3 to 15 times better than 
AP to BL transport based on apparent permeability coefficients and percent of 
drug in the receiver reservoir.  These data indicate that P-gp substrate 
recognition is high in the case of all three parent drugs, which limits bioavailability 
and, quite likely, blood brain barrier permeation.  Significantly imporved transport 
in the AP to BL direction of approximately 3 to 6-fold was observed for the L-Val, 
L-Phe, and L-leu prodrugs of Ind and Saq.  Also, compared to parent drug, efflux 
was approximately one half for the Ind amino acid prodrugs.  However, it is 
important to note that BL to AP transport was still significantly higher for these 
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prodrugs compared to their AP to BL transport, and over time, the Saq prodrugs 
in particular were susceptible to hydrolysis.  Saq-Phe also had greater transport 
in both directions compared to Saq, which suggests a passive diffusion 
enhancement from the lipophilic Phe moiety.  Still, these data indicate that better 
systemic exposure is probably possible through the amino acid prodrug strategy 
on Saq and Ind.  Unfortunately, the perfectly rational design of the tyrosinyl side 
chains to target amino acid transporters appears to have failed.  In all cases, this 
derivatization resulted in a loss of transport in both directions.  Only the Ind(14)-
C(O)C1Tyr prodrug could be detected in the receiver chamber, and it exhibited 
less than half the transport of Ind in the absorptive direction and about 9 times 
less transport in the secretory direction (Rouquayrol, Gaucher et al. 2002).    
 
Concluding Remarks 
An extensive literature regarding the design and testing of amino acid 
prodrugs has been presented.  The overarching theme throughout many studies 
is that amino acid prodrug design can result in substantial improvements in drug 
delivery, depending on the drug in question and its target location.  Also, the 
necessity for appropriate stability studies has been illustrated.  For the purposes 
of our study, the amino acid ester design was chosen as a water-solubilizing 
modification for MNTD, and the approach is much like that used by Bundgaard 
and others to enhance water solubility of metronidazole for parenteral delivery.   
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1.9 PTD prodrug design to treat alcoholism 
 
 
ACE-ESTER 
 
ME-CARBONATE      
    
PIV-ESTER 
 
PORP-ESTER 
 
ETH-CARBONATE 
 
ISOVAL-ESTER 
 
BUT-ESTER 
 
PROP-CARBONATE 
 
ETBUT-ESTER 
 
VAL-ESTER 
 
BUT-CARBONATE 
 
ISOBUTYRL-ESTER 
 
HEX-ESTER 
 
PENT-CARBONATE 
 
ISOPROP-CARBONATE 
 
HEP-ESTER 
 
ISOPROP-CARBONATE 
 
t-BUT-CARBONATE 
 
 
Figure 1.25 Straight-chain and branched-chain alkyl esters of NTX for PTD.  
Adapted from (Stinchcomb, Swaan et al. 2002, Pillai, Hamad et al. 2004, 
Vaddi, Hamad et al. 2005). 
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This section discusses the history of the transdermal NTX and NTXOL 
prodrugs project as it relates to passive transdermal delivery (PTD), and MNTD 
delivery is discussed as the final entry to this introductory chapter. 
Figure 1.25 shows the structures of the straight-chain and branched-chain alkyl 
esters and carbonates that were prepared and tested (Stinchcomb, Swaan et al. 
2002, Pillai, Hamad et al. 2004, Vaddi, Hamad et al. 2005).    
In this PTD paradigm, the straight-chain alkyl ester prodrugs of NTX and NTX 
base were dissolved in light mineral oil, and human skin diffusion studies were 
carried out (Stinchcomb, Swaan et al. 2002).  Prodrugs showed increased flux 
compared to NTX base, with the exception of the BUT-ESTER compound.  ACE-
ESTER, PROP-ESTER, and HEX-ESTER gave the best flux-enhancement 
compared to NTX base.  All of the prodrugs were found to extensively bioconvert 
to parent NTX during a diffusion experiment, which resulted in rapid systemic 
delivery of NTX after the SC permeation event.  ACE-ESTER showed the best 
mean molar percentage of regenerated NTX to total drug extracted from the skin 
(91%) out of the six esters studied.  Prodrug stability in buffer was not assayed in 
this study.  
ACE, PROP, and HEX esters were also formulated into PTD patches and 
applied to the dorsal region of hairless guinea pigs.  In vivo evaluation of plasma 
NTX, NTXOL and prodrug levels was carried out using LC-MS (Valiveti, Hammell 
et al. 2005).  All of the prodrugs rapidly cleaved to form parent drug in the plasma 
following i.v. dosing, and sustained levels of NTXOL were observed throughout 
all bolus experiments.  The transdermal delivery experiments revealed several 
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critical observations.  ACE-ESTER delivered greater amounts of NTX 
systemically to guinea pigs compared to NTX base, PROP-ESTER and HEX-
ESTER.  During 48 hours of PTD the greatest Cmax, Css, AUC0-48, and 
enhancement factor measurements were observed with ACE-ESTER formulated 
patches.  These data indicate that higher plasma levels of NTX are achieved 
over 48 hours of patch placement, and that greater steady state concentrations 
of NTX can be delivered systemically by ACE-ESTER as compared to NTX base 
and the other two straight-chain alkyl ester prodrugs.  Trace amounts of NTXOL 
and prodrug were recovered in some plasma samples, but these levels had no 
significant impact on total drug plasma concentrations.  Also, fold-enhancement 
factors of flux were similar in these in vivo studies as compared to in vitro human 
skin diffusion data which suggests that the hairless guinea pig is an appropriate 
animal model for in vitro-in vivo comparison of transdermal NTX prodrugs.  
A follow up in vitro study of the straight-chain promoiety theme was 
undertaken with modification of the linker from an ester design to a carbonate 
design (Pillai, Hamad et al. 2004).  In the straight-chain carbonate series, pH 7.4 
stabilities ranged from 73 to 315 hours in the usual manner one would expect 
based on alkyl chain length.  Every prodrug showed evidence of bioconversion in 
the skin during diffusion experiments; however, the amount of intact prodrug 
found in the receiver compartment at the end of diffusion experiments ranged 
from 11-51%.  This is in contrast to the trace amounts of intact prodrug found in 
receiver solutions in the straight-chain ester series.  It is especially noteworthy 
that straight-chain esters showed better flux behaviors compared to their 
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carbonate cohorts.  Therefore, further evidence was accumulated to suggest that 
the rate of skin transport to the systemic circulation following SC permeation is 
partly dependent on the rate of bioconversion of lipophilic prodrug to the more 
hydrophilic parent NTX.  Skin disposition studies corroborated these findings 
since more NTX was extracted from skin samples in the alkyl ester series than 
the carbonate series.  ME-CARBONATE (named ME-NTX in the original paper) 
was the only prodrug in this series that showed statistically significant increases 
in transdermal flux compared to NTX control, and it also was responsible for the 
greatest concentration of NTX extracted from skin in the drug disposition studies 
that were conducted following diffusion experiments.  These date collectively 
suggest that short straight-chain alkyl esters outperform higher alkyl homologues 
or their carbonate counterparts in in vitro PTD transport studies.  
Branched-chain alkyl esters and carbonates of NTX have also been prepared 
and analyzed for physiochemical characteristics and human in vitro skin diffusion 
behaviors (Vaddi, Hamad et al. 2005).  These studies were done for direct 
comparison with the straight-chain cousins reviewed above.  Overall, it was 
observed that chain branching affords no particular advantage in PTD of NTX 
esters or carbonates, although increased stability in aqueous media (enzymatic 
and non-enzymatic) was an outcome of the design.  Decreased skin permeability 
coefficients were observed along with lower transdermal flux rates.  Also, the skin 
bioconversion rates suffered as compared to compounds designed with straight-
chain promoieties.  The latter effect of the branched-chain structural modification 
on the promoiety likely contributed greatly to reduced transdermal flux rates, 
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which provides further evidence for the role of prodrug bioconversion in viable 
skin tissue as a contributing factor in parent drug delivery rate enhancement.   
None of these prodrugs significantly outperformed NTX base in terms of 
transdermal flux.  
Bioconversion rates of VAL-ESTER and ETBUT-ESTER prodrugs were 
compared between a human skin epidermis models and fresh human skin 
surgical waste samples (Hammell, Stolarczyk et al. 2005).  This study also 
characterized the metabolic formation of NTXOL from NTX in the human 
epidermis models and fresh surgical waste samples.    
Metabolic conversion of NTX to NTXOL in human waste skin was not 
significantly different than that observed in intact EpiDermTM  human skin 
equivalent.  Disposition studies showed that the same behavior was also 
observed in extracted skin samples following diffusion experiments.   Flux and 
bioconversion data were comparable between the human skin samples and the 
human skin models.  VAL-ESTER was again established as a more appropriate 
prodrug than ETBUT-ESTER.  Compared to human skin samples, VAL-ESTER 
flux data were some 30-fold higher in EpiDerm 606 as measured in NTX 
equivalents (NTX + Prodrug in receiver); however, the percent of NTX found in 
receiver solution and the fold-increase of flux enhancement was comparable to 
human skin.  Disposition data were also comparable in human skin and human 
skin model for both prodrugs.  These data suggest that the Epiderm human skin 
models can be predictive substitutes for actual human skin if one takes care not 
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to overestimate rate data.  In the absence of available human skin surgical waste 
samples, these models may be useful for PTD studies. 
 
 1.10 MNTD prodrug design to treat alcoholism  
Previously in our labs, various pegylated 3-O-carboxylate and 3-O-carbamate 
ester prodrugs of NTX (Fig. 1.26) were prepared and tested (Yerramreddy, 
Milewski et al. 2010). All of the prodrugs demonstrated adequate stability at pH 
5.0 to be considered candidates for skin diffusion studies.  Also, the prodrugs 
had pH 7.4 stability profiles that suggested rapid conversion of prodrug to parent 
drug at physiological pH.  Prodrug solubilities in 0.3 M acetate buffer (pH 5.0) 
were typically 2-fold or 3-fold higher compared to NTX.  However, the 
carboxylate ester prodrug where R = H (YTR-NTX-20) was advanced to skin 
diffusion studies, and it was found that micro-channel fluxes of the prodrug were 
not superior to NTX at any concentration (Milewski, Yerramreddy et al. 2010).  A 
more thorough review of the latter study is given in Section 1.12 on MNTD.  
Apparently, the large increases in donor vehicle viscosity resulting from saturated 
solutions of the pegylated prodrug were sufficient to retard prodrug traversal of 
aqueous microchannels, regardless of increased water-solubility over NTX.   
It is particularly interesting to note that the YTR series of pegylated prodrugs 
in Fig. 1.26 all share a common diethylene glycol (DEG) arrangement of atoms 
on the pro-moieties.  The viscosity of diethylene glycol itself is roughly 36 times 
that of pure water at 20 °C (ME Global 2005).   The exact concentration-
dependent viscosities (n=3) of YTR-NTX-20 in 0.3 M acetate donor vehicle at 
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32°C were measured, and it was found that the average viscosity of 0.3 M 
acetate donor with no prodrug present was 0.83 cP.  However, at 952 mM, YTR-
NTX-20 concentration in the same vehicle, ƞ avg = 6.35 cP, a nearly 8-fold 
increase in donor viscosity was observed (data unpublished).   
 
 
 
Figure 1.26 Novel Pegylated 3-O-carboxylate and 3-O-carbamate prodrugs 
of NTX.  Adapted from (Yerramreddy, Milewski et al. 2010). 
 
As a general defense of the amino acid ester prodrug design detailed in the 
current body of work, it is not possible to predict a priori what viscosity behaviors 
can be expected for non-pegylated prodrugs.  One study of amino acid 
viscosities in water and MgCl2 solution is of particular value in analyzing inherent 
viscosity properties of Gly, Ala, and Leu promoieties (Lark, Patyar et al. 2007).   
The data are presented in Table 1.1, where [mM]water refers to the concentration 
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of amino acid in pure water and [mM]electrolyte denotes amino acid concentration in 
50.1 mM MgCl2.  The ƞ -values are expressed as relative viscosities of amino 
acid solutions compared to blank solvent at 35°C.   
 
Amino 
Acid 
 
[mM]wate
r 
Ƞwater 
(cP) 
[mM]electroly
te 
Ƞelectrolyte 
(cP) 
Glycine 420.1 1.062 492.7 1.074 
L-Alanine 484.8 1.123 493.5 1.128 
L-Leucine 96.5 1.046 95.9 1.044 
 
Table 1.1 Viscosity of amino acids (35°C).  Adapted from (Lark, Patyar et al. 
2007). 
 
1.11 Codrugs 
The bulk of the present study was focused on synthesis and stability studies of 
NXT and NTXOL amino acid ester prodrugs for MNTD.  Only one prodrug that 
was prepared and assayed in this work can be classified as a codrug (CYT-
NTX).  Due to space limitations, the following section will only cover commercial 
codrugs, and those codrugs that have previously been explored in transdermal 
delivery efforts within our labs.  The reader should access the recent book 
chapter by Crooks, et al. for a detailed discussion of other codrugs and their 
utility in various drug delivery situations (Crooks, Dhooper et al. 2011).  Other 
reviews have also been noted in Section 1.7.  A discussion about the defining 
features of codrugs was also given above in Section 1.7. 
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Figure 1.27 Marketed Codrugs.  Adapted from (Baltzer, Binderup et al. 1980, 
Peppercorn 1984, Crooks, Dhooper et al. 2011). 
 
Sultamicillin (SA, Unasyn®, Fig 1.27) is a codrug comprised of the antibiotic 
ampicillin (AMP) and the β-lactamase inhibitor penicillanic acid sulfone (PAS).  
This successful codrug (or mutual prodrug) design was approached by Baltzer et 
al. (Baltzer, Binderup et al. 1980), because AMP and PAS exhibit the following 
features: (1) poor oral absorption; (2) similar volumes of distribution and 
elimination rates; (3) appropriate 1:1 optimal synergy, and (4) PAS prevents 
bacterial β-lactamase from hydrolyzing the β-lactam ring of ampicillin, which 
would render it inactive.  Under challenge in various enzymatic media, SA 
showed desirous instability with a half life range on the order of approximately 
one to nine minutes.  The codrug is a tripartite species that releases the two 
parent carboxylic acids and a molar equivalent of formaldehyde upon hydrolysis.  
In healthy human volunteers, the codrug was found to be well absorbed and 
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rapidly bioconverted to the two parent drugs with symmetric plasma 
concentration profiles that indicated 1:1 drug delivery.  These are the ideal 
behaviors that a codrug should possess, and SA has made it all the way to the 
clinic as a result of this mutual prodrug design effort.   
Sulfasalazine (SASP, Azulfidine®, Fig. 1.27) is a marketed codrug of 
sulfapyridine (SP) and 5-aminosalicylic acid (5-ASA, mesalamine, Lialda®).  The 
codrug is used in the treatment of ulcerative colitis (Peppercorn 1984).  Bacterial 
enzymes cleave the azo bond in the colon which results in the release of the two 
therapeutic agents (Das, Eastwood et al. 1973, Das, Chowdhury et al. 1979).  5-
ASA is an anti-inflammatory agent while the SP moiety has antibacterial 
properties.  The advantages and drawbacks of the SASP design were discussed 
above in the amino acid prodrugs section entitled Amino acid prodrugs of 5-
aminosalacylic acid for colonic delivery.  Though SASP is a marketed codrug, 
some patients suffer from hypersensitivity to the SP moiety when it is released as 
free drug (Das, Eastwood et al. 1973, Taffet and Das 1983, Peppercorn 1984).  
Therefore, amino acid prodrugs of 5-ASA have also been prepared and tested 
(Pellicciari, Garzon-Aburbeh et al. 1993).  Nonetheless, the SASP codrug design 
avoids pre-colonic absorption and elimination of 5-ASA, and the codrug also 
affords the advantage of colonic delivery of an anti-inflammatory agent and an 
antibacterial agent simultaneously.   These features have rendered SASP a 
successful clinical agent for many years.      
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Benorylate is another example of a marketed codrug compound; however, it 
is not available in the USA.  The codrug is a bipartate ester conjugate of 
acetylsalicylic acid (aspirin) and paracetamol (acetaminophen).  The mutual 
prodrug is rapidly cleaved systemically such that oral dosing in man results in 
plasma detection of only the parent drugs (Robertson, Glynn et al. 1972).  
Another attractive feature of this drug design is that the ester formed from 
conjugation masks the free carboxylic acid that is present when aspirin is dosed 
alone.  Free carboxylic acids are suspect as the cause of gastric irritation that 
accompanies NSAID therapy.  In turn, the latter side effect limits the therapeutic 
utility of NSAIDs (Mahdi and Alsaad 2012).  Benorylate is an effective analgesic 
and anti-inflammatory agent for use in the treatment of rheumatoid arthritis.  
Indeed, it has been shown that its analgesia and its anti-inflammatory properties 
are similar to aspirin and paracetamol (Beales, Burry et al. 1972).  However, one 
limitation of the drug is that it does not demonstrate superior antipyretic effects 
compared to a physical mixture of aspirin and acetaminophen in children 
between 4 months and 12 years of age (Simila, Keinanen et al. 1975). 
 
PTD Codrugs of NTX, bupropion and hydroxybupropion for alcohol abuse 
or alcohol-tobacco co-abuse 
The codrugs in Figure 1.28 have been prepared and tested in a PTD 
paradigm.  The original idea surrounding this research is well-founded in that 
alcohol and tobacco co-abuse is a pervasive problem (Mello, Mendelson et al. 
1987, Frosch, Shoptaw et al. 2000).  During the course of research efforts to 
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prepare codrugs of bupropion and hydroxybupropion with NTX and NTXOL, the 
three compounds in Figure 1.28 were afforded for study (Hamad, Kiptoo et al. 
2006).  Each molecule is conjugated by a carbonate linker. 
Bupropion (BUP) is FDA-approved as a smoking cessation agent, and it has 
been shown to permeate human skin at rates sufficient to achieve therapeutic 
PTD (Kiptoo, Paudel et al. 2009).  On the other hand, hydroxybupropion 
(BUPOH), an active metabolite of BUP, was found to need modification to a butyl 
carbamate prodrug in order to achieve acceptable transdermal flux rates (Kiptoo, 
Paudel et al. 2009).  These observations taken together suggest that BUP and                               
BUPOH could possibly improve the poor PTD profiles of NTX and NTXOL if 
lipophilic codrugs containing them were designed and synthesized.  Furthermore, 
such codrugs could be of great clinical utility in the treatment of comorbid alcohol 
and tobacco abuse. 
Although BUP is effective as a PTD agent, it is extremely unstable in the free 
base form required for PTD formulation.  Furthermore, attempts to conjugate 
BUP to NTX or NTXOL by phosgenation chemistry failed due to rapid 
intramolecular cyclization to a product with no available handle for acylation.  On 
the other hand, reaction of BUPOH with phosgene in toluene resulted in a 
BUPOH carbamate intermediate with a free terminal hydroxyl group available for 
further acylation chemistry.  Reaction of the cyclized BUPOH intermediate first 
with phosgene, and then with NTX or NTXOL in the presence of triethylamine 
afforded CB-NTX-BUPOH and CB-NTXOL-BUPOH respectively.   
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Figure 1.28 PTD codrugs for alcohol abuse or alcohol-tobacco co-abuse.  
Adapted from (Hammell, Hamad et al. 2004, Hamad, Kiptoo et al. 2006, 
Kiptoo, Hamad et al. 2006, Kiptoo, Paudel et al. 2008). 
 
The Gemini prodrug was afforded as an accidental product when phosgenation 
of NTX was approached as an alternate first step in efforts to prepare a codrug of 
BUP and NTX.  Each of these reactions, and their proposed mechanisms, is 
detailed in Hamad et al. (Hamad, Kiptoo et al. 2006).  At this writing, synthesis of 
the BUP-NTX codrug itself has never been achieved (see further efforts in 
Chapter 5).  
 
93 
 
Stability studies of CB-NTX-BUPOH and CB-NTXOL-BUPOH were carried 
out in isotonic phosphate buffer (pH 7.4) (Hamad, Kiptoo et al. 2006, Kiptoo, 
Hamad et al. 2006).  These studies showed that the rate of codrug 
disappearance corresponded to the rate of NTX appearance, while the rate of 
appearance of BUPOH relied on the degradation of the 2,4-oxazolidine ring of 
the BUPOH intermediate, as expected.   Further evidence of hydrolysis of the 
BUPOH 2,4-oxazolidine species was confirmed by summation of molar 
equivalents of BUPOH and its intermediate over the course of time, which 
coincided with molar equivalents of released NTX.  The same behaviors were 
observed for both codrugs, and the authors noted that the delayed conversion of 
the BUPOH 2,4-oxazolidine intermediate to BUPOH could likely be dramatically 
accelerated in vivo by enzymatic activity.  In the latter case, delivery of NTX and 
BUPOH might be expected to be more symmetric.  In vitro enzymatic rate 
enhancement studies in GP plasma confirmed a much enhanced rate of 
hydrolysis in the presence of esterases; however, the same two-step kinetics for 
BUPOH formation were observed (Kiptoo, Paudel et al. 2008). 
In vitro (Kiptoo, Hamad et al. 2006) and in vivo (Kiptoo, Paudel et al. 2008) 
characterization of CB-NTXOL-BUPOH as a PTD codrug has also been 
performed.  In the in vitro work, Jmax values of the codrug were measured in 
NTXOL equivalents and found to be four-fold greater than NTXOL control.  
BUPOH delivery was statistically the same as NTXOL, indicating that the codrug 
was responsible for the presence of NTXOL in receiver solution.  Disposition 
studies confirmed extensive codrug bioconversion to BUPOH and NTXOL in the 
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skin, which was likely responsible in part for the four-fold increase in PTD of 
NTXOL by this method.  Nonetheless, the calculated therapeutic window for 
NTXOL delivery based on NTX (11 – 197 nmol•cm-2•hr-1) was not reached in the 
in vitro studies.  
In vivo studies in GPs showed that approximately five-fold higher steady state 
plasma levels were maintained for 48 hours following application of CB-NTXOL-
BUPOH compared to NTXOL control.  The AUC0-48 of NTXOL was also 
significantly higher than NTXOL control by about 4.2-fold following topical gel 
administration of codrug.  Only trace amounts of codrug and the BUPOH 
intermediate were observed in the plasma samples, and these were not 
quantified.  The enhancement factor for the codrug was found to be 5.3, and 
these data suggest that the codrug does significantly improve the delivery of 
NTXOL in vivo and that the BUPOH intermediate 2,4-oxazolidine may be an 
insignificant and rapidly cleaved species in the live GP.  Unfortunately, NTXOL 
delivery did not reach therapeutic levels in these studies either. 
The duplex Gemini codrug of NTX (Fig. 1.28) was also tested in a PTD 
paradigm (Hammell, Hamad et al. 2004).  The codrug hydrolyzed extensively in 
the skin and small quantities of intact codrug were observed in receiver solution.  
Flux of NTX equivalents was about two-fold for codrug compared to NTX base.  
Human skin homogenate studies revealed a half-life of 31 minutes for the 
codrug, which supported rapid skin bioconversion as a likely permeation 
enhancer of the codrug.  In further studies, skin bioconversion was also 
supported as the key permeation enhancer.  For instance, the SC partition 
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coefficients of NTX and the codrug were not significantly different.  Light mineral 
oil solubilities between NTX and the codrug were also not significantly different 
(when expressed as equivalents of NTX).  Therefore, no concentration gradient 
differences due to light mineral oil solubilities could have contributed to the two-
fold enhanced flux of NTX due to codrug.  Overall, therapeutic levels of NTX 
delivery were not obtainable by the duplex NTX codrug approach either, but this 
study does provide further evidence that rapid skin bioconversion of codrugs and 
prodrugs is desirous for percutaneous delivery of prodrugs. 
In Sections 1.7 – 1.11, prodrugs and codrugs have been introduced, and an 
extensive literature regarding their design and their uses in multiple drug delivery 
goals has been presented.  The amino acid prodrugs that were prepared in this 
body of work were intended for MNTD, whereas the codrug (CYT-NTX) proved to 
be a more appropriate candidate for oral delivery studies.  A section regarding 
the relatively new drug delivery area of MNTD is presented next.  Collectively, a 
rationale for switching to MNTD for percutaneous delivery of NTX prodrugs can 
be appreciated from Sections 1.9 – 1.12. 
    
1.12 Microneedle-enhanced transdermal delivery (MNTD) 
Transdermal delivery of xenobiotics is an attractive route of drug delivery for 
compounds that have considerable first-pass metabolism, gastric instability or 
side effects, or poor oral bioavailability.  Compounds that can be delivered by 
passive transdermal delivery (PTD) methods must be able to diffuse across the 
outermost protective layer of the skin; the stratum corneum (SC).  Several key 
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physiochemical features are typically considered as guidelines for predicting 
which compounds can surmount the barrier properties of the SC.  Among them 
are the following:  logP (logKO/W) of approximately 2; low melting point; and 
molecular weight < 500 g/mol (Bos and Meinardi 2000).  As previously reviewed, 
NTX and NTXOL have been shown to lack sufficient transdermal flux to achieve 
therapeutic blood levels when they are exposed to intact SC.  Therefore, the 
barrier properties of the SC must be compromised in order to deliver them in 
sufficient quantities to affect a therapeutic outcome. 
Microneedle-enhanced transdermal delivery (MNTD) is a method that briefly 
compromises the barrier properties of SC through the creation of aqueous 
micropores in the SC.  There are a number of different permutations of MNTD 
which are applicable in different cases depending on the nature of the molecules 
which are intended for delivery.  The different methods, compounds which are 
best suited for them, and the specifics of formulation techniques that best 
optimize delivery by these techniques have been reviewed (Prausnitz 2004, 
Milewski, Brogden et al. 2010).  For the purposes of the present study, only solid 
microneedles were employed in a paradigm variously described as ―poke with 
patch‖ or ―poke and patch‖ which simply denotes two separate steps that are 
involved in the MNTD patch application process.  Specifically, in the poke and 
patch paradigm, an array of solid microneedles is inserted into the SC to create 
aqueous microchannels.  Subsequently, a gel, or an occlusive patch formulation 
containing the drug of interest, is placed atop the aqueous microchannels in 
order to assay the delivery profile of the drug over the course of time.  Since no 
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other MNTD paradigm was employed in the present work, the reader is referred 
to the cited reviews for information on MNTD techniques other than poke and 
patch. 
Silicon wafers and stainless steel solid microneedle arrays are typically used 
in MNTD studies (Gill and Prausnitz 2007).   Utilizing a deep plasma etching 
technique to prepare microneedles from silicon wafers, Henry et al. created 20-
by-20 microneedle arrays measuring 80 µm at the base with a 150 µm length 
and demonstrated that calcein (Fig. 1.29) delivery through cadaver skin could be 
enhanced by three to four orders of magnitude following SC compromise (Henry, 
McAllister et al. 1998).  The extent of increased calcein delivery was found to be 
dependent on the amount of time the microneedle array was applied to the skin, 
and whether or not the array was left in place during delivery.  The best increase 
over intact skin, 25000-fold, was achieved with one hour microneedle insertion 
and removal of the array before skin exposure to the model compound.  It is 
noteworthy that calcein is a fairly large compound in terms of transdermal 
delivery candidates (622.55 g/mol) and that it should be significantly ionic at skin 
relevant ~pH 5.0 with its multiple carboxylic acid groups and a couple of tertiary 
amine moieties present too.  Indeed, permeability of calcein through intact SC 
was found to be poor and on the order of 10-6 cm/h.  This study was the first 
study to demonstrate that the delivery profile of a large and fairly hydrophilic 
compound can be dramatically improved with MNTD. 
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Figure 1.29 Structure of Calcein. 
 
In a follow-up study by McAllister et al., the scope of molecules that can be 
delivered by MNTD was demonstrated (McAllister, Wang et al. 2003).  In this 
study, macromolecules and nanoparticles of up to 100 nm diameter were found 
to be transported across microchannels following insertion of microneedles.  
Insulin and bovine serum albumin (BSA) are large proteins which do not traverse 
the skin without SC compromise.  Using the same 20-by-20 microneedle arrays 
as Henry et al., it was confirmed in this study that insulin and BSA permeability 
increased by orders of magnitude with microneedle insertion if the array was left 
in place, and by an additional order of magnitude if the array was removed 
following microneedle insertion.  
The MNTD transport of compounds which cover a molecular weight range of 
538 Da – 72 kDa has been confirmed (Verbaan, Bal et al. 2007).  4 x 4 arrays 
were prepared from commercial 30G stainless steel hypodermic needles at 
lengths of 300, 550, 700 and 900 µm.  Using human dermatomed skin treated 
with microneedles compared to no microneedle treatment as a control, Cascade 
Blue (538 Da) and Cascade Blue-Dextran (10 kDa) greatly out-performed FTIC-
Dextran (72 kDa) transport by the MNTD route, and both the kDa molecular 
weight dyes showed some decrease in flux at approximately 5 hours which 
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increased again later after about 13 hours for 10 kDa and 16 hours for 72 kDa.  
The flux profile over time for Cascade Blue had smooth increase toward steady 
state over a 20 hour time course.  In all cases, flux values were far greater with 
microneedle treatment over the course of 20 hours of the experiments.  With 
regard to microneedle length, no significant difference in total accumulated 
amount was observed as a function of microneedle length, although a trend 
could be seen that suggested increased transport with longer needle length in 
the case of Cascade Blue and Cascade Blue-Dextran. 
Collectively, these studies suggest that the pool of compounds which can use 
MNTD as a transport vehicle is much larger than that which can be delivered by 
classic PTD.  Hydrophilic compounds with large molecular weights and ionic 
charge have been shown to have far greater permeability by the MNTD route 
than they do in the presence of uncompromised SC.  Inasmuch, it is expected 
that small molecules with poor transdermal permeation due to hydrophilic 
character can be formulated in vehicles that can utilize MNTD as a means of 
improved systemic exposure via the skin.  NTX and its active metabolite NTXOL 
serve as a case-in-point. 
To test the hypothesis that percutaneous delivery of NTX can be improved by 
the use of a salt form of the drug and microneedle pretreatment of the skin, 
Wermeling et al. tested NTX hydrochloride on nine male and female volunteers 
(Wermeling, Banks et al. 2008).  Four 6.7 cm2 NTX•HCl patches were used per 
patient.  Six patients were treated with four 5X10 arrays of solid stainless steel 
microneedle of 620 µm length, and three control subjects were left untreated with 
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microneedles.  In patients who were treated with microneedle arrays, detectable 
blood plasma levels were observed within 15 to 30 minutes, and approximate 
zero order delivery of 2.5 ng/mL blood plasma concentrations was maintained for 
48 hours.  Inter-patient differences in maximum concentration values were 
observed; however, it is important to note that 2.5 ng/mL blood plasma 
concentrations of NTX are consistent with the lower level of the therapeutic 
window of the FDA-approved depot formulation, Vivitrol ®.  Subjects who were 
untreated with microneedles had undetectable blood plasma levels of NTX, 
which is consistent with previous studies that clearly show that NTX is not 
permeable in sufficient quanitities for therapeutic outcomes when applied to 
intact SC. 
In order to expound further on the effect of molecular charge versus MNTD 
skin transport, Banks et al. investigated the charge-dependent flux of NTX and 
NTXOL in vitro (Banks, Pinninti et al. 2008).  Stainless steel microneedles were 
applied as a row of 5 with 750 µm length.  NTX base exhibited roughly 4-fold 
better flux than the corresponding hydrochloride salt with intact hairless guinea 
pig (GP) skin; however, when microneedles were applied to the GP skin, the 
hydrochloride salt had approximately 2.3-fold greater flux.  In the case of intact 
skin, lag times between NTX base and hydrochloride were not statistically 
different.  However, when microneedle treatment was used, lag times for the 
hydrochloride salt were less than those observed for the free base.  The free 
base itself showed no difference in steady state flux or lag time between intact 
and microneedle-treated GP skin, which indicates that there is no difference in 
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the permeation pathway that the free base follows under these two very different 
structural states of the SC.  In contrast, the hydrochloride salt had about an order 
of magnitude increase in steady state flux under microneedle treatment as 
compared to the intact SC case, and the lag time under microneedle treatment 
was also roughly 1/10th the time necessary to achieve steady state flux in 
untreated GP skin samples.   With regard to human skin samples treated under 
the same conditions, the hydrochloride salt had about 8-fold better flux in 
microneedle treated skin and approximately half the lag time to reach steady 
state.  NTXOL held at pH 4.5 showed 1.3-fold increased flux over NTX•HCl in 
microneedle-treated GP skin; albeit, with similar permeability values between the 
two.  Microneedle treatment also resulted in reduced lag times for samples of 
NTXOL held at pH 4.5 as compared to samples held at pH 8.5.   
Overall, it was determined that charge does not influence the driving force 
across skin; rather, the effect of charge on solubility is responsible for flux 
enhancement of NTX and NTXOL across microneedle-treated skin.  Diffusion 
studies of the compounds revealed this by demonstrating that at low equimolar 
concentrations of NTX held at pH 4.5 and at pH 8.5, enhanced flux and 
decreased lag time are still observed.  Yet, there was no significant difference in 
permeability between the two charged states of the molecule in intact GP skin or 
microneedle-treated GP skin.  Therefore, significant increases in permeability of 
drug only occur at higher concentrations where increases in solubility provide a 
driving force of diffusion across the aqueous microchannels. 
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A follow up pharmacokinetics study was conducted to assess the transdermal 
delivery of NTXOL free base and its hydrochloride salt from 2% 
hydroxyethylcellulose gel formulations.  Along with transdermal delivery, skin 
permeability lifetime following microneedle treatment of GP skin was also 
investigated (Banks, Pinninti et al. 2010).  Again, stainless steel microneedles 
were applied as a row of 5 with 750 µm length.  GPs who were not treated with 
microneedles before occlusive patch placement showed very small levels of 
NTXOL or its hydrochloride salt in plasma samples while those treated with 
microneedles before patch placement showed increased steady state 
concentrations of both the free base and the salt.  About a 5-fold increase was 
observed for free base, and the salt had a steady state concentration of 4 times 
the free base (about 20 times higher than hydrochloride control animals).  
Seemingly, solubility was the limiting factor in these results; the hydrochloride 
being more hydrophilic and able to create a greater diffusion gradient across 
aqueous microchannels.  Further, it was found that transepidermal water loss 
(TEWL) measurements increased at 24 and 48 hours, but not at 72 hours on 
occluded skin samples versus control.  These findings correlated well with the 
observed profiles of drug delivery since the most consistent plasma levels were 
measured up to 48 hours.  These data suggest that a 48 hour time course of 
drug delivery was obtained by a poke and patch paradigm. 
So far, the studies covered in this section have suggested that increased 
water solubility of a compound can have the most dramatic effect on improved 
percutaneous delivery via MNTD.  In order to investigate the dependence of 
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permeation on concentration, Milewski et al. conducted MNTD skin transport 
experiments on a pegylated prodrug of naltrexone over a wide concentration 
range.  Polyethyleneglycol-NTX (PEG-NTX, Figure 1.26) is approximately two 
times as soluble as parent NTX in 0.3M acetate buffer held at pH 5.0 (629 mM 
compared to 338 mM).  Six concentrations of PEG-NTX from 10 mM up to 
saturation were assayed in diffusion cells containing microneedle-pretreated 
Yucatan minipig skin samples.  In the concentration range from 63-252 mM, a 
linear relationship was observed between increase in flux versus increase in 
prodrug concentration.  However, this relationship did not hold at higher 
concentration values (440-629 mM) where a curvilinear relationship was 
observed.   Furthermore NTX•HCl actually out-performed the PEG-NTX prodrug 
with higher flux values obtained at every corresponding concentration tested.  
Overall, it was found that changes in the viscosity of the donor solution as a 
function of prodrug concentration accounted for the nonlinear behavior of prodrug 
flux values. 
In a separate study involving NTX•HCl, binary mixtures of propylene glycol 
(PG) and water were prepared with varying amounts of PG (Milewski and 
Stinchcomb 2011).  In 25:75 PG:water, steady state levels of NTX•HCl were 
rapidly obtained with MN-treated skin as opposed to untreated skin.  In terms of 
flux, the greatest flux enhancement with MN-treatment was observed in pure 
water, and the least was observed in pure PG; however, the decrease in flux with 
increased concentrations of PG was nonlinear in nature.  Surprisingly, the 
greatest changes in flux occurred in water rich solutions rather than PG rich 
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solutions.  Approximately 40-fold difference in flux magnitude was observed, 
indicating that donor solution viscosity has a dramatic effect on the transport of 
NTX•HCl through aqueous microchannels.   The difference in flux values in 
untreated skin samples were nowhere near as large as those observed in MN-
treated skin samples.  The ratio of flux through MN-treated skin to that through 
untreated skin revealed an enhancement factor of 17 in 100% water compared to 
3 in PG rich donors (40 – 100% PG).  Therefore, flux enhancement varies 
considerably as a function of donor composition.  Furthermore, an inverse 
relationship between donor solution viscosity and transdermal flux through 
microchannels was observed.  In this work, the vehicle composition itself was 
tested, and PEG influenced drug flux values.  Moreover, viscosity issues also  
affected microchannel transport rates of pegylated NTX prodrugs compared to 
NTX•HCl.  These data suggest that microchannel transport is not totally reliant on 
drug solubility alone, and that the MNTD prodrug approach may be most 
appropriate for highly lipophilic drugs with virtually no water solubility or 
microneedle transport capabilities.  Nonetheless, the amino acids that we 
employed in our later generation prodrugs do not have the same viscosity 
enhancing properties as PEG chains, and we decided to pursue the amino acid 
prodrugs for stability evaluation and possible MNTD studies (Chapter 6)    
1.13 Concluding Remarks 
Within this introductory chapter, the overall aims of the present study have been 
summarized and rationalized with an extensive background literature.  The group 
of prodrugs intended for MNTD was designed with amino acid promoieties to 
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enhance ionization at pH 5.0, and, thus, solubility of the prodrugs compared to 
NTX•HCl or NTXOL•HCl.  This drug design is in contrast to the typical strategy 
that is desired with amino acid prodrug design.  Our compounds were not meant 
to be dosed orally, although some of them may well be candidates for that drug 
delivery approach.  Rather, our prodrugs were meant for MNTD, and this 
represents a novel approach to transdermal prodrug design using well-
documented amino acid prodrug strategies.  On the other hand, CYT-NTX was 
prepared with the sole intention of oral drug delivery, and it is an extension of the 
work that was done on transdermal codrugs for alcohol and tobacco co-abuse.  
The following data chapters tell the story of the challenges and successes that 
we encountered in our pursuit to find new potential clinical candidates for the 
treatment of alcohol and/or nicotine addictions; two of the most pervasive causes 
of preventable death in our society.  
 
 
 
 
 
 
 
 
 
 
Copyright © Joshua A. Eldridge 2013 
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Chapter 2 
Synthesis of 3-O-NTX amino acid esters  
2.1 Synthetic design considerations 
The phenolic hydroxyl group is by far the best nucleophile available for prodrug 
derivitization on NTX or NTXOL.  Indeed, access to all the other hydroxyl groups 
on NTX or NTXOL requires more sophisticated protection and deprotection 
strategies to afford regioselctive promoiety derivitization on the oxymorphinan 
scaffold.   Without protective group strategies one would expect reaction to first 
occur on the phenolic hydroxyl group.  Of course, protecting group chemistry is 
always the last option to pursue since it is well known that such strategies are 
executed at the expense of synthetic step economy and yield.  Even in the case 
of preparing 3-O-NTX/NTXOL amino acid ester conjugates, at least one 
protecting group has to be present on the amino acid nitrogen to suppress 
undesired side-reactions in the coupling procedures and to avoid purification 
problems.  Access to the 6-O position of NTXOL requires an additional protective 
strategy, and the 14-O position of NTX or NTXOL is accessible only through the 
introduction of yet a third protecting group.  The complexities of 6-O and 14-O 
coupling are the subject of Chapters 3 and 4.  Returning to 3-O conjugation, 
though it was expected that there could be some stability issues in 0.3 M acetate 
(pH 5.0) donor solution, the development of 3-O-amino acid ester chemistry was 
approached first, because it was the simplest case of prodrug synthesis on NTX 
or NTXOL.  Schemes 2.1 and 2.2 show the best possibilities that could be used 
to prepare 3-O-amino acid ester end products from commercially available 
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protected amino acids.  Both methods had their own unique set of potential 
advantages and drawbacks that were critical to consider in the synthetic design, 
and they are mentioned here for the sake of completeness.  Referring to 
Scheme 2.1, the t-butyloxycarbonyl (BOC) method of prodrug synthesis is 
depicted; whereas Scheme 2.2 shows the carbobenzyloxy (Cbz) method of 
prodrug synthesis.  In both cases, it was envisioned that carbodiimide coupling 
strategies would work well to form the ester linkers; however, from a mechanistic 
point of view, carbodiimide coupling is not simple, and there are side products 
that must be considered in the synthetic design.  Figure 2.1 details a mechanism 
of carbodiimide coupling to illustrate the species that are involved.  As the 
mechanism shows, the common side products that form in carbodiimide coupling 
strategies are ureas and N-acylureas, each of which is specific to the particular 
cabodiimide reagent employed in the synthesis.  Consideration of these side 
products is very important because they add complexity to the purification 
process that is required to afford analytically pure prodrug precursors.   
Throughout the course of the experimental work involved in forming any NTX or 
NTXOL amino acid ester prodrug, all of the commercially available carbodiimide 
coupling reagents were employed at one time or another, and it was found that 
the ureas formed from dicyclohexylcarbodiimide (DCC) and 
diisopropylcarbodiimide (DIC) were the most difficult to remove from prodrug 
precursor samples, whereas the EDC urea was removed by workup and 
chromatography.  In every case, there was no evidence of the formation of N-
acylureas when dichloromethane (DCM) was used as the solvent.  Referring 
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back to Scheme 2.1, it was expected that there could be some problems with the 
BOC approach in terms of the acidic nature of reagents that are needed to 
remove the BOC group and the possibility of hydrolysis of the prodrug ester 
bond.  Scheme 2.2 was expected to have a possible drawback in the form of 
reduction of the 6-O ketone to some extent.  In Scheme 2.1, the final product is a 
dihydrochloride salt, and in Scheme 2.2, the end product is a free base.  It was 
decided that the BOC strategy should be employed first on the amino terminus 
since the salt end products would be more water soluble than free base esters.  It 
was also decided that trifunctional protected amino acid starting materials should 
be used first as a means to investigate the utility of BOC and Cbz methodologies 
simultaneously.  Three protected amino acid materials were used for these initial 
investigations.  BOC-Thr(Bzl)-OH, BOC-Lys(Cbz)-OH, and BOC-Asp(OBzl)-OH 
were materials that had protective groups that were labile under acidic conditions 
(BOC), and under the conditions of hydrogenolysis (Bzl and Cbz).  All three 
protected amino acid starting materials were used to develop the carbodiimide 
coupling procedures; however, the material that was first selected to investigate 
deblocking methods was 3-O-Thr(Bzl)-NTX. 
2.2 Synthesis of trifunctional amino acid ester prodrugs 
The general synthetic strategy depicted in Scheme 2.1 was utilized first to afford 
3-O-NTX-amino acid esters.  EDC•HCl coupling was established as the 
carbodiimide coupling procedure of choice due to the relative ease of purification 
of the EDC side products compared to those of DCC and DIC; however, the 
isolation yield of precursors was less with EDC (80-87% with EDC and ~ 90% 
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with DIC).  It was found by trial and error that 1.7 equivalents of EDC•HCl 
coupling reagent and 1.7 equivalents of BOC-protected amino acid were required 
to drive the coupling reaction to completion.  EDC•HCl did add one dimension of 
difficulty to the chemistry in that its HCl salt apparently also protonated NTX in an 
exchange equilibrium.  This was apparent since workup with deionized water first 
to attempt to remove excess EDC•HCl and its associated products reduced the 
yield of isolated prodrug precursors by about ten percent.  Five percent aqueous 
sodium bicarbonate was employed instead to remove some of the excess Boc-
protected amino acid, leaving some deprotonated EDC and its urea behind in the 
organic phase.  Luckily, column chromatography proved to be successful in 
removing the EDC products such that good yields (80 – 87%) of prodrug 
precursors could be obtained.  The first prodrug precursors that were prepared 
were trifunctional amino acid ester conjugates with hydrophilic R-groups since 
MNTD was the target method of drug delivery.  More hydrophilic compounds are 
indicated for use in MNTD, and the needed protected amino acid starting 
materials with hydrophilic side groups were available commercially at a 
reasonable price.  The structures of the three prodrug precursors and their 
Electrospray ionization mass spectra (ESI-MS) are provided in Figures 2.2-2.4.  
After successful development of the coupling chemistry to afford the 3-O-amino 
acid ester precursors of NTX in good yield, it was decided that the benzyl group 
of the threonyl prodrug should be targeted first for removal.  The debenzylation 
step also served as a model reaction to determine if the Cbz method shown in 
Scheme 2.2 would likely be of any merit in forming free base 3-O amino acid 
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esters.  It was expected that the aliphatic benzyl ether substitution of threonine 
might be fairly resistant to the normal conditions that are generally employed for 
palladium-catalyzed hydrogenolysis, and that is exactly what turned out to be the 
case. Under a balloon atmosphere of hydrogen gas, and with palladium on 
carbon (Pd-C) as the catalyst, the benzyl ether showed no deprotection after 48 
hours.  The latter result was observed regardless of the solvent that was used to 
attempt the deblocking procedure.  The conditions that were attempted are 
summarized in Scheme 2.3.  The results were disappointing, because it was 
expected that a change to a stronger catalyst such as palladium black or 
palladium hydroxide would result in non-stereoselective reduction of the 6-keto 
position of NTX to form the 6-α/β-NTXOL scaffold.  Of course, only the 6-β-
NTXOL isomer would be an acceptable product, and the formation of either a 
diastereomeric mixture of the 6-α/β-NTXOL or an enantiopure 6-β-NTXOL 
product would ruin the possibility of obtaining a 3-O-threonyl prodrug of NTX—
the FDA approved parent drug.  It was therefore determined that the strongest 
hydrogenolysis solvent should be maintained (MeOH), and the compound should 
be subjected to hydrogenolysis with Pd-C under a 50 psi atmosphere of 
hydrogen using a Parr hydrogenator.  This reaction led to some disappointing 
and important discoveries.     
First, even under these conditions, the major peak shown at rt =12.99 min in the 
LC-UV chromatogram of Figures 2.5 or 2.6 gave a mass for the parent 
benzylated derivative (See Figure 2.4 for the mass spectrum).  Therefore, 
stronger palladium catalysts like palladium black appeared to be necessary to 
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cleave the aliphatic benzyl ether of the threonine side chain.  The latter 
observation also suggested that a keto-protection protocol would have to be 
devised to make use of hydrogenolysis of aliphatic benzyl ether-protected amino 
acid side chains in general (threonine and serine side chains).  A second critical 
observation is shown in Figure 2.6.  Following 48 hours of hydrogenolysis, there 
was a small peak in the LC-UV at rt=10.21 minutes that gave the expected mass 
for the desired debenzylated product (542.9 peak / MW = 542.62).  The small 
amount of conversion also reinforced the possibility that stronger palladium 
catalysts would be needed for successful debenzylation of the threonine side 
chain.    A third observation was that the small peak at rt=13.43 minutes in the 
LC-UV gave a mass of 636.9.   The interpretation of this result is not so straight 
forward since the main peak of the reaction mixture chromatogram shows a 
parent mass of 632.9 (MW = 632.74 for the fully protected compound) along with 
other mass peaks of 633.9 and 634.9 m/z.  However, it is noteworthy to say, 
qualitatively, that the largest intensity of these peaks corresponds to the 
expected 632.9 m/z for the fully protected compound and the M+H peak appears 
to be the second largest in intensity.  Following up, the 636.9 m/z may 
correspond to a keto-reduced material.  All things remaining equal with the other 
mass spectra, 634.9 m/z would correspond to the parent ion mass of the reduced 
ketone species, and 636.9 could be the same compound as well since this M+2H 
behavior was seen for the parent compound.  Alternatively, another possibility is 
that the 634.9 m/z found under the major peak actually does result from the 
reduced ketone material that co-elutes with the original keto species.  At any 
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rate, no evidence of keto reduction could be seen in the crude 1H NMR spectrum 
(data not shown), so the reduced species would have been present in less than 
5% of the material yield.   The total ion count associated with these masses is 
shown in Figure 2.7 along with arrows to indicate the peaks that correspond to 
the various species in solution.  It was discovered by another colleague nearly 
simultaneously in a different prodrug synthesis that keto-reduction was indeed a 
problem on the NTX scaffold when attempts were made to employ 
hydrogenolytically labile protective groups (Reddy, unpublished).  Therefore, 
these data led to the conclusion that this type of strategy, while viable in terms of 
retention of the critical ester linker, would not be amenable to the formation of 3-
O-amino acid ester prodrugs with R-hydroxyl substitution on the pro-moiety 
(threonyl and serinyl prodrugs) since extensive reduction of the ketone would be 
likely before a suitable amount of the benzyl ether side chain could be deblocked.  
Use of stronger catalysts would have accelerated the unwanted reduction side 
reaction.  Therefore, a keto-protection protocol would be necessary to access the 
desired prodrugs.   
An attempt to deblock the benzyl ester of 3-O-BOC-Asp(OBzl)-NTX was 
conducted, but the ester linker was labile to intramolecular cyclization of the 
carboxylate side chain.   The Cbz carbamate of 3-O-BOC-Lys(Cbz)-OH was not 
deblocked since reduction of the ketone would have been a universal problem.  
Therefore, attention was turned to the removal of the BOC group to see if it could 
at least be maintained as the amino protecting group. 
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In attempting to deblock the Boc group, small quantities of the Boc-protected 
precursors were divided up between separate flasks to investigate different 
deblocking conditions.  It was found that TFA in DCM, SnCl4 in DCM, H3PO4 in 
THF, and 2M HCl in diethyl ether or ethyl acetate were not viable methods for the 
removal of BOC in any case.  HCl in ether or ethyl acetate simply led to 
immediate precipitation of a salt.  Otherwise, with the other methods, the spots 
that emerged on the triethylamine-deactivated TLC plates were identical in Rf 
value to naltrexone starting material, and isolation of the ―NTX-like‖ spot in each 
system with 1% sodium bicarbonate workup and TEA-deactivated silica gel 
chromatography proved that the material was always identical to NTX (as judged 
by 1H NMR).   These deblocking failures occurred, presumably because the TFA, 
SnCl4, and H3PO4 reagents were appreciably hygroscopic, and none of them 
were supplied by the manufacturer in septa-sealed bottles.  This was the first 
evidence that strongly acidic solutions with appreciable water content would 
prove to be detrimental to the preservation of the prodrug ester bond of 3-O-
phenolic prodrugs.  Furthermore, the TFA, SnCl4, and H3PO4 reagents were all 
found to cleave the ester bonds in any useful dilution that could remove BOC, 
and it became obvious that an anhydrous deblocking reagent or a different 
protecting strategy would be necessary for further progress to be realized.   
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2.3 Synthesis of bifunctional amino acid ester prodrugs (R=alkyl) 
In order to simplify matters to investigate the stability of 3-O-amino acid esters of 
NTX, the original lysine, threonine, and aspartic acid pro-moieties were replaced 
with valine, leucine, and alanine.  The rationale for this approach was that 
hydrogenolysis of the side group protecting moieties had been identified as a 
problem, and the side groups of lysine and aspartic acid could participate in 
intramolecular degradation of the final prodrugs by cyclization.  Also, as 
discussed in the introduction to this dissertation, valine is known to stabilize the 
ester bond in multiple prodrugs that have been prepared, including the 
commercial blockbusters valacyclovir and valganciclovir (see Chapter 1 for 
references).  Leucine and alanine were logical pro-moieties for stability 
comparison to valine, because they are also aliphatic in nature, but with different 
R-substitution.  For instance, an extra methylene unit is present in the R-group of 
leucine compared to valine.  In contrast, a simple methyl group is present as the 
R-group in the case of alanine.  Therefore, it was expected that we may see 
some interesting differences in the simple chemical hydrolysis rates of 3-O-Val-
NTX, 3-O-Leu-NTX, and 3-O-Ala-NTX in accord with steric and field-releasing 
factors associated with R-substitution on the amino acid side chains.   
The coupling reagent of choice to form the three new 3-O-amino acid esters 
actually turned out to be DIC.  It was chosen because EDC has a tertiary amine 
present, and it was an attractive idea to simply salt out the final prodrugs as 
dihydrochloride esters by deblocking the BOC group with anhydrous 4N HCl in 
dioxane that was available at modest cost.  Residual DIC side products from the 
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coupling step were expected to wash out of the final prodrug salts with ether or 
acetonitrile.  The isolation yield of DIC-coupled precursors was also a bit higher 
than what was observed in EDC coupling (~ 90%).  The general synthetic 
strategy that was used to prepare 3-O-Val-NTX, 3-O-Leu-NTX, and 3-O-Ala-NTX 
dihydrochlorides is shown in Scheme 2.4.  Pleasingly, the DIC urea side 
products were removed completely by the trituration procedure and cold 
acetonitrile washes that followed BOC removal.  4N HCl in dioxane was used as 
the sole solvent of the deblocking reaction, and it afforded the final prodrug 
products as dihydrochloride salts in 40-60% overall yields following flooding with 
ether and trituration.  A significant material loss was incurred by incomplete 
precipitation in each case, and better yields could have quite likely been realized 
by the total removal of the dioxane.  However, such a procedure was not to be as 
easy as simple solvent removal under vacuum due to the high concentration of 
toxic HCl gas dissolved in solution.  Moreover, dioxane is high-boiling and 
problematic to remove without heating, so it was expected that the prodrugs 
might degrade with elevated temperature.  Overall, the yields were sufficient for 
analytical purposes, and it was thought that optimization could be approached at 
a later time if in fact the 3-O-amino acid conjugates of valine, leucine, and 
alanine proved to show stability characteristics that were desirable for future skin 
diffusion and solubility studies (t90 ≥ 48 hours).   The specific details of the 
reactions to afford the three 3-O-amino acid esters of NTX are summarized 
below.  LC-UV/ESI-MS, 1H NMR, and 13C NMR spectra are included for each 
prodrug.  The t90 values that are specific to the three final dihydrochloride 
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prodrugs where R=alkyl are shown in Figure 2.8 along with the prodrug 
structures.  These data were determined using pH 5.0 acetate buffer held at 32 
°C.     
It turns out that the decision to accept an unoptimized yield and move forward 
with the 3-O-amino acid esters of NTX was an appropriate decision, as it can be 
seen in Fig. 2.8 that none of the three 3-O-amino acid ester prodrugs that was 
prepared came even close to being stable enough for future MNTD work (t90<<48 
hours).  Therefore, it was determined that no more phenolic amino acid ester 
conjugates should be prepared for assay, since valine is the pilot promoiety for 
stability comparisons in this class of prodrugs, and even 3-O-Val-NTX 
dihydrochloride was too unstable for future MNTD work (t90 = 1.5 h).  
 
2.4 Future Directions 
Some possible modifications can be made to the 3-O-coupling chemistry 
presented herein.  For instance, a tripartate prodrug design could possibly be 
utilized to solve the problem of phenolic amino acid prodrug instability.  It has 
been shown that phenolic alkyloxycarbonyloxymethyl (AOCOM) linkers can be 
installed under phase transfer synthesis conditions to form prodrugs that are 
more stabile to biological challenge compared to phenolic esters (Thomas and 
Sloan 2007).  These linkers release a molar equivalent of formaldehyde during 
hydrolytic cleavage, but that has proven to be of no concern in prodrug design.  A 
commercial example of a prodrug that releases a molar equivalent of 
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formaldehyde systemically is fosphenytoin (Kai, Tapani et al. 2009).  One 
drawback to this suggested design is the possibility of increased viscosity due to 
the AOCOM arrangement of atoms.  It is somewhat similar to a short chain 
polyethylene glycol linker, and PEG linkers definitely have a negative effect on 
MNTD prodrug flux at high prodrug concentrations (Milewski, Yerramreddy et al. 
2010).  Therefore, the AOCOM approach may be useful for MNTD prodrug 
design if, and only if, a critical balance between phenolic prodrug stability 
enhancement and viscosity levels can be realized.  We decided to proceed with 
the 6-O-NTXOL prodrug design detailed in Chapter 3 to afford greater prodrug 
stability, because we were also interested in MNTD experiments involving 
NTXOL.   
 
2.5 Experimental Section 
Materials: All reagents were purchased from, Acros Organics, Sigma-Aldrich, and 
Advanced Chemtech, and were used without further purification.  Naltrexone was 
a gift from Mallinckrodt-Covidien.  All solvents were dried and stored over 
molecular sieves prior to use.  
LC-ESI-MS characterization:  Mass spectral data were obtained using an Agilent 
1200 series HPLC system coupled to an Agilent 6120 LC-ESI-MS electrospray 
ionization detector.  A  Zorbax  Eclipse XDB-C18 column was employed, and the 
mobile phase was 0.1% formic acid:acetonitrile set on a gradient elution program 
95:5 to 5:95 over the course of 12 min. 
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NMR: All NMR spectra were obtained on a Varian 300 MHz or a Varian 500 mHz 
instrument.  Line data and integral values for 1H NMR spectra were acquired with 
Mestrenova Lite (Mesterlab Research Chemistry Software Solutions, Escondido, 
CA) using 500 MHz spectra.  13C NMR frequencies were obtained from Varian 
Mercury 300 MHz NMR software.  TMS was used as an internal standard. 
General synthesis of 3-O-BOC-amino acid-NTX precursors (R=alkyl) 
100.0 mg of naltrexone (0.2930 mmol) was weighed and dissolved in 
dichloromethane (DCM) with vigorous stirring.  The NTX solution was set aside.  
In a separate flask, 0.498 mmol (1.70 eq.) of the BOC-L-amino acid starting 
material was also dissolved in DCM with rapid stirring.  The latter solution was 
treated dropwise over the course of 10 minutes at room temperature with a 
mixture of 62.8 mg (0.498 mmol, 1.70 eq.) of diisopropylcarbodiimide (DIC) that 
was slightly diluted in DCM.  The BOC-L-amino acid and DIC mixture was then 
allowed to stir for 15 minutes after which time needle-like crystals of DIC-urea 
began to form.  The crystals were filtered through a cotton filter as the activated 
anhydride solution of the protected amino acid and DIC coupling reagent was 
delivered slowly at room temperature to the flask containing NTX.  No base was 
added, because phenolic coupling is easier to achieve than aliphatic hydroxyl 
coupling, and the excess of carbodiimide was expected to provide sufficient 
excess base.  The reaction was followed by thin layer chromatography (TLC) 
using 1:1 hexanes and ethyl acetate containing 1 drop of triethylamine (TEA) 
base.  After 24-36 hours, no spot for NTX could be detected on the TLC plate (36 
hours required for BOC-Val-OH coupling only).   The reaction mixture was 
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poured into a 125 mL separatory funnel and worked up with 5% sodium 
bicarbonate solution (15 mL x 3).  The aqueous fraction was washed with DCM, 
and the organic fractions were collected and washed once with 15 mL of 
deionized water and twice with 15 mL portions of brine.  The solvent was 
reduced in vacuo, and the mixture was chromatographed over silica which had 
previously been deactivated by a mixture of 1% TEA in hexanes.  The BOC 
protected prodrug precursor was obtained by elution with 20% ethyl acetate in 
hexanes following several column washes with 100% hexanes to remove DIC 
and some of its associated urea.  The isolated precursor was further washed with 
a mixture of 1:1 diethyl ether and hexanes to remove more of the DIC and its 
urea.   Removal of the DIC urea was a challenge.  The final material was dried to 
a constant weight to afford crude material that was mostly the desired 3-O-BOC-
amino acid-NTX prodrug precursor.  Since the DIC associated side products 
were not fully removed by this method, all intermediate materials were used 
without further purification.  The DIC side products were removed in the final step 
when the prodrugs were salted out as dihydrochlorides.   
Synthesis of 3-O-amino acid-NTX dihydrochloride prodrugs (R=alkyl) 
For each prodrug, the crude material enriched in the desired 3-O-BOC-L-amino 
acid-NTX prodrug precursor was placed into a 25 mL round bottom flask and 
flooded with 4N HCl in dioxane.  The material initially went into solution 
sluggishly until dissolution was complete.  After ten minutes of reaction time, a 
gummy material began to precipitate out and bind to the glass.  The reaction was 
continued with vigorous stirring for one hour, after which time the dioxane 
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solution was charged with diethyl ether.  There was an immediate formation of 
copious white precipitate.  The gummy material on the bottom of the flask also 
became uniform as a white precipitate in the dioxane/diethyl ether solution 
following trituration with a spatula for fifteen minutes.  The precipitated 
amorphous white powder was collected via filtration over a cotton plug, and the 
material was washed with a lot of chilled diethyl ether to remove all traces of 
dioxane and HCl.  The powder was allowed to air dry.  Subsequently, it was 
transferred to another round bottom flask and washed 3 times with chilled 
acetonitrile to remove all DIC urea. The acetonitrile was washed out with more 
chilled ether, and the final salt was stripped of solvent to a constant weight.  The 
yields were moderate to good in all cases (40-60%), and the materials were 
characterized by 1H NMR and 13C NMR spectrometry, and LC-UV/ESI-MS 
analysis (Figures 2.9-2.17).  The end yields are tabulated in Table 2.1.  The 1H 
NMR spectra were acquired after the 13C NMR experiments were conducted, and 
it can be seen that some degradation of the prodrugs to parent NTX•HCl took 
place in d6-DMSO within the time frame of the experiments (compare the 
prodrug and NTX•HCl proton NMR spectra provided). LC-UV/ESI-MS data did 
not show peaks for NTX, because the chromatograms were obtained before the 
prodrugs were dissolved in d6-DMSO for NMR spectral analysis.  These data 
further demonstrate the instability of phenolic amino acid ester prodrugs of NTX. 
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3-O-Val-NTX 
 1H NMR (d6-DMSO) 500 MHz:    δ 9.14 (s, 1H, broad), 8.84 (s, 3H, broad), 7.20 
(s, 1H, broad), 7.07 (d, 1H, J=10 Hz), 6.89 (d, 1H,  J=10 Hz), 5.25 (s, 1H), 4.17 
(m, 1H), 4.10 (d J=5.0 Hz, 1H), 3.5 (d, J=18 Hz, 1H), 3.34 (DMSO water peak), 
3.21-3.08(m, 2H), 3.08-2.99(m, 1H), 2.99-2.92 (m, 1H), 2.83-2.63 (m, 2H), 2.50 
(DMSO, overlap), 2.40-2.31 (m, 1H), 2.18-1.96 (m, 3H), 1.55-1.42 (m, 2H), 1.16 
(d, J=5Hz, 3H), 1.12 (d, J=5Hz, 3H), 0.74-0.67 (m, 1H), 0.66-0.59 (m, 1H), 0.58-
0.51 (m, 1H), 0.46-0.38 (m,1H) ppm.  
 
13C NMR (d6-DMSO) 300 MHz: δ 205.97 (C=O, 6-O ketone), 166.61, (C=O, 
ester), 147.08, 131.02, 129.54, 128.94, 123.38, 120.31, 89.82, 69.56, 60.54, 
57.16, 56.70, 48.65, 45.69, 34.92, 30.58, 29.72, 27.16, 23.40, 18.52, 17.42, 5.80, 
5.25, 2.79 ppm. 
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3-O-Leu-NTX 
1H NMR (d6-DMSO) 500 MHz:  δ 9.17 (s, 1H, broad), 8.88 (s, 3H, broad), 7.24 (s, 
< 1H, broad), 7.08 (d, 1H, J=10 Hz), 6.88 (d, 1H,  J=10 Hz), 5.26 (s, 1H), 4.25 
(m, 1H), 4.10 (d J=5.0 Hz, 1H), 3.56 (d, J=5 Hz, 2H), 3.50 (DMSO water peak), 
3.40-3.30 (m,  1H), 3.21-2.99(m, 3H), 2.99-2.92 (m, 1H), 2.83-2.63 (m, 1H), 2.50 
(DMSO, overlap), 2.17-2.06 (m, 2H), 1.97-1.89 (m, 1H), 1.86-1.80 (m, 2H), 1.55-
1.44 (d, J=5 Hz, 2H), 1.20-1.07(m, 1H), 1.0 (s, 1H), 0.99-0.94 (overlap, doublets, 
6H), 0.74-0.66 (m, 1H), 0.65-0.58 (m, 1H), 0.58-0.51 (m, 1H), 0.45-0.38 (m,1H) 
ppm. 
 
13C NMR (d6-DMSO) 300 MHz:  δ 206.08 (C=O, 6-O ketone), 167.67 (C=O, 
ester), 147.01, 131.05, 129.47, 128.91, 123.20, 120.22, 89.71, 69.53, 66.30, 
60.48, 56.67, 50.50, 48.62, 45.65, 34.94, 30.60, 27.18, 23.79, 23.34, 22.31, 
22.12, 5.78, 5.23, 2.79 ppm. 
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3-O-Ala-NTX 
1H NMR (d6-DMSO) 500 MHz:  δ 9.17 (s, broad, 1H), 8.81 (s, broad, 3H), 7.21 (s, 
broad, <1H), 7.07 (d, J=10 Hz, 1H), 6.88 (d, J=10 Hz, 1H), 5.76 (d, J=5Hz, <1H), 
5.25 (s, 1H), 4.42 (m, 1H), 4.10 (d, J=5 Hz, 1H), 3.49 (DMSO water peak), 3.41-
3.30 (m, 2H), 3.20-2.99 (m, 4H), 2.98-2.90 (m, 1H), 2.80-2.71 (m, 1H), 2.54 (m, 
<1H), 2.52-2.41 (DMSO overlap region), 2.18-2.06 (m, 2H), 1.60 (d, J=5 Hz, 3H), 
1.55-1.44 (m, 2H), 1.17-1.06 (m, 1H), 0.73-0.66 (m, 1H), 0.66-0.58 (m, 1H), 0.58-
0.50 (m, 1H), 0.46-0.38 (m, 1H) ppm. 
 
13C NMR (d6-DMSO) 300 MHz:  δ 206.09 (C=O, 6-O ketone), 167.90 (C=O, 
ester), 146.98, 131.11, 129.48, 128.88, 123.21, 120.25, 89.67, 69.55, 60.51, 
56.70, 48.62, 47.79, 45.65, 34.92, 30.60, 27.21, 23.38, 15.94, 5.78, 5.22, 2.80 
ppm. 
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Table 2.1 3-O-NTX amino acid dihydrochlorides material recovery. 
 
 
 
 
 
 
 
 3-O-Val-NTX 3-O-Leu-NTX 3-O-Ala-NTX 
 
MW base (g mol-1) 
 
440.53 
 
454.56 
 
412.48 
 
MW salt (g mol-1) 
 
513.45 
 
527.48 
 
485.40 
 
mg isolated 
 
90.2 
 
81.3 
 
56.8 
 
Theoretical yield 
 
150.4 
 
154.5 
 
142.2 
 
% yield 
 
60.0 
 
52.6 
 
40.0 
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Scheme 2.1 BOC method to form 3-O-NTX amino acid ester prodrugs. 
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Scheme 2.2 Cbz method to form 3-O-NTX amino acid ester prodrugs. 
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Scheme 2.3 First attempted debenzylations of 3-O-Boc-Thr(Bzl)-NTX. 
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Scheme 2.4 Synthesis of 3-O-NTX amino acid dihydrochlorides. 
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Figure 2.1 Mechanism of carbodiimide coupling (PG = protecting group).  
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Figure 2.1 Mechanism of carbodiimide coupling (continued). 
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Figure 2.1 Mechanism of carbodiimide coupling (continued). 
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Figure 2.1 Mechanism of carbodiimide coupling (continued). 
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Figure 2.2 ESI-MS of 3-O-BOC-Asp(OBzl)-NTX. 
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Figure 2.3 ESI-MS of 3-O-BOC-Lys(Z)-NTX. 
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Figure 2.4 ESI-MS of 3-O-BOC-Thr(Bzl)-NTX.  
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Figure 2.5 LC-UV/ESI-MS of 3-O-BOC-Thr(Bzl)-NTX after 48 h 
hydrogenolysis @ 50 psi H2 with Pd-C.  Mass spectrum extracted from r.t.= 
13.43 min. 
 
Molecular weight: 634.76 
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Figure 2.6 LC-UV/ESI-MS of 3-O-BOC-Thr(Bzl)-NTX after 48 h 
hydrogenolysis @ 50 psi H2 with Pd-C.  Mass spectrum extracted from the 
peak at r.t.= 10.21 min. 
 
Molecular weight: 542.62 
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Figure 2.7 Total Ion Count (ESI-MS Positive Scan Mode). 
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Figure 2.8 Stability of 3-O-NTX amino acid dihydrochlorides R=alkyl in pH 
5.0 acetate buffer (32 °C). 
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Figure 2.9 1H NMR spectra of the 3-O-Val-NTX dihydrochloride prodrug and 
NTX•HCl. 
NTX•HCl  
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Figure 2.10 13C NMR spectrum of 3-O-Val-NTX dihydrochloride prodrug. 
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Figure 2.11 LC-UV/ESI-MS of 3-O-Val-NTX prodrug. 
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Figure 2.12 1H NMR spectra of the 3-O-Leu-NTX dihydrochloride prodrug 
and NTX•HCl. 
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Figure 2.13 13C NMR spectrum of 3-O-Leu-NTX dihydrochloride prodrug. 
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Figure 2.14 LC-UV/ESI-MS of 3-O-Leu-NTX prodrug. 
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Figure 2.15 1H NMR spectra of the 3-O-Ala-NTX dihydrochloride prodrug 
and NTX•HCl. 
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Figure 2.16 13C NMR spectrum of 3-O-Ala-NTX dihydrochloride prodrug. 
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Figure 2.17 LC-UV/ESI-MS of 3-O-Ala-NTX prodrug. 
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Chapter 3 
Synthesis of 6-O-NTXOL amino acid esters  
3.1 Synthetic Design Considerations 
Due to poor stability that was observed in the 3-O-amino acid ester series of NTX 
prodrugs, it was decided that attention should be turned to the development 6-O-
amino acid ester prodrugs of NTXOL.  The only other options for prodrug 
development on NTX/NTXOL without the addition of linkers would have required 
one of two approaches. Specifically, the 14-O position of NTX or NTXOL could 
have been accessed, or the 6-O ketone of NTX could have possibly been 
exploited as an enolate acylation position (see evidence for enolate coupling in 
Chapter 4).  In any of these cases, the requirement for additional protecting 
group strategies would have been unavoidable to ensure regioselective 
synthesis.   Therefore, it was considered most attractive to go for the easiest 
aliphatic nucleophile with which to couple--the 6-O-NTXOL hydroxyl position. 
NTXOL was obtained in 85-92.7% yield, depending on reaction scale, by the 
method of De Costa et al. (De Costa et al. 1992). The reaction was found to be 
reliable and reproducible throughout this body of work.     
Following the preparation of NTXOL, a number of viable strategies were possible 
to protect the phenolic position of NTXOL in order to proceed with prodrug 
synthesis.  For instance, it was envisaged that Fmoc-protected amino acids could 
be coupled to a 3-OBn-NTXOL synthon to furnish orthogonally protected 3-OBn-
6-O-Fmoc-amino acid-NTXOL ester prodrug precursors.  Otherwise, it was also 
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envisioned that a global hydrogenolysis deprotection scheme could be employed 
to afford amino acid ester prodrugs if 3-OBn-NTXOL and Cbz-protected amino 
acids could first be coupled and then deblocked simultaneously in the final 
synthetic step.   
3.2 Synthesis of trifunctional amino acid ester prodrugs of NTXOL 
The Fmoc/OBn approach was tested first to check for possible problems that can 
occur in global deblocking protocols.  3-OBn-NTXOL was prepared as the first 
synthon (Scheme 3.1, Step 1).   Luckily, a simple method was employed that 
afforded the desired benzyl protected synthon in 94.5% yield without the need for 
column chromatography.  The first Fmoc-protected pro-moiety that was chosen 
for conjugation was Fmoc-Asp(OBzl)-OH.  The use of this pro-moiety was 
incorporated into the synthetic design to check the feasibility of using trifunctional 
amino acids in the 6-O-NTXOL prodrug design. Such an approach would give the 
best range of increased hydrophilicity for MNTD studies.  Also, the benzyl ester 
protecting group on the carboxylate side chain of aspartic acid is susceptible to 
hydrogenolysis similar to the 3-OBn moiety of NTXOL; however, the final Fmoc 
removal would still impart an orthogonal final step.  Though intramolecular 
cyclization of the free carboxylate side chain on the aliphatic ester was a 
possibility, it was still an attractive idea to see if the aspartic acid prodrug could 
be prepared and assayed for stability.  Also, the need for hydrogenolysis was 
synthetically inconsequential to the structural integrity of NTXOL, due to its lack 
of a ketone functional group.  Scheme 1, Step 2 shows the approach that was 
utilized to access the desired prodrug.  The EDC carbodiimide coupling strategy 
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was employed in this case; however, the lower reactivity of the 6-O aliphatic 
hydroxyl functional group compared to the 3-O phenolic hydroxyl group forced an 
increase in the amount of excess carbodiimide that was required to drive the 
reaction to completion as compared to the EDC protocol that worked for the 
phenolic NTX esters (2.5 eq vs. 1.7 eq).  In this case, the yield went down in 
recovering the coupled product (~75%), and the purification was more difficult.  
This reaction also proceeded more smoothly with the addition of a catalytic 
amount of DMAP base, which is an indicator of the lower reactivity of the 
aliphatic alcohol. 
Regarding the lower yield due to more difficult purification, one is simply forced to 
drive these coupling reactions to completion when using NTX or NTXOL, 
because the coupled conjugates, although apparently much more lipophilic than 
parent drug, adsorb to silica gel quite strongly.  NTX and NTXOL are also very 
difficult to recover from silica gel in high purity.  Even with TEA deactivation of 
silica, recovery of NTX/NTXOL-containing compounds in acceptable purity is a 
major challenge, and starting material is present in the prodrug precursor 
samples following chromatography if the reactions are not fully driven to 
completion.   
Scheme 3.1 and Figures 3.1 – 3.4 adequately summarize the story of the 
aspartic acid prodrug chemistry. First, 3-OBn-6-O-Fmoc-Asp(OBzl)-NTXOL was 
isolated in 75% yield as depicted in the 1H NMR spectrum shown in Figure 3.1.  
To approach removal of the Fmoc protecting group, a standard protocol was 
used that is common in solid phase peptide synthesis.  5% piperidine in DMF 
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was charged to a round bottom flask containing the Fmoc-protected prodrug.  
Deblocking was very fast (~15 minutes), but it became apparent very quickly that 
a more volatile base or a base that could be removed more easily would be a 
better route to success, because it was very difficult to remove all of the 
piperidine from the reaction mixture.  Aqueous work up and two columns were 
required to get rid of it completely.  Eventually, the piperidine was removed, and 
about 50% of the deblocked material was able to be recovered in satisfactory 
purity.  The proton NMR spectrum for the product, 3-OBn-6-O-Asp(OBzl)-NTXOL 
is shown in Figure 3.2.  It was during the next step, global deblocking of the 
benzyl ether and benzyl ester, that major problems began to emerge.   
Figures 3.3 and 3.4 show the spectral data that were obtained following 15 
minutes of hydrogenolysis of 3-OBn-6-O-Asp(OBzl)-NTXOL.  Methanol was used 
as the solvent, because the compound did not dissolve in ethyl acetate or 
ethanol.  Hydrogen was supplied to the reaction mixture containing 10 wt % Pd-C 
via a balloon and needle.  When the TLC showed clear signs of degradation, the 
reaction was stopped, the catalyst was filtered over celite, and the filtrate was 
stripped of solvent and analyzed by ESI-MS (Figure 3.3) and 1H NMR spectrum 
(Figure 3.4).  The masses of the structures provided in Figure 3.3 gave some 
clarification to the complicated NMR spectrum.   There were many undesired 
side reactions taking place in the hydrogenolysis cocktail.  For instance, the 
major peak at 549 makes sense, because there were two ways that it could have 
formed.  The most likely main contributor is expected to be the free carboxylate 
compound that forms when the benzyl ester of the aspartic acid pro-moiety is 
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cleaved (Figure 3.3, compound II).  The second, and most likely minor 
contributor, would be expected to be the benzyl ether deblocked prodrug with the 
benzyl ester still intact (Figure 3.3, compound III).   The mass at m/z = 459 
resulted from the presence of the desired prodrug in the reaction mixture (Figure 
3.3, compound IV).  A small peak of starting material was also noticed at m/z = 
639 (Figure 3.3, compound I), and NTXOL was also present in the mass 
spectrum at m/z = 344.  Without the 1H NMR spectral data (Figure 3.4), it would 
be difficult to determine that all of these species were actually present in the 
reaction mixture, because the ESI-MS in this case was also complicated by the 
presence of M-18 dehydration peaks that typically only arise when high energy 
ionization is employed (i.e. EI-MS).  Under those conditions, a number of ether 
and ester cleavage reactions could occur in the mass collision chamber.  
However, Figure 3.4 clearly shows a great deal of doubling in all regions of the 
1H NMR spectrum.  In particular, the phenyl protons of NTXOL showed that many 
NTXOL-containing compounds existed. Close inspection of the pre-
hydrogenolysis proton spectra (Figures 3.1 & 3.2) illustrate this fact.  NTXOL 
was definitely a product of the reaction, along with the other intermediates that 
were in various stages of hydrogenolysis.  However, the formation of NTXOL was 
probably a hydrolytic process, and not a hydrogenolytic process, and this was 
probably the result of cyclization on the ester by the freed carboxylic acid side 
chain of ASP.  At this point, it became important to determine whether or not the 
ester instability under these conditions was due to cyclization of the free 
carboxylate on the ester (a five-membered lactone-mediated hydrolysis), or if the 
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ester was simply unstable to hydrogenolysis in general.  This hypothesis could 
not be tested without the synthesis of another prodrug precursor that did not 
contain the free carboxylate moiety.  It turns out that a simultaneous series of 
observations were made by another chemist working on Pegylated carboxy-ester 
prodrugs conjugated at the 6-O position of NTXOL (T. Reddy, unpublished).  
Instability of the ester was again observed under hydrogenolytic conditions using 
substrates that did not have groups present that could cyclize on the ester linker. 
However, it will be shown later in this chapter that not all amino acid esters of 
NTXOL are unstable to hydrogenolysis conditions.   
1,4-cyclohexadiene and 10 wt% Pd-C was used as an alternative cocktail on a 
separate batch of 3-OBn-6-O-Asp(OBzl)-NTXOL just to see if catalytic transfer 
hydrogenolysis could be used instead of H2 gas.  The results were identical, with 
the exception that the reaction rate was even faster.  At this time other protecting 
strategies were pursued. 
3.3 Synthesis of amino acid esters of NTXOL by solid phase strategies 
Next, attention was turned to the possibility of docking NTXOL onto solid 
supports that are commonly used in peptide synthesis.  The rationale for this 
approach was to utilize a solid support as the phenolic protecting group such that 
excess reagents for the coupling and deblocking procedures could be easily 
washed away from the resin-bound prodrug at various stages of the synthetic 
process.  Such techniques are gaining more wide-spread popularity due to 
purification problems of some synthetic procedures, and this type of approach is 
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now becoming the mainstay of modern peptide synthesis (Misicka 2012).  The 
synthetic approaches that were attempted are detailed in Schemes 3.2 and 3.3.  
Two commercially available solid phase peptide synthesis resins were employed 
to test the feasibility of the solid phase approach, Hydroxymethyl polystyrene 
resin (HMPR) and SASRIN®.  To begin, the much cheaper HMPR was used.  At 
the time of this work, it had already been established that activated p-nitrophenyl 
carbonates (PNP) were useful NTX/NTXOL coupling synthons.  HMPR had also 
already been utilized by another group as a substrate for PNP activation to dock 
alcohol-containing drugs and substrates (Dressman, Spangle et al. 1996).  Using 
the exact methods of the latter reference, HMPR-PNP resin was produced on a 
multi-gram scale to move forward with NTXOL loading tests.  Scheme 3.2 shows 
the overall plan that was to be employed if loading of the NTXOL drug proved to 
be successful.   
As depicted in the scheme, successful loading of the drug was to be followed up 
by carbodiimide coupling and Fmoc deblocking on resin.  The final step would 
have been to isolate the TFA salt of the final prodrug.  One drawback to this type 
of strategy is that solid phase resins are known to require swelling and shrinking 
stages between reagent additions, and there was a fairly large cost to be 
incurred with the extra amount of drug needed for resin loading (excess could be 
recovered, but a large amount was needed for multistage loading).  Also, 
additional reagent and solvent loads were needed for the multiple synthetic 
steps.  However, in comparison, previous reactions had also been very difficult to 
purify, so it was expected that the ease of purification that might be gained from 
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this type of solid phase approach might overshadow some of the inherent 
wastefulness of the procedures.  HMPR-PNP was first loaded with phenol as a 
model compound in order to determine the loading economy of a phenolic 
substituent in general.  The activated synthon resin was reacted with phenol 
under a variety of conditions.  Table 3.1 summarizes the three conditions that 
were employed in the phenol loading studies.  Microwave irradiation (MWI) was 
used, since it had been discovered in a previous codrug synthesis (CYT-NTX, 
Chapter 5) that nucleophilic attack on p-nitrophenyl activated carbonates is 
faster and more efficient with the use of microwave chemistry.  As shown in 
Table 3.1, there were three samples prepared for gravimetric analysis.  In all 
samples 1-3, the amount of resin and phenol (1.1 eq compared to resin) was 
kept constant.  DCM was used as the solvent in samples one and two, but not 
sample three.  THF had to be used with the sodium salt of phenol.  Where TEA 
was used as the base, it was present in 1.5 eq. compared to the loading capacity 
of HMPR-PNP.  The residual amount of material remaining following resin 
washing, aqueous workup (to remove p-nitrophenol) and solvent evaporation 
(which also removes TEA) was used in the calculations.  Any material left on 
resin was assumed to be covalently bonded as a carbonate when no more 
washes produced residual material or UV activity on TLC.  In Table 3.1, the 
conditions for samples one and two differed only by the temperature at which the 
microwave reaction was carried out.  In sample one, the microwave reaction was 
conducted at 50°C for ten minutes, while in sample two, the reaction was 
performed for ten minutes at 100°C.  There was essentially no difference in the 
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amount of material that was loaded on the resin as a function of temperature 
(sample one = 26.3% and sample two = 27.3%).  Phenol was converted to 
sodium phenolate in sample three.  It is interesting to note that the loading was 
worse in that case (14.1%), which was not expected.  The latter result was not 
too much of an inconvenience though, because it would be very difficult to 
actually employ sodium hydride to activate the phenol of NTXOL regioselectively.  
One could expect at least some activation of the 6-OH, and possibly even the 14-
OH, under which conditions there would quite likely have been problems with 
non-specific docking of the NTXOL substrate.  A second cycle of the conditions 
used for sample one revealed that the maximum loading of phenol had 
essentially been reached in one cycle, which did not bode well for the loading of 
NTXOL, an even larger molecule.  Still, with the loaded resin in hand, it made 
sense to at least determine how much TFA would be required to dislodge the 
phenol substrate from the solid support.  The results were not too promising, as 
90% TFA in DCM was needed to recover all of the phenol, and it had to be done 
in two consecutive cycles.  It was not expected that amino acid ester prodrugs 
would be able to survive such harshly acidic conditions since TFA had already 
caused plenty of trouble in the deblocking procedures of the Boc group in the 3-
O-NTX amino acid ester series. 
Despite the drawbacks that emerged in the phenol loading tests, it was decided 
that the loading of NTXOL to HMPR-PNP should be attempted to see if there 
were any useful differences between NTXOL and phenol.  In keeping with the 
phenol study, 18.8 mg NTXOL (1.1 eq) was added dry to pre-swelled resin in 
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DCM containing 1.5 eq. TEA, and the slurry was agitated for several minutes to 
dissolve the NTXOL base.  The mixture was then stirred for ten minutes at 50°C 
in a Biotage Initiator microwave reactor, and the solid support was removed by 
filtration and washed with copious amounts of DCM.  The filtrate was evaporated 
in the same manner as phenol to remove solvent and TEA, and it was found that 
20% had been loaded on the resin.  There was also the need for about 90% TFA 
in DCM to dislodge the NTX substrate from the resin.  Thus, use of the HMPR-
PNP resin was abandoned at this stage.   
SASRIN, a much more acid sensitive resin, was explored in one loading attempt 
(Scheme 3.3).  The same PNP-activation protocol was used.  The results 
indicated approximately 18 % drug loading on SASRIN, so the idea of solid 
phase chemistry to afford 6-O-amino acid ester prodrugs was abandoned 
altogether at this stage.  The reason for abandonment of the solid phase strategy 
was that 18 - 20% loading of the substrate of interest means that ~80% of the 
active resin conjugation area is available for side reactions.  It is not really 
advantageous to approach a scheme that is designed to improve purification 
efficiency with a method that guarantees purification problems (i.e. amino acid 
coupling to these solid phase conjugation sites is known to be very efficient).  
The solid phase reactions were also very cumbersome to deal with manually.  
Clearly, a new strategy was needed. 
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3.4 Synthesis of bifunctional amino acid esters by multiple protective 
group strategies 
The very popular method of TBDMS (t-butyldimethylsilyl) ether protection was 
investigated next (Scheme 3.4).  Surprisingly, there was no evidence of 3-O-
TBDMS-NTXOL formation by TLC or 1H NMR analysis (data not shown) following 
up to 24 hours of reaction time with NTXOL using a very popular technique for 
these blocking procedures (Corey and Venkateswarlu 1972).  Typically, in the 
case of phenolic substrates, reactions with t-butyldimethylsilyl chloride 
(TBDMSCl), DMF, and imidazole result in very high yields of the desired phenolic 
silyl ether synthons.  Yet, NTXOL was simply unreactive toward TBDMSCl under 
these conditions.  Alternative blocking cocktails also produced no TBDMS-
protected NTXOL, including the conditions that were used to form the 3-OBn-
NTXOL compound (Scheme 3.4), and alternative strategies had to be pursued.  
Allylation of the phenolic 3-O position of NTXOL was considered next, and Fmoc 
or Boc seemed reasonable choices for the amino-terminus protecting groups.   
Fmoc was pursued first, since there was talk of forming different salts of the final 
prodrugs at the time of this work.  Boc had been restricted to dihydrochlorides in 
the phenolic NTX prodrug series due to instability of the esters under various 
deblocking conditions.   Scheme 3.5 summarizes the general prodrug synthesis 
strategy proceeding from 3-O-allyl-NTXOL, and this proved to be the best 
strategy to employ in order to afford the desired 6-O-amino acid esters of NTXOL 
for stability assays. 
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It was envisaged that allyl bromide could be directly substituted for benzyl 
bromide in Step 1 of Scheme 3.1 in order to afford 3-O-allyl-NTXOL.  Indeed, 
the yields were similar in this case (93.2%).  With regard to the coupling step, 
carbodiimide reagents were avoided at first in an attempt to simplify purification 
procedures, and β-alanine was chosen as the first pro-moiety.   Pre-activation of 
Fmoc-β-Ala-OH to the active ester synthon, Fmoc-β-Ala-Cl, was accomplished 
with thionyl chloride and sonication in DCM within 1 h, as described by 
Sureshbabu et al. (Sureshbabu and Hemantha 2008).    Coupling of 3-O-Allyl-
NTXOL with the activated acid chloride was then conducted.  Purification after 
coupling was achieved by aqueous work up followed by column chromatography 
over silica that had been pretreated with 1% TEA in hexanes (76.6% isolation 
yield).   Deallylation was performed utilizing the methods of Chandrasekhar et al. 
(Chandrasekhar, Raji et al. 2001) with significant modifications.  It was found that 
5 mol% of homogenous tetrakis triphenylphosphine palladium catalyst 
[(Ph3P)4Pd], 3.0 equivalents of polymethylhydrosiloxane (PMHS), and excess 
zinc chloride (2M in diethyl ether) had to be reacted with the protected substrate 
over the course of 24h to completely remove the allyl protecting group from the 
phenolic functional group.  The biggest challenge that emerged at this point was 
the purification.  Insoluble material was formed (insoluble meaning insoluble in all 
common laboratory solvents) that was extremely fine in particle size.  The solid 
material was very difficult to filter, often completely clogging filter papers and 
celite, even under hard vacuum.  The reaction mixture at this stage was also 
quite difficult to work up.  Thick emulsions formed that were nearly impossible to 
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resolve, even with additions of brine and methanol.  Ether and hexanes washing 
was attempted to remove some of the PMHS and zinc materials, since 
naltrexone containing compounds do not appreciably dissolve in these solvents 
in most cases. However, these washes had minimal effect on improving the ease 
of work up and preparation for column chromatography.  At the chromatography 
stage, silica also had the tendency to become clogged with the reaction mixture 
when it was introduced.  For these reasons, preparative TLC was employed on a 
sample of the deallylated synthon; however, the results of the purification 
compared to a silica column did not warrant further use of prep-TLC—an 
expensive and quantitatively restrictive technique.  After several attempts to work 
out the purification problems following the deallylation step, 6-O-Fmoc-β-Ala-
NTXOL was eventually isolated in 70% yield with sufficient purity to move 
forward.   
Fmoc removal was accomplished by 24h treatment with DBU base (25 mol%) 
and octanethiol (10 eq.) in dry THF, as described by  Sheppeck et al. (Sheppeck, 
Kar et al. 2000).  The final free amine was isolated by trituration from diethyl 
ether (60% yield).   An overall yield of 32.2% 6-O-β-ala-NTXOL was achieved, 
and that was good enough to test the material for stability.  These tests are 
summarized in Chapter 6.  
The same methods were used in an attempt to prepare the 6-O-α-amino acid 
ester prodrugs of NTXOL containing the following promoieties:  Val, Pro, Ala, Ile, 
Leu, and Met.  However, the final purification of these prodrugs required a final 
column chromatography step.  Recovery of the prodrugs from TEA-deactivated 
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silica was difficult in all cases.  The less lipophilic the R-group on the amino acid 
promoiety side chain, the more difficult was the isolation procedure.  For 
instance, 6-O-Ile-NTXOL could be washed free from silica with 100% ethyl 
acetate, while 6-O-Ala-NTXOL required acetone and small amounts of TEA and 
methanol to be liberated from the column.  Indeed, in the latter case, this resulted 
in some degradation of the end product (see NMR data in Figure 3.22).  6-O-
Pro-NTXOL was as difficult as 6-O-Ala-NTXOL to purify, and it went through 
some degradation in the purification process as well (Figures 3.24 and 3.25).  
Evidence of degradation can be seen in the 13C NMR spectra for 6-O-Ala-NTXOL 
and 6-O-Pro-NTXOL, because it appears that multiple NTXOL-containing 
compounds are present.  The stability data presented in Chapter 6 confirm that 
6-O-Ala-NTXOL and 6-O-Pro-NTXOL are not very stable, and TEA in the 
presence of methanol and acetone appears to degrade these two prodrugs to an 
appreciable extent.  In Milewski’s pH 5.0 stability studies, it was noted that these 
two prodrug samples contained NTXOL at the start of a stability experiment.  6-
O-Met-NTXOL also could not be isolated cleanly from the column, and it was not 
pursued further.  
The detailed LC-UV/ESI-MS and NMR spectral data relevant to the β-Ala, Val, 
Ile, and Leu prodrugs are summarized in Figures 3.9-3.21, and their stability 
data are the subject of Chapter 6.  6-O-Ile-NTXOL was also crystalline in nature, 
and it’s crystal structure is shown in Figure 3.14. 
As Table 6.2 of Chapter 6 indicates, further work to develop the chemistry to 
afford 6-O-Pro-NTXOL or 6-O-Ala-NTXOL was not necessary, because neither of 
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these prodrugs met our minimum criteria for candidacy in MNTD applications.  
Following stability assays, it was determined that 6-O-β-Ala-NTXOL was the lead 
compound that should be pursued for scale up and MNTD skin diffusion 
experiments.  Unfortunately, attempts to upscale 6-O-β-Ala-NTXOL to the ~1.0 g 
scale failed using the 3-O-allyl/Fmoc strategies summarized in Scheme 3.5.  The 
short summary of many efforts is that the practical limit of scale for Scheme 3.5 
was found to be on the order of 200 mg of final prodrug; not enough for drug 
development studies using MNTD strategies.  Therefore, a number of modified 
deblocking strategies were investigated in an attempt to prepare the β-Ala 
prodrug, because yield losses were incurred in the deblocking steps following 
promoiety coupling. 
Attention was first turned to the most problematic step of the synthetic sequence; 
the deallylation step.  Indeed the problems with column chromatography at this 
stage only multiplied when the scale became larger, so there was a need to 
change the deblocking procedure to a strategy that would avoid the need for the 
PMHS-ZnCl2 system.  Also, the homogenous tetrakistriphenylphosphine 
palladium catalyst had proven quite difficult to remove completely on a column.  
Indeed, homogenous palladium catalysts, though excellent in the scope of their 
synthetic applications, pose purification problems in the pharmaceutical industry 
in general.  With these facts in mind, attempts to deblock the allyl group from the 
naltrexol scaffold by heterogeneous palladium catalysis were explored.  In case a 
homogenous palladium catalyst proved to be necessary, PdCl2 was also 
investigated as a substitute homogenous catalyst, and N,N-dimethylbarbituric 
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acid (NMBA) was employed as an allyl scavenger under a variety of conditions 
as a modification of the deallylation procedure described by Tsukamoto et al. 
(Tsukamoto and Kondo 2003).   
As depicted in Scheme 3.6, allyloxybenzene was prepared by the same allylation 
protocol that was used for NTXOL; however, the reaction never reached 
completion despite the amount of excess allyl bromide employed.  Column 
chromatography was required to isolate the product in pure form in this case, and 
83% of the desired allyl-protected phenol was isolated.  The first deallylations 
were designed using the same homogenous palladium catalyst, (Ph3P)4Pd, in 
order to establish the optimum amount of NMBA to use in the reaction mixture.  It 
was found that 6.0 equivalents of NMBA were required to fully deblock the 
allyloxybenzene material to afford native phenol.  Utilizing the established 
optimum of NMBA, the homogenous catalyst PdCl2 was substituted in place of 
(PH3P)4Pd to determine whether or not it might be an optional reagent that could 
afford easier purification (Scheme 3.7).  Simultaneously, the same conditions 
were employed on allyloxybenzene with a change to three other heterogeneous 
catalysts, palladium black, palladium hydroxide, and palladium on carbon.  
Unfortunately, the PdCl2 reaction was found to be a viable alternative to the 
(Ph3P)4Pd-catlayzed reaction; however, no advantage in purification was 
observed with this substitution.  This could be seen in the proton NMR spectra of 
the final products, because even tiny amounts of palladium in the end product 
caused multiple chemical shifts for every proton.  The (Ph3P)4Pd-catalyzed 
reaction was easier to purify when NMBA was used as an allyl scavenger as 
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compared to the PMHS-ZnCl2 system, because much of the excess NMBA could 
be removed by aqueous work up with 1% NaHCO3.  Heterogenous catalysts 
were apparently unable to form the necessary palladium-allyl charged complex 
that results in allyl deblocking.  There was no change in the protected state of 
allyloxybenzene after many days, as judged by TLC and crude NMR spectral 
data, when Pd-C, Pd black, or Pd(OH)2 were substituted for the homogenous 
palladium catalysts, so surface adsorption catalysis could not be used as a 
method to simplify purification.  Therefore, it was decided that the palladium 
catalyst should remain (Ph3P)4Pd and the allyl scavenger should be changed to 
NMBA for scale up attempts to optimize the problematic deallylation step to 
afford 6-O-β-Ala-NTXOL.  Unfortunately, even with excess of greater than 10 
equivalents of NMBA, the allyl group could not be removed from 3-O-allyl-6-O-
Fmoc-β-Ala-NTXOL completely, so the model syntheses failed to produce a 
useful alternative to the original (Ph3P)4Pd / PMHS-ZnCl2 system in this case.   
Next, an attempt to deblock the allyl and Fmoc protecting groups was attempted 
in a one-pot fashion.  Thiols are good nucleophiles that will add to alkenes.  This 
is the entire basis of using octanethiol to scavenge dibenzofulvene in Fmoc 
deblocking procedures.  The problematic species that complicated purification of 
the PMHS-ZnCl2 deallyation cocktail was likely to be a polymer of PMHS that 
formed under the conditions of the reaction (higher polymers tend to be insoluble 
materials).  Naturally, it was envisaged that one could simply use octanethiol (or 
a similar thiol) from the Fmoc deblocking step, combine the two in one-pot with 
the fully protected synthon and DBU, and the end result may be a global 
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deprotection that would need only a solvent wash to afford the final prodrug 
(Scheme 3.8).  Although the plan was logical, a mixture of products resulted, and 
the allyl moiety was not fully removed.   
Attention was next turned to improving yields in the final synthetic step.  As 
shown in Scheme 3.9, the Boc chemistry that had been developed to afford 3-O-
amino acid esters of NTX (Chapter 2) was investigated as a replacement for 
Fmoc since there were also some product loss issues associated with Fmoc.  
This method also had its share of problems, because the allyl protecting group 
was still present under the original Fmoc/Oallyl conditions, and the final products 
were not possible to isolate as pure dihydrochloride salts.  The compounds were 
very hygroscopic in nature with the free phenol and two moles of HCl per mole of 
prodrug.  Therefore, the Boc method was also not an alternative to approach for 
upscale of 6-O-β-Ala-NTXOL. 
The decision was made to try to avoid allyl chemistry altogether by exploring the 
feasibility of 3,6-O-bis-coupling on NTXOL with Fmoc-β-Ala-Cl (Scheme 3.10).  
The compound 3,6-O-bis-NTXOL was synthesized in a small amount for LC-
UV/ESI-MS analysis by doubling the amount of DMAP and Fmoc-β-Ala-Cl 
prepared as in Scheme 3.5.  As can be seen in Figure 3.5, the fully protected 
compound (m/z = 930.8) could be 3-O deblocked to afford the free phenol (m/z = 
636.9) using the same DBU/octanethiol cocktail as before; however, it takes too 
long for the 3-O-ester to degrade, and the Fmoc group also deblocks under these 
conditions.  Precipitation of the final prodrug with concomitant precipitation of free 
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β-alanine caused separation problems.  Therefore, this scheme was also not a 
route to upscale.    
As a final attempt to solve the upscale problem so that the skin diffusion and 
solubility studies could be performed on 6-O-β-Ala-NTXOL, attention was turned 
once again to deblocking strategies that could use hydrogen gas and Pd-C.  
Previously, in the attempts to prepare 6-O-Asp-NTXOL, it had been observed 
that the ester bond was rapidly cleaved under the traditional deblocking 
conditions of H2/Pd-C in MeOH.  However, in that case there was a free 
carboxylate present that could contribute to cyclization on the ester.  To test 
prodrug ester stability to hydrogenolysis again, palladium black was mixed with a 
sample of 6-O-Leu-NTXOL prodrug in THF, and the material was stirred 
vigorously overnight under a balloon reservoir of H2 gas.  At the time of the 
experiment, stability studies of the final prodrugs at pH 5.0 and 7.4 were 
underway, so it seemed reasonable to inject samples of the filtered reaction 
mixture on the HPLC to examine the area ratios of peaks for prodrug and NTXOL 
as compared to a control of the 6-O-Leu-NTXOL prodrug that had not been 
exposed to the hydrogenolysis mixture.  The area ratio data were converted to 
area percents to see if an appreciable amount of NTXOL was being formed by 
degradation of the ester linker under hydrogenolytic conditions.  The reaction 
was assayed at 24 hours reaction time. To ensure peak identity, the peaks were 
confirmed as prodrug and NTXOL by spiking one set of reaction samples with 
NTX and a separate set of reaction samples with prodrug.  The data shown in 
Table 3.2 represent the average values (n=3) obtained from the analysis, and 
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representative chromatograms are shown in Figure 3.6.  The data clearly 
showed that no appreciable degradation of the prodrug ester bond had occurred 
at 24 hours reaction time in the presence of palladium black catalyst, H2 gas (1 
atm.), and THF.  Therefore, following the hydrogenolysis test, attention was 
again turned toward benzyl protection of the phenolic hydroxyl group of NTXOL.  
Also, carboxybenzoyl carbamates (Cbz-protected amino-terminus) of the desired 
amino acids were sought as promoiety precursors.  Both of these protecting 
groups are removed under hydrogenolysis conditions, and it was expected that 
the desired 6-O-β-Ala ester of NTXOL could be afforded in larger quantities using 
a global deprotection strategy.  Ultimately, such an approach would solve the 
problems incurred in the allyl chemistry that was used previously, because 
hydrogenolysis proceeds cleanly with heterogeneous palladium catalysts under 
most circumstances.  Unfortunately, this plan also did not work.   
Significant work to optimize the conditions of this chemistry was directed toward 
6-O-β-Ala-NTXOL, having been established as the most promising prodrug 
candidate. The various permutations of the synthetic strategy are summarized in 
Scheme 3.11.  3-OBn-NTXOL was obtained in high yield in a single upscaled 
effort to afford 3.4 g of material for optimization work. Cbz-β-Ala-OH was 
converted to Cbz-β-Ala-Cl in the exact same manner as the Fmoc material 
previously, but with excess DMAP present to mop up HCl.  Twofold excess of the 
activated acid chloride was charged to a solution of 3-OBn-NTXOL in DCM 
containing two equivalents of DMAP.  The desired 3-OBn-6-O-Cbz-β-Ala-NTXOL 
prodrug precursor was isolated in good purity at 82.5% yield for hydrogenolysis 
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optimization, and many different hydrogenolytic cocktails were tested for their 
ability to afford the desired deprotected prodrug in acceptable final yields.  
Figures 3.7and 3.8 show a brief summary of the typical results obtained by LC-
UV/ESI-MS.  In Figure 3.7, the major peak at 11.01 minutes with m/z 548.8 
corresponds to a compound with the 3-OBn group deblocked to free phenol.  The 
next major peak at 13.79 minutes with m/z 638.8 corresponds to the fully 
protected prodrug precursor.  There was no evidence of an intermediate with 
only the Cbz group removed, and it became apparent throughout the course of 
this work that Cbz could never be removed completely from the protected starting 
material before the catalyst was poisoned.  The only evidence of the fully 
deprotected prodrug appears to be the peak at 4.20 minutes which does show 
the m/z 414.9 peak that is akin to the m/z parent molecular ion seen in Figure 
3.11;  the mass spectrum of the original, clean 6-O-β-Ala-NTXOL prodrug 
prepared by the techniques summarized in Scheme 3.5.  However, it is 
problematic that the peak at 4.20 minutes in Figure 3.7 does not give an 
extracted mass spectrum that matches Figure 3.11 exactly, so it is not possible 
to say that the peak does indeed correspond to the desired prodrug.  In Figure 
3.8, the amount of catalyst was increased to attempt to fully deprotect the starting 
material without poisoning the catalyst, but the washing procedure required to 
recover any material from the reaction involved the use of THF, and the mass 
spectrum was too complicated to indicate the prodrug was present.  It should be 
noted that clean 1H NMR spectra were never obtained for the final prodrug under 
any of the conditions tested.  The palladium black catalyst was poisoned in many 
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of the attempts to afford the final prodrug, and the addition of zinc dust resulted in 
intractable mixtures.  Also, the requisite threefold weight ratio of catalyst 
compared to the protected prodrug precursor that was needed to avoid poisoning 
resulted in very tiny amounts of isolated material after solvent washing.  
Apparently, the 6-O-β-Ala-NTXOL prodrug strongly adsorbs to the palladium 
catalyst surfaces, or it is complexed with palladium somehow.  In any event, the 
conditions of Scheme 3.5, although limited in their scalability, represent the only 
synthetic approach that has proven to work to any acceptable degree at all to 
afford 6-O-amino acid esters of NTXOL.  Therefore, the work to prepare these 
materials was concluded at this stage, and the solubility and skin diffusion 
studies were never able to be conducted.  However, plasma stability studies 
were conducted to investigate the candidacy of these materials in an MNTD 
paradigm (Chapter 6).  Overall, 6-O-NTXOL amino acid prodrugs were not 
simple enough to purify on a large scale to be considered good prodrugs. 
3.5  Experimental Section 
Materials: All reagents were purchased from, Acros Organics, Sigma-Aldrich, and 
Advanced Chemtech, and were used without further purification.  Naltrexone was 
obtained from Mallinckrodt-Covidien.  All solvents were dried and stored over 
molecular sieves prior to use.  
LC-ESI-MS characterization:  Mass spectral data were obtained from the Mass 
Spectral facility at UK, or by using an Agilent 1200 series HPLC system coupled 
to an Agilent 6120 LC-ESI-MS electrospray ionization detector.  A  Zorbax 
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Eclipse XDB-C18 column was employed, and the mobile phase was 0.1% formic 
acid:acetonitrile set on a gradient elution program 95:5 to 5:95 over the course of 
12 min.  Spectra are scanned copies of the original printed data. 
NMR: All NMR spectra were obtained on a Varian 300 MHz or a Varian 500 mHz 
instrument.  Line data and integral values for 1H NMR were acquired with 
Mestrenova Lite (Mesterlab Research Chemistry Software Solutions, Escondido, 
CA) using 500 MHz spectra.  13C NMR frequencies were obtained from Varian 
Mercury 300 MHz NMR software.  TMS was used as an internal standard. 
Synthesis of 6-β-NTXOL 
 
 
 
The synthesis of NTXOL utilized the exact method of De Costa et al. (De Costa 
et al. 1992), and afforded white crystals in multi-gram scale at 84 – 85% yield 
consistently at the 500 mg scale.  The synthesis performed better in upscale in 
this case (2.7981 grams from 3.0000 g NTX, 92.7%) so one is advised to prepare 
large quantities of NTXOL in a single synthetic event rather than to prepare 
smaller batches. 
    
1H NMR (CDCl3) 500 MHz: δ 6.71 (d, J=10 Hz, 1H), 6.56 (d, J=10 Hz, 1H), 4.53 
(d, J=10 Hz, 1H), 3.63-3.55 (m, 1H), 3.50 (d, J=5 Hz, 1H), 3.10 (d, J=5 Hz, 1H), 
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3.03 (d, J=15 Hz, 1H), 2.68-2.52 (m, 2H), 2.36 (d, J=5 Hz, 2H), 2.29-2.22 (m, 
1H), ), 2.18-2.11 (m, 2H), 2.04-1.94 (m, 1H), 1.68-1.59 (m, 1H), 1.52-1.47 (m, 
1H), 1.41-1.34 (m, 2H), 0.88 -0.80 (m, 1H), 0.56-0.51 (m, 2H), 0.15-0.11 (m, 2H) 
ppm. 
 
LC-MS: 344.9 (MH+); r.t. = 8.74 min (ESI-MS positive mode). 
 
Synthesis of 3-OBn-NTXOL 
 
 
 
 
 
2.798 grams of NTXOL was dissolved in about 50 mL of acetone containing 
4.505 g K2CO3 (4.0 eq) held at reflux.  The solution was charged immediately with 
1.533 g benzyl bromide (1.1 eq), and the reaction was conducted for 5.5 hours at 
reflux.  The mixture was allowed to cool to room temperature, and the acetone 
was stripped in vacuo.  Copious amounts of DCM were used to wash the desired 
synthon away from the solid materials in the reaction flask, and the DMC volume 
was then reduced under vacuum, and the crude organic mixture was washed 3 
times with DI water and twice with brine (100 mL each).  The organic layer was 
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dried over sodium sulfate, collected, and evaporated to a constant weight, and 
multiple washes with hexanes were carried out to remove the residual benzyl 
bromide.  Following these washes, the product was dried under hard vacuum 
overnight to afford 3.336 g (94.5%) of a waxy white solid.  The final material was 
characterized by 1H NMR analysis and found to be the desired 3-OBn-NTXOL 
sython.   
 
1H NMR (CDCl3) 300 MHz:   
δ 7.22-7.45 (m, 5H), 6.71 (d, J=10 Hz, 1H), 6.56 (d, J=10 Hz, 1H), 5.20 (s, 2H), 
4.45 (d, J=10 Hz, 1H), 3.46-3.42 (m, 1H), 3.50 (d, J=5 Hz, 1H), 3.10 (d, J=5 Hz, 
1H), 3.03 (d, J=15 Hz, 1H), 2.68-2.52 (m, 2H), 2.36 (d, J=5 Hz, 2H), 2.29-2.22 
(m, 1H), ), 2.18-2.11 (m, 2H), 2.04-1.94 (m, 1H), 1.68-1.59 (m, 1H), 1.52-1.47 (m, 
1H), 1.41-1.34 (m, 2H), 0.88 -0.80 (m, 1H), 0.56-0.51 (m, 2H), 0.15-0.11 (m, 2H) 
ppm. 
Synthesis of 3-O-allyl-NTXOL 
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5.000 grams of NTXOL was dissolved in about 50 mL of acetone containing 
8.049 g K2CO3 (4.0 eq) held at reflux.  The solution was charged immediately with 
1.938 g allyl bromide (1.1 eq), and the reaction was conducted for 5.5 hours at 
reflux.  The mixture was allowed to cool to room temperature, and the acetone 
was stripped in vacuo.  Copious amounts of DCM were used to wash the desired 
synthon away from the solid materials in the reaction flask, and the DMC volume 
was then reduced under vacuum, and the crude organic mixture was washed 3 
times with DI water and twice with brine (100 mL each).  The organic layer was 
dried over sodium sulfate, collected, and evaporated to a constant weight, and 
multiple washes with hexanes were carried out to remove the residual allyl 
bromide.  Following these washes, the product was dried under hard vacuum 
overnight to afford 5.204 g (93.2%) of translucent oil.  The final material was 
characterized by 1H NMR spectrometry and found to be the desired 3-O-allyl-
NTXOL sython.   
1H NMR (CDCl3) 300 MHz:   
δ 6.71 (d, J=10 Hz, 1H), 6.56 (d, J=10 Hz, 1H), 6.11-6.02 (m, 1H), 5.39 (d, J=10 
Hz, 1H), 5.26 (d, J=10 Hz, 1H), 4.70-4.60 (m, 2H), 4.50 (d, J=10 Hz, 1H), 3.65-
3.55 (m, 1H), 3.52 (d, J=5 Hz, 1H), 3.10 (d, J=5 Hz, 1H), 3.03 (d, J=15 Hz, 1H), 
2.68-2.52 (m, 2H), 2.36 (d, J=5 Hz, 2H), 2.29-2.22 (m, 1H), ), 2.18-2.11 (m, 2H), 
2.04-1.94 (m, 1H), 1.68-1.59 (m, 1H), 1.52-1.47 (m, 1H), 1.41-1.34 (m, 2H), 0.88 
-0.80 (m, 1H), 0.56-0.51 (m, 2H), 0.15-0.11 (m, 2H) ppm. 
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General Synthesis of the 3-O-allyl-6-O-Fmoc-amino acid NTXOL ester 
conjugates 
For each coupling reaction 300 mg of 3-O-allyl-NTXOL and two equivalents of 
DMAP were dissolved at room temperature in DCM.  The Fmoc-protected amino 
acid promoiety was converted to the activated acid chloride in a separate flask by 
sonicating it in DCM with thionyl chloride under an argon stream.  Relative to 3-
O-allyl-NTXOL, 2.00 equivalents of the amino acid precursor and 1.99 
equivalents of thionyl chloride were used.  The preactivation reactions were 
complete within one hour in each case, as described by Sureshbabu et al. 
(Sureshbabu and Hemantha 2008), and the residual HCl that had not been blown 
off in the argon stream was quenched with 2.00 equivalents of DMAP base 
(DMAP served the purpose of activating the 6-OH group to coupling as well as a 
quenching agent).  The cocktail containing 3-O-allyl-NTXOL and DMAP was then 
added dropwise to the acid chloride solution over the course of two minutes at 
0°C, and the reaction mixture was warmed to room temperature and left to react 
for four hours.  In every case, the reactions were worked up with DI water and 
brine, and the organic fraction was dried over anhydrous sodium sulfate.  Final 
purification was achieved by chromatography over silica that had been pretreated 
with 1% TEA in hexanes.  It was very difficult to remove all of the Fmoc-protected 
pro-moiety starting materials in these reactions, so they were present in the final 
NMR spectra in a small percentage.  The acid chlorides were quenched in the 
workup and chromatography steps, and the presence of free carboxylic acid of 
the pro-moiety was inconsequential for the deallylation chemistry. Two columns 
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were required to completely remove the promoiety precursors, so it was decided 
that these unwanted materials could best be removed in the purification 
procedures of the deallylation step.  Therefore, the crude mixtures were used 
without further purification in every case.  Estimated isolation yields were on the 
order of 75 - 90%. 
 
General Synthesis of the 6-O-Fmoc-amino acid NTXOL ester conjugates by 
3-O deallylation 
Deallylation was performed utilizing the methods of Chandrasekhar et al. 
(Chandrasekhar, Raji et al. 2001) with significant modifications.  The fully 
protected 3-O-allyl-6-O-Fmoc-amino acid ester conjugate was dissolved in about 
9.0 mL of dry THF and treated with 5 mol% of (PPh3)4Pd and 3.0 eq. of 
polymethylhydrosiloxane (PMHS). 52 drops of diethyl ether 2M in zinc chloride 
was added with rapid stirring, and the reaction was run for 24 h.  The THF was 
evaporated under an argon stream, and the gummy residue was reconstituted in 
DCM for workup.  The crude material was then worked up with DI water and 
brine and dried over sodium sulfate.  The combined organic fractions were 
concentrated and chromatographed as before to afford the deallylated prodrug 
product in estimated yields ranging from 50 to 85%.  As mentioned earlier in the 
chapter, the purification of these materials was very difficult such that the 
cleanest fractions obtained from chromatography were advanced to the next step 
177 
 
without further purification.  The Fmoc-protected promoiety contaminants from 
the previous step were removed completely at this stage.  
 
General Synthesis of the 6-O-amino acid NTXOL ester conjugates by Fmoc 
removal 
 Fmoc removal was accomplished by 24h treatment with DBU base (25 mol%) 
and octanethiol (10 eq.) in dry THF, as described by  Sheppeck et al. (Sheppeck, 
Kar et al. 2000).  In the case of 6-O-β-Ala-NTXOL, the final prodrug was isolated 
by precipitation and trituration from diethyl ether (60% yield).  The α-amino acid 
ester prodrugs were recovered via aqueous workup (exactly as described above) 
and column chromatography.  Again, silica was deactivated with 1% TEA in 
hexanes, and the final prodrugs were eluted with copious column washes using 
ethyl acetate.  6-O-Ala-NTXOL and 6-O-Pro-NTXOL required acetone and TEA 
to be eluted from the columns, and hydrolytic degradation of these prodrugs 
resulted.  The range of yields at this stage was 20% (6-O-Ala-NTXOL) to 80% (6-
O-Ile-NTXOL).  The final overall yields of the prodrugs are summarized in Table 
3.3. 
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6-O-β-Ala-NTXOL 
 
 
 
 
1H NMR 500 MHz (d6-DMSO): δ 6.59 (d, J=10 Hz, 1H), 6.53 (d, J=10 Hz, 1H), 
4.87 (s, broad), 4.45 (m, 2H), 3.64-3.57 (m, 1H), 3.03 (d, J=5 Hz, 1H), 2.96 (d, 
J=20 Hz 1H), 2.76 (t, J=15 Hz, 2H), 2.62-2.53 (td, 2H), 2.40 (t, J=15 Hz, 2H), 
2.36-2.27 (m, 2H), 2.23-2.12 (m, 1H), 1.85-1.72 (m, 2H), 1.70-1.57 (m, 2H), 1.48 
(d, J=10 Hz, 1H), 1.33-1.19 (m, 3H), 0.87-0.79 (m, 1H), 0.42-0.51 (m, 2H), 0.16-
0.06 (m, 2H) ppm. 
13C NMR (d6-DMSO) 300 MHz:  δ 171.49, 165.90, 141.62, 140.31, 131.11, 
123.21, 118.63, 117.05, 90.43, 75.09, 69.33, 61.45, 58.33, 53.9, 47.30, 43.44, 
37.93, 30.23, 29.28, 23.26, 22.15, 9.31, 3.78 ppm. 
 
LC-UV/ESI-MS: r.t = 3.50 min; (MH+) m/z 415.9 
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6-O-Ile-NTXOL 
 
 
 
 
 
1H NMR 500 MHz CDCl3: δ 7.70-7.65 (m, <1H), 7.58-7.53 (m, <1H), 7.50-7.44 
(m, <1H), 6.70 (d, J=10Hz, 1H), 6.58 (d, J=10Hz, 1H), 4.85-4.94 (m, 1H), 4.52 (d, 
J=5Hz, 1H), 3.67 (d, J=5Hz, 1H), 3.10 (d, J=5Hz, 1H), 3.02 (d, J=15 Hz, 1H), 
2.69-2.55 (m, 2H), 2.39 (d, J=5Hz, 2H), 2.31-2.21 (m, 1H), 2.2-2.12 (m, 1H), 
2.12-2.02 (m, 1H), 1.96-1.85 (m, 1H), 1.70-1.57 (m, 2H), 1.53-1.44 (m, 2H), 1.44-
1.36 (m, 1H), 1.30-1.19 (m, 2H), 0.95-0.89 (m, 7H), 0.89-0.79 (m, 2H), 0.58-0.50 
(m, 2H), 0.19-0.09 (m, 2H) ppm.   
13C NMR (CDCl3) 300 MHz:  δ 175.58, 142.01, 140.98, 132.29, 130.83, 128.54, 
123.11, 119.58, 118.66, 92.29, 70.12, 62.46, 59.43, 57.60, 48.33, 44.16, 39.24, 
30.99, 29.67, 25.86, 24.34, 22.88, 15.56, 12.33, 9.81, 4.28 ppm. 
 
LC-UV/ESI-MS: r.t = 2.99 min; (MH+) m/z 457.9 
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6-O-Leu-NTXOL 
 
 
 
 
 
1H NMR 500 MHz (CDCl3): δ 7.70-7.65 (d, J=10Hz, 1H), 6.59 (d, J=10Hz, 1H), 
4.91-4.83 (m, 1H), 4.54 (d, J=5Hz, 1H), 3.68 (t, J=15 Hz, 1H), 3.11 (d, J=5Hz, 
1H), 3.03 (d, J=20Hz, 1H), 2.70-2.56 (m, 2H), 2.39 (d, J=5Hz, 2H), 2.30-2.22 (m, 
1H), 2.21-2.12 (m, 1H), 2.12-2.02 (m, 1H), 1.87-1.75 (m, 1H), 1.71-1.62 (m, 2H), 
1.62-1.58 (m, 1H), 1.58-1.52 (m, 1H), 1.52-1.44 (m, 3H), 0.92 (t, 7H, overlap with 
cyclopropyl methine), 0.59-0.50 (m, 2H), 0.19-0.12 (m, 2H) ppm. 
 
13C NMR (CDCl3) 300 MHz:  δ 176.91, 142.00, 141.15, 130.87, 119.66, 118.75, 
92.37, 76.52, 70.19, 62.55, 59.50, 52.31, 48.40, 44.22, 43.92, 31.08, 29.66, 
25.04, 24.21, 23.01, 22.93, 22.63, 9.84, 4.34 ppm. 
 
LC-UV/ESI-MS: r.t = 2.89 min; (MH+) m/z 457.8 
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6-O-Val-NTXOL 
 
 
 
 
 
1H NMR 500 MHz (CDCl3): 7.72-7.63 (m, <1H), 7.60-7.53 (m, <1H), 7.50-7.44 
(m, <1H), 6.71 (d, J=10Hz, 1H), 6.59 (d, J=10Hz, 1H), 4.95-4.82 (m, 1H), 4.53 (d, 
J=10Hz, 1H), 3.56 (d, J=5Hz, 1H), 3.11 (d, J=5Hz, 1H), 3.03 (d, J=15Hz, 1H), 
2.69-2.55 (m, 2H), 2.39 (d, J=5Hz, 2H), 2.31-2.21 (m, 1H), 2.20-2.10 (m, 2H), 
2.10-2.01 (m, 1H), 1.76-1.65 (m, 1H), 1.64-1.57 (m, 1H), 1.53-1.42 (m, 2H), 1.33-
1.19 (m, 2H), 1.04 (d, J=5Hz, ½ H), 1.00 (d, J=5Hz, 3H), 0.97 (d, J=5Hz, ½ H) 
0.93 (d, J=5Hz, 3 H), 0.89-0.79 (m, 3H), 0.58-0.48 (m, 2H), 0.19-0.09 (m, 2H) 
ppm. 
 
13C NMR (CDCl3) 300 MHz:  δ 175.48, 141.98, 141.01, 132.14, 130.82, 128.69, 
123.01, 119.58, 118.70, 92.34, 70.09, 62.41, 59.42, 58.77, 48.30, 44.16, 31.98, 
31.01, 29.59, 24.31, 22.85, 19.00, 17.96, 9.77, 4.30 ppm. 
 
LC-UV/ESI-MS: r.t = 3.50 min; (MH+) m/z 443.9 
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  Table 3.1 Phenol loading on HMPR-PNP solid phase synthesis resin. 
 
 
Sample 
 
 
Amount of 
Resin (mg) 
 
 
Amount of 
PhOH (mg) 
 
Amount of 
TEA (mg) 
 
MWI  
temp/time 
(°C/min) 
 
 
% loaded 
to resin 
 
1 
 
 
50.0 
 
51.8 
 
75.9 
 
50/10 
 
26.3 
 
2 
 
 
50.0 
 
51.8 
 
75.9 
 
100/10 
 
27.3 
 
3 
 
 
50.0 
 
51.8 
 
None* 
 
 
50/10 
 
14.1 
 
* PhOH was preactivated as the sodium salt with 0.99 eq. NaH 
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Table 3.2 6-O-Leu-NTXOL ester hydrogenolysis test. 
Sample RT 
(min) 
Avg. Area% 
(215 nm) 
NTXOL control 1.87 0.63 
Prodrug control 2.52 99.37 
Hydrogenolysis (24 h)   1.88 0.93 
Hydrogenolysis (24h) 2.56 99.07 
Hydrogenolysis (24 h + 
NTXOL spike) 
1.89 83.34 
Hydrogenolysis (24 h + 
NTXOL spike) 
2.55 16.66 
Hydrogenolysis (24 h + 
prodrug spike) 
1.88 0.83 
Hydrogenolysis (24 h + 
prodrug spike) 
2.51 99.17 
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Table 3.3 6-O-NTXOL amino acid esters final material recovery. 
 
Compound 
 
 
MW 
(g/mol) 
 
mg 
isolated 
 
Theoretical 
yield (mg) 
(overall) 
 
 
% Yield 
(overall) 
 
 
6-O-Ile-NTXOL 
 
456.57 
 
142.9 
 
357.2 
 
40.0 
 
6-O-β-Ala-NTXOL 
 
414.49 
 
97.3 
 
324.3 
 
32.2 
 
6-O-Val-NTXOL 
 
442.55 
 
125.3 
 
346.2 
 
36.2 
 
6-O-Leu-NTXOL 
 
456.57 
 
137.2 
 
357.2 
 
38.4 
 
6-O-Ala-NTXOL 
 
414.49 
 
27.2 
 
324.3 
 
~8.4 
 
6-O-Pro-NTXOL 
 
440.53 
 
21.0 
 
344.6 
 
~6.1 
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Scheme 3.1 Synthesis of 6-O-Asp-NTXOL by the Fmoc/OBn route. 
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Scheme 3.2 Hydroxymethyl polystyrene resin solid phase synthesis 
approach to 6-O-amino acid esters of NTXOL. 
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Scheme 3.3 SASRIN resin solid phase synthesis approach to 6-O-amino 
acid esters of NTXOL. 
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Scheme 3.4 Synthesis of 3-O-TBDMS-NTXOL ether synthon. 
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Scheme 3.5 Synthesis of 6-O-amino acid esters of NTXOL by the 
Fmoc/OAllyl route. 
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Scheme 3.6 Allyloxybenzene model deallylation with homogenous 
palladium catalyst and NMBA allyl scavenger. 
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 Scheme 3.7 Allyloxybenzene model deallylation with PdCl2 and alternative 
heterogenous palladium catalysts using NMBA allyl scavenger. 
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Scheme 3.8 Synthesis of 6-O-amino acid esters of NTXOL by the 
Fmoc/OAllyl global deblocking route. 
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Scheme 3.9 Synthesis of 6-O-amino acid esters of NTXOL by the Boc/OAllyl 
route. 
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Scheme 3.10 Synthesis of 6-O-amino acid esters of NTXOL by the Bis-
coupling route. 
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Scheme 3.11 Synthesis of 6-O-β-Ala-NTXOL by the Cbz/OBn route. 
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Figure 3.1 1H NMR spectrum of 3-OBn-6-O-Fmoc-Asp(OBzl)-NTXOL. 
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Figure 3.2 1H NMR spectrum of 3-OBn-6-O-Asp(OBzl)-NTXOL. 
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Figure 3.3 ESI-MS of 3-OBn-6-O-Asp(OBzl)-NTXOL hydrogenolysis 
products. 
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Figure 3.3 (cont.) ESI-MS of 3-OBn-6-O-Asp(OBzl)-NTXOL hydrogenolysis 
products.  
 
 
  
  
Compound I Compound II 
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Figure 3.4 1H NMR spectrum of 3-OBn-6-O-Asp(OBzl)-NTXOL 
hydrogenolysis products. 
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Figure 3.5 LC-UV/ESI-MS of 3,6-O-Bis-Fmoc-β-Ala-NTXOL deblocking test. 
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6-O-Leu-NTXOL (control) 
 
6-O-Leu-NTXOL (Hydrogenolysis 24 h) 
 
Figure 3.6 6-O-Leu-NTXOL ester hydrogenolysis test. 
 
 
 
 
 
prodrug NTXOL 
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6-O-Leu-NTXOL (Hydrogenolysis 24 h + NTXOL spike) 
 
6-O-Leu-NTXOL (Hydrogenolysis 24 h + prodrug spike) 
 
Figure 3.6 (cont.) 6-O-Leu-NTXOL ester hydrogenolysis test. 
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Figure 3.7 LC-UV/ESI-MS of 3-OBn-6-O-Cbz-β-Ala-NTXOL hydrogenolysis 
products.  Conditions:  10 mol% Pd Black / EtOAc / H2 @ 50 psi / 4 days. 
205 
 
 
 
 
 
 
 
 
Figure 3.8 LC-UV/ESI-MS of 3-OBn-6O-Cbz-β-Ala-NTXOL hydrogenolysis 
products.  Conditions:  Pd Black 3 x wt%  / EtOAC/ THF wash / 24 h / H2 @ 50 
psi. 
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Figure 3.9 1H NMR spectrum of 6-O-β-Ala-NTXOL. 
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 Figure 3.10 13C NMR spectrum of 6-O-β-Ala-NTXOL. 
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Figure 3.11 LC-UV/ESI-MS of 6-O-β-Ala-NTXOL. 
 
 
209 
 
 
 
 
 
Figure 3.12 1H NMR spectrum of 6-O-Ile-NTXOL. 
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Figure 3.13 13C NMR spectrum of 6-O-Ile-NTXOL. 
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Figure 3.14 X-ray crystal structure of 6-O-Ile-NTXOL.  
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Figure 3.15 LC-UV/ESI-MS of 6-O-Ile-NTXOL. 
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Figure 3.16 1H NMR spectrum of 6-O-Leu-NTXOL. 
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Figure 3.17 13C NMR spectrum of 6-O-Leu-NTXOL. 
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Figure 3.18 LC-UV/ESI-MS of 6-O-Leu-NTXOL. 
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Figure 3.19 1H NMR spectrum of 6-O-Val-NTXOL. 
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Figure 3.20 13C NMR spectrum of 6-O-Val-NTXOL. 
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Figure 3.21 LC-UV/ESI-MS of 6-O-Val-NTXOL. 
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Figure 3.22 13C NMR spectrum of 6-O-Ala-NTXOL.  
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Figure 3.23 LC-UV/ESI-MS of 6-O-Ala-NTXOL.  
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Figure 3.24 13C NMR spectrum of 6-O-Pro-NTXOL.  
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Figure 3.25 LC-UV/ESI-MS of 6-O-Pro-NTXOL. 
 
Copyright © Joshua A. Eldridge 2013 
 
 
223 
 
Chapter 4 
Synthesis of 14-O-amino acid esters and miscellaneous prodrugs of NTX 
 
In order to exploit all the possible acylation positions on NTX and NTXOL, the 
poorly reactive 14-O position of the morphinan ring system was also considered 
in synthetic designs.  It was envisioned that esters formed at the tertiary aliphatic 
hydroxyl position of NTX would have interesting stability characteristics 
compared to their 3-O-phenolic and 6-O-aliphatic counterparts, in particular with 
respect to enzyme kinetics of hydrolysis at the more sterically-hindered 14-O 
position.  Synthesis of the desired esters was not simple to achieve however, 
because the 14-O positions of NTX and NTXOL have proven to be highly 
unreactive under a variety of conditions, as is indicated by the lack of need for a 
protecting group on the 14-O position in other hydroxyl coupling reactions. 
Ultimately, the recurrent evidence in our laboratories has shown that the 14-O 
position requires the assistance of microwave irradiation to become reactive 
toward electrophilic coupling reagents.  In the case of 14-O-amino acid esters of 
NTX, microwave irradiation was found to be required for 14-O coupling as well.  
Sonication and simple heating were also explored as alternatives to microwave 
irradiation, but there was no evidence of coupling in the crude 1H NMR spectra of 
reaction products from those conditions.  Overall, the coupling step was found to 
require the Fmoc-β-Ala-Cl synthon that had originally been employed in the 6-O-
NTXOL amino acid ester prodrug series (Chapter 3).  Carbodiimide strategies 
failed under all conditions, as determined by 1H NMR spectrometric analysis of 
crude reaction products.  The best coupling results that were obtained from many 
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attempts under various reaction conditions are summarized in Scheme 4.1.  
Aside from generally poor coupling at the 14-O position under all conditions, 
even with up to 6 equivalents of the amino acid activated acid chloride, a 
problematic side reaction involving the enolate of the 6-keto group of the 
morphinan scaffold furnished a bis-coupled prodrug precursor as a significant 
side product.  Nonetheless, the major product could be separated by column 
chromatography and analyzed gravimetrically to indicate a 15% yield.  The 7% 
undesired bis-coupled side product also appeared as one spot on TLC under a 
variety of conditions.  In general, the major product, and the minor product had 
complicated NMR spectra (Figures 4.1, 4.2, 4.4, and 4.5) and fairly clean 
MALDI-TOFMS spectra (Figures 4.3 and 4.6).  The proton NMR spectra in the 
case of both the major product, 3-O-allyl-14-O-Fmoc-β-Ala-NTX (Fig. 4.1), and 
the minor product, 3-O-allyl-6-O,14-O-bis-Fmoc-β-Ala-NTX (Fig. 4.4), show an 
interesting shift of the cyclopropyl methylene peaks upfield of TMS.  This is 
unexpected since the crystal structure of 6-O-Ile-NTXOL in Fig. 3.14 does not 
suggest that a 14-O-amino acid conjugate of β-alanine should have steric 
characteristics that add significantly to the ring strain on the relatively distant 
cyclopropylmethyl amine substituent.  Nonetheless, it seems that 14-O-coupling 
shows this characteristic, and the minor product is expected to be a 14-O-
conjugate as well.  With so many other overlapped peaks and doubling in many 
of the regions of the proton NMR spectrum of the major product, multiple 
conformers seem to be showing in the NMR spectrum.  The MALDI-TOFMS 
spectra provide additional evidence that the two products are as suggested in 
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Scheme 4.1 (m/z = 675 & 968 compared to MW = 674.78 & 968.10).  13C NMR 
spectra are also shown in Figures 4.2 and 4.5; however these spectra do not 
seem to indicate that the single spots on TLC for the major and minor products 
are indicative of totally clean prodrug precursors.  For instance, the major product 
C41H42N2O7 has more than 41 carbon peaks, and the minor product C59H57N3O10 
has more than 63 unique carbons in the NMR.  It is likely that stable 
conformations and/or hydrogen bonding phenomena could play a role in the 
number of peaks observed in these spectra.   
In terms of competing reactions, it was also evident that a large amount of the 
coupling synthon was quenched to the parent carboxylic acid, regardless of the 
use of dried solvents, under the harsh conditions of 80°C microwave irradiation 
for thirty minutes.  Also, a twofold excess of DMAP base was required to quench 
HCl formed in the preactivation and coupling reactions, but those conditions also 
favored premature removal of Fmoc under the microwave coupling reaction 
conditions.  The obvious problems associated with the Fmoc removal at the 
coupling stage were peptide polymerization of the β-Ala pro-moiety, and free 
amine-dibenzofulvene adduct formation with the deblocked prodrug precursor 
and dibenzofulvene (DBF).  In order to suppress these side reactions, alternative 
secondary amine bases were explored to replace DMAP, a tertiary base that 
cannot participate in scavenging of the DBF Michael acceptor that forms in Fmoc 
removal. When other bases were used as scavengers, the 14-O coupling yield 
suffered even more.  Therefore, the optimized conditions for coupling using Fmoc 
and allyl protecting group strategies were achieved with disappointing results.  In 
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order to attempt suppression of the 6-O-enolate ester that formed in the reaction, 
6-keto blocking was explored using the typical 1,4-dioxane and 1,4-dithiane 
approaches that employ ethylene glycol and 1,2-ethanedithiol, respectively 
(Scheme 4.2).   
Referring to Scheme 4.2, the 6-(1,4-dioxaspiro-ethylene)-NTX synthon did form 
with conditions ―i‖ and ―ii,‖ while the 6-(1,4-dithiaspiro-ethylene)-NTX synthon 
could not be obtained at all using conditions ―iv‖ and ―v.‖  6-(1,4-Dioxaspiro-
ethylene)-NTX was also inaccessible by conditions ―iii.‖  The evidence supporting 
the 6-(1,4-dioxaspiro-ethylene)-NTX observations was obtained via 13C NMR 
analysis, as there was no apparent new spot on TLC under any conditions, and 
one can most easily surmise reaction progress in this case by looking for the 
characteristic chemical shift of the ketone carbonyl carbon in the NMR spectrum.  
Figure 4.8 shows the reference 13C NMR spectrum for NTX [Fig. 4.8(a)], the 
crude 13C NMR spectrum of ―Scheme 4.2 Conditions iii [Fig. 4.8(b)],‖ and the 13C 
NMR spectrum of the crude product of ―Scheme 4.2 Conditions i and ii [Fig. 
4.8(c)].‖   Figure 4.8(c) represents a snapshot of the reaction progress at 8 hours 
reflux in toluene (following 4 hours without trimethyl orthoformate and 4 hours 
with trimethyl orthoformate).  There is clear evidence that NTX is still present in 
the 13C NMR spectrum, as the line data imply; however, there is also evidence of 
a new material with the expected peaks present in the 120-118 ppm range 
(hemiketal carbon) and at around 65 ppm (methylene carbons of the dioxane 
ring).  In the case of the materials reacted with BF3 etherate (conditions iii and iv), 
there was no sign of a new naltrexone-containing compound following workup 
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with 5% sodium bicarbonate.  For instance, Figure 4.8(b) is identical to NTX, 
Figure 4.8(a).  When the cupric Lewis acid catalyst was used (conditions v), as 
per a recent literature method (Oksdath-Mansilla and Penenory 2007), only a 
multi-solvent insoluble material was formed.  Therefore, attention was turned 
predominantly to the optimization of conditions ii, the tosylic acid-catalyzed 
reaction under dehydrating conditions (ethylene glycol is extremely hygroscopic, 
and the reaction favored water loss to drive the equilibrium).  However, even with 
24h of reflux in a Dean Stark apparatus and the addition of trimethyl orthoformate 
for added dehydrating power, the desired 6-(1,4-dioxaspiro-ethylene)-NTX 
synthon could not be formed quantitatively.  The problem then arose that 
purification of the desired keto-protected material from the mixture with NTX was 
simply not possible.  NTX and the 6-(1,4-dioxaspiro-ethylene)-NTX synthon had 
identical migration on silica gel plates under all solvent conditions, even with TEA 
treatment to destroy the acidity of the silica.  Since no suitable method for keto 
protection could be found, the 14-O-amino acid ester prodrugs of NTX were 
abandoned at this stage.  The final steps to afford the end products from the 
protected intermediates would have had all the same problems that the 6-O-
amino acid esters of NTXOL had exhibited, and with vast diminishing returns to 
scale following a disappointing coupling yield, pursuit of this chemistry was not 
time and cost effective.  For instance, removal of the allyl protecting group on 
phenol would have required palladium-catalyzed tributyl tin hydride chemistry 
that had previously proved unsuccessful in the 6-O-NTXOL amino acid esters 
work.  Ketones are easily reduced non-stereospecifically to secondary alcohols 
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using the PMHS-ZnCl2 and homogenous palladium catalyst system 
(Chandrasekhar, Reddy et al. 1997).  The latter would have resulted in a mixture 
of 6-α/β-NTXOL diastereomers that would have complicated purification 
procedures to an unacceptable degree.  Benzylation of the phenol group was out 
of the question due to the susceptibility of the 6-keto substituent to yet another 
non-stereospecific reduction under the conditions of hydrogenolysis, and TBDMS 
ether formation on the 3-O phenol had also previously failed.   Still, it would be 
extremely interesting to know the differences in hydrolytic behavior between the 
6-O-NTXOL amino acid prodrugs and their 14-O-NTX counterparts, with regard 
to enzyme-catalyzed hydrolysis in particular. 
Aside from 14-O amino acid esters, which conclude the development of amino 
acid esters in this body of work, it was also envisioned that the 6-keto position of 
NTX might serve as a site of nucleophilic substitution by the free amine of amino 
acids, which could then possibly be further converted by microwave chemistry 
into novel, ring-closed 1-oxa-4-azaspiro prodrugs via an imine intermediate 
(Scheme 4.3).  The idea is perhaps a mechanistic long-shot; however, brief 
attempts were made to investigate the feasibility of preparing these materials for 
assay as potential prodrug candidates.  There is no particular hydrophilicity 
increase to be gained by this approach.  Yet, classical transdermal delivery is 
enhanced by increased lipophilicity on the parent NTX scaffold (see Chapter 1), 
and it was expected that successful chemistry to afford these interesting spiro 
prodrug species might lend some utility to the classical transdermal podrugs 
literature.  Because the stereochemistry of such a reaction would be the object of 
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intense study, it was decided to simplify the R-group influence of the substituted 
α-amino acids and check the reaction with glycine (R=H).  β-Alanine would have 
also been a good choice for the initial investigations; however, it would have 
formed a 6-membered ring compared to the expected 5-membered ring with the 
glycine reaction.  Since 5-membered ring closures represent the most rapid ring-
closing reactions in organic chemistry, the 5-membered ring that could be 
obtained from glycine was expected to be better able to out-compete the water 
nucleophile that would form if the reaction proceeded.  With these thoughts in 
mind, the reaction was pursued with various iterations using microwave 
chemistry.  Unfortunately, employing the various conditions depicted in Scheme 
4.3, there was no evidence of any reaction at all in dry DMF.  Methanol could not 
be used for obvious reasons.  Other solvents simply do not dissolve glycine to 
any useful extent, so the desired spiro prodrug product could not be obtained by 
this approach.  
Next, a model reaction was conducted to confirm reactivity of the 6-ketone 
functionality of NTX toward the free amine group of α-amino acids (Scheme 4.4).  
This was done simply to rule out the possibility that these amines do not form 
imine intermediates on NTX.  The best way to trap the imine in an irreversible 
reaction is to employ the standard procedure of reductive amination.  Within the 
laboratory, NH2-Val-O-t-Bu was available for the model reaction.  This particular 
t-Bu ester-protected amino acid was a perfect species for the model synthesis, 
because the carboxylic acid was blocked from nucleophilic attack on the imine.  
The reductive amination could then be performed using sodium 
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cyanoborohydride, the results of which provided ESI-MS evidence for the 
formation of the desired 6-NH-Val-O-t-Bu analogue(s) (Figure 4.7).  Although the 
model compound is certainly an interesting precursor whose chemistry could be 
refined, optimized, and taken all the way to the fully deblocked 6-NH-Val-O-t-Bu 
opioid analogue with relative ease (no hydrolysis would occur on this compound 
under acidic deblocking conditions), the goal of this body of work was to develop 
prodrugs of NTX, and not analogues.  Overall, the results of this model reaction 
indicate that the necessary imine intermediate does form, and one might be able 
to make the desired spiro compounds for assay using other techniques.   
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Scheme 4.1 Synthesis of 3-O-allyl-14-O-Fmoc-β-Ala-NTX. 
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Scheme 4.2 Synthesis of keto-protected NTX synthons. 
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Scheme 4.3 Synthesis of 6-(1-oxa-4-azaspiro-glycinyl)-NTX. 
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Scheme 4.4 Synthesis of 6-NH-Val-tBu-NTX.  
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Figure 4.1 1H NMR spectrum of 3-O-allyl-14-O-Fmoc-β-Ala-NTX. 
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>41 unique carbons above the noise level 
C41H42N2O7 
 
Figure 4.2 13C NMR spectrum of 3-O-allyl-14-O-Fmoc-β-Ala-NTX. 
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Figure 4.3 MALDI-TOFMS of 3-O-allyl-14-O-Fmoc-β-Ala-NTX. 
 
 
 
 
 
 
Molecular weight: 674.78 
238 
 
 
 
 
 
 
Figure 4.4 1H NMR spectrum of 3-O-allyl-6-O,14-O-bis-Fmoc-β-Ala-NTX. 
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> 63 unique carbons above the noise level  
C59H57N3O10 
Figure 4.5 13C NMR spectrum of 3-O-allyl-6-O,14-O-bis-Fmoc-β-Ala-NTX. 
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Figure 4.6 MALDI-TOFMS of 3-O-allyl-6-O,14-O-bis-Fmoc-β-Ala-NTX. 
 
 
 
 
 
 
 
Molecular Weight: 968.10 
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Figure 4.7 ESI-MS of 6-NH-Val-tBu-NTX. 
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13C NMR (CDCl3) 300 MHz: δ 209.97 (C=O, 6-O ketone), 143.70, 139.00, 
129.23, 124.31, 120.01, 118.09, 90.78, 70.68, 62.25, 59.49, 51.33, 43.94, 36.53, 
31.67, 30.95, 22.97, 9.77, 4.43, 4.18 ppm. 
Figure 4.8 Comparison of 13C NMR spectral data obtained from Scheme 4.2. 
 
 
Fig. 4.8 (a) 13C NMR spectrum 
of Naltrexone (CDCl3) 
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13C NMR (CDCl3) 300 MHz: δ 209.97 (C=O, 6-O ketone), 143.70, 139.00, 
129.23, 124.31, 120.01, 118.09, 90.78, 70.68, 62.25, 59.49, 51.33, 43.94, 36.53, 
31.67, 30.95, 22.97, 9.77, 4.43, 4.18 ppm. (Identical to NTX with some impurity 
peaks not associated with the expected hemiketal carbon @ ~ 120) 
Figure 4.8 Comparison of 13C NMR spectral data obtained from Scheme 4.2 
(continued). 
 
 
 
Fig. 4.8 (b) 13C NMR spectrum 
of Scheme 4.2 Conditions iii 
(CDCl3) 
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13C NMR (CDCl3) 300 MHz: δ 209.97 (C=O, 6-O ketone), 143.70, 139.00, 
129.23, 124.31, 120.01, 118.09, 90.78, 70.68, 62.25, 59.49, 51.33, 43.94, 36.53, 
31.67, 30.95, 22.97, 9.77, 4.43, 4.18 ppm. (NTX set)  New Peaks: δ 209.97 
(C=O, 6-O ketone) still present, several new peaks as expected in the range of 
120-118 ppm (hemiketal carbon) and 65 ppm (methylenes of the dioxane ring).   
Figure 4.8 Comparison of 13C NMR spectral data obtained from Scheme 4.2 
(continued). 
Copyright © Joshua A. Eldridge 2013 
 
 
Fig. 4.8 (c) 13C NMR of Scheme 4.2 
Conditions i and ii (CDCl3) 
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Chapter 5 
Synthesis of Codrugs of Naltrexone with Bupropion and (-)-Cytisine 
 
Within the present study, a revisit was paid to the synthesis of a codrug of NTX 
and bupropion (BUP) (Figure 5.1).  However, like the efforts before it (Hamad, 
Kiptoo et al. 2006), the synthesis of BUP-NTX was not successful under any 
conditions.  Several attempts to form that compound will be discussed.  The 
codrug that did come to fruition in this body of work is 3-O-(-)-cytisine-naltrexone 
(CYT-NTX), which is a secondary carbamate conjugate of (-)-cytisine (CYT) and 
NTX (Figure 5.1).  Its preparation is discussed first. 
5.1 (-)-Cytisine-NTX (CYT-NTX) carbamate as a codrug for oral delivery 
Throughout the duration of this dissertation, microneedle-enhanced transdermal 
delivery has been the intended drug delivery system for all of the prodrugs that 
have been designed.  CYT-NTX is a unique compound in the present body of 
work, because it is a codrug, and we evaluated it in an oral drug delivery 
paradigm.  The stability studies of CYT-NTX are the subject of Chapters 6 and 
7.  The following discussion summarizes the synthesis of CYT-NTX.   
5.2 Synthesis of CYT-NTX carbamate 
Scheme 5.1 shows the synthesis of CYT- NTX (MW=557.64 g•mol-1) that worked 
the best.  The 3-O-PNP carbonate synthon of NTX was first prepared by Y.T. 
Reddy and given as a gift to attempt the synthesis, and TEA and DMAP bases 
were employed as proton mops.  However, the 3-O-PNP-NTX synthon is very 
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difficult to purify completely due to its instability in solution, and its isolation later 
proved to be unnecessary.  Despite the fact that CYT should be a really good 
nucleophile, the reaction did not really progress much over a temperature range 
from 0°C up to room temperature in dry DCM when CYT was reacted with 3-O-
PNP-NTX in the presence of DMAP or TEA bases.  Therefore, it was decided to 
use microwave chemistry with dry THF as a solvent.   
The reaction was run in dry THF at 50 °C in a Biotage Initiator microwave reactor 
for ten minutes.  3-O-PNP-NTX was formed from NTX and 4-
nitrophenylchloroformate in situ at 0 °C with DMAP and NTX in excess, and CYT 
was subsequently reacted directly in a one-pot procedure in the Biotage 
microwave reactor.  The codrug product conveniently crashed out of solution 
under these conditions, and was isolated in 80% yield.  All of the excess 
reagents could be washed away with cold THF and cold methanol washes.  
Unreacted NTX and CYT were recovered by washing with ether, and then they 
were isolated from each other by column chromatography.  Regarding recovery 
of the desired product, the procedure thus described had the following 
advantages: (1) one-pot synthesis; (2) no chromatography, and (3) substantial 
yield.  However, the caveat was that CYT-NTX formed under these conditions 
was actually not one compound.  Rather, it appears as though a mixture of two 
geometric isomers was isolated (see spectral data discussion below).  This was 
an expected result since CYT is an asymmetric secondary amine, and carbamate 
rotation about the amido bond is restricted, as is observed in amides.  Some 
attempts were made to separate the compounds as individual isomers; however, 
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these attempts failed under a variety of conditions.  Therefore, it is important that 
the reader understand that ―CYT-NTX‖ refers to a mixture of geometric isomers, 
and not to one individual codrug molecule. It is noteworthy to mention that the 
small amount of CYT-NTX formed under non-microwave conditions was 
spectroscopically identical to CYT-NTX prepared by microwave assisted 
synthesis.  Only the yields were different.  Therefore, microwave synthesis did 
not affect the end products; rather, it greatly enhanced the amount of conversion 
of starting materials to CYT-NTX.  
ESI-MS, HPLC, 1H NMR, and 13C NMR spectra of the final material are shown in 
Figures 5.2 - 5.4.  A discussion about the data appears in the experimental 
section. 
5.3 Attempted syntheses of BUP-NTX carbonate 
From a drug design point of view, BUP-NTX (Fig 5.1) could be a desirable 
codrug molecule with the following properties: (1) equimolar delivery of two FDA-
approved medications that can simultaneously treat alcohol and tobacco co-
abuse following bioconversion; (2) physiochemical properties that allow 
transdermal delivery; and (3) a secondary carbamate linker that is likely to be 
formulation stable and cleavable in vivo.  With regard to premise (3), these 
linkers often require hepatic metabolism to be cleaved in vivo (see Chapter 7 on 
in vivo pharmacokinetics of CYT-NTX), so BUP-NTX may well be a potential oral 
delivery candidate as well.   
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Many attempts were made to prepare the BUP-NTX codrug that had originally 
been pursued in the PTD codrugs project (Hamad, Kiptoo et al. 2006).  From the 
previous work, it had become obvious that phosgenation of the bupropion 
molecule, whether by enol trapping or N-conjugation, resulted in rapid 5-
membered ring cyclization to form a cyclic enol carbamate intermediate (See 
Figures 5.5 and 5.8).  In the series of reactions that were conducted by Hamad, 
it was also noted that attempts to phosgenate NTX to prepare a chloroformate 
synthon also failed and resulted in the formation of the ―Gemini‖ NTX-NTX duplex 
codrug (Hammell, Hamad et al. 2004, Hamad, Kiptoo et al. 2006).  In a new 
chapter of synthetic methodology, the 3-O-PNP-NTX carbonate synthon was 
developed in our labs, and it had proven to be useful in the synthesis of a variety 
of NTX prodrugs (Yerramreddy, Milewski et al. 2010).  Before the microwave 
chemistry to afford CYT-NTX had been established, work had already been 
initiated to attempt to prepare an activated PNP carbamate synthon of BUP, or to 
simply react BUP with the already developed 3-O-PNP-NTX carbonate. Later, 
the same conditions that afforded CYT-NTX were attempted.  With great 
misfortune, none of these methods eventually afforded the desired BUP-NTX 
carbamate prodrug.  Nontheless, insights can be gained from the failed attempts 
to prepare this material, and they are included here as a significant portion of the 
work that was executed in our attempts to make codrugs of smoking cessation 
agents and NTX.   
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5.3.1  Attempt to prepare N-PNP-BUP carbamate. 
Scheme 5.2 shows the conditions that were utilized to attempt the preparation of 
N-PNP-BUP carbamate.  BUP•HCl salt was converted to its free base using the 
technique of Hamad et al (Hamad, Kiptoo et al. 2006).  In working with BUP, one 
must always prepare the free base from the hydrochloride salt, because the free 
base is extremely labile to oxidation in air in just a very short while.  The free 
base in solution has a considerably longer lifetime, especially when DCM is used 
as the solvent.   Following recovery of the freebase, the material was 
immediately dissolved in dry DCM containing 1.5 eq. DMAP base, and the 
reaction flask was purged under argon to prevent degradation.  The flask was 
also jacketed with aluminum foil since BUP is photosensitive as well.  1.1 
equivalent of 4-nitrophenyl- chloroformate was added dropwise in DCM at 0 °C 
over the course of 10 minutes, and the reaction was allowed to stir for 15 minutes 
before checking the evolution of products by TLC.  The TLC showed BUP as a 
prominent spot, and only a slight bit of any new products, so the reaction was 
continued and monitored over the course of several hours.  The temperature was 
allowed to warm to room temperature, and the reaction was continued overnight.  
When the BUP had not been consumed by morning, an additional 0.5 eq. of the 
chloroformate was added, and the reaction mixture was brought to reflux under 
argon.  BUP was never consumed under any of these conditions, so the reaction 
was stopped, and a sample was injected onto GC-MS for analysis of the product 
distribution.  Figures 5.5 – 5.9 show the GC chromatogram and the EI mass 
spectrum.  It is very clear from the chromatogram and the identified peaks that 
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this approach has all the same problems as the previous phosgenation 
chemistry.  BUP is very sluggish to react in the first place, and when it does, it 
forms the unwanted cyclized 2,4-oxazolidine material very rapidly.  A second 
attempt at this reaction was done only at 0 °C to see if temperature would help 
solve the unwanted cyclization issue, since BUP is significantly sterically 
hindered.  The results were identical.  Another iteration of this reaction with no 
DMAP base was also conducted to see if enolate formation could be suppressed, 
but this afforded the exact same results as well.  BUP activation was simply a 
failed route to the codrug.  These results are not really surprising since five-
membered intramolecular cyclizations of this type are kinetically favored.   
5.3.2 Attempts to prepare BUP-NTX via 3-O-PNP-NTX carbonate 
With evidence of prodrug formation via 3-O-PNP-NTX already well established at 
the time of these experiments, the next most logical route to pursue in an attempt 
to afford BUP-NTX was obvious.  Scheme 5.3 shows the next methods that were 
employed to prepare BUP-NTX.  Reactions A and B used the same molar 
equivalents of reactants, but different reaction conditions. Reaction A was run at 
room temperature in THF for 24 hours and then refluxed for 5 hours when no 
spots on TLC indicated a new material other than NTX or 4-p-nitrophenol. 
Reaction B utilized microwave chemistry in THF since those conditions were 
known to afford CYT-NTX in good yield.  However, BUP-NTX could not be 
formed under any of these conditions.  Aliquots were submitted for ESI-MS, and 
the mass spectra are shown in Figure 5.10 and 5.11.  In the case of reaction A, it 
appears that reflux in THF resulted in degradation of 3-O-PNP-NTX to NTX.  No 
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mass for the desired product was observed (MW=607.14).  Interestingly, 
Reaction B also resulted in degradation of 3-O-PNP-NTX, but the m/z = 709.5 
major product happens to coincide with the mass of the NTX-NTX Gemini 
prodrug (MW=708.80) that was formed as an accidental side product in the 
original syntheses conducted by Hamad et al (Hamad, Kiptoo et al. 2006).  This 
result is particularly interesting, because the CYT-NTX microwave chemistry did 
not result in the formation of the Gemini prodrug, which means that the 
secondary amine nucleophile CYT reacted with 3-O-PNP-NTX at a fast enough 
rate to suppress its degradation and subsequent reaction with released NTX.  
Bupropion is much more sterically hindered than CYT, and that was the reason 
why CYT was used to replace it in the first place.  These data indicate that 
synthesis of the BUP-NTX codrug would require a very different strategy, such as 
building up the linker between NTX and t-butylamine before reacting with m-
chloropropiophenone. Nonetheless, for the purposes of this body of work, BUP-
NTX was not isolated under any conditions, and CYT-NTX proved to be a very 
interesting material to work with in in vitro and in vivo stability studies (Chapters 
6 and 7).   
5.4  Experimental Section 
Materials: All reagents were purchased from Acros Organics or Sigma-Aldrich 
and were used without further purification.  Naltrexone was obtained from 
Mallinckrodt-Covidien.  (-)-Cytisine was purchased from Fisher via special order 
from Astatech.  All solvents were dried and stored over molecular sieves prior to 
use.  
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NMR:  All NMR spectra were obtained on a Varian 300 MHz or a Varian 500 
mHz instrument.  Line data and integral values for 1H NMR were acquired with 
Mestrenova Lite (Mesterlab Research Chemistry Software Solutions, Escondido, 
CA) using 500 MHz spectra.  13C NMR frequencies were obtained from Varian 
Mercury 300 MHz NMR software.  TMS was used as an internal standard. 
MS data:  ESI-MS data were acquired by Dr. Jack Goodman at the University of 
Kentucky Mass Spectral Facility.  EI-MS data were acquired on an Agilent 1100 
series GC-MS instrument.  
Synthesis of CYT-NTX codrug (geometric isomers) 
 
3-O-(4-nitrophenyl) NTX carbonate (3-O-PNP-NTX) was formed in situ for direct 
reaction with CYT.  The solvent was dry THF.  The reaction was designed to 
proceed in two separate stages with an overall one-pot goal.  50.0 mg of CYT 
would yield 146.56 mg of CYT-NTX codrug for testing, assuming 100% yield, and 
the equivalents of other reagents were designed around that amount of CYT. 3-
O-PNP-NTX was formed at 0 °C by dissolving NTX (107.7 mg, 1.2 Eq.) and 
DMAP (38.5 mg, 1.2 Eq.) in a 5.0 mL microwave reactor vial containing dry THF.  
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In a separate dry vial, 4-nitrophenlychloroformate (52.9 mg, 1.0 Eq.) was 
dissolved in dry THF under argon, and this solution was added to the microwave 
vial containing NTX and DMAP with dropwise addition and heavy stirring over the 
course of 5 minutes under argon.  After the spot for 4-nitrophenylchloroformate 
appeared to be consumed on TLC (10 minutes), the vial septum was removed, 
and 50.0 mg CYT (1.0 Eq.) was charged to the reaction vial.  The vial was then 
sealed with a microwave reaction cap to hold pressure, and the reaction solution 
was irradiated for 10 minutes at 50 °C with a Biotage Initiator EXP-US microwave 
reactor.  The solvent volume was approximately 4.0 mL.  
Reaction progress was visibly detectable by the brilliant yellow color of the 
liberated 4-nitrophenol in solution and the codrug product precipitated as a fine 
white amorphous solid.  The precipitate was washed with 3 x10 mL cold THF 
followed by 3 x10 mL cold methanol and analyzed by TLC as only one spot.  The 
material yield after drying was (117.2 mg, 80%).  The material was analyzed by 
Electrospray Ionization Mass Spectroscopy, 1H NMR and 13C NMR spectrometry, 
and HPLC.  NMR spectral data suggested the presence of two unique isomers of 
CYT-NTX. 
1H NMR (CDCl3) 500 MHz:   
δ 7.30 – 7.37 (m, ~2H [overlap with CDCl3 in peak portion from 7.2 -7.3]), 6.75 
(d, J=5 Hz, 1H), 6.41 – 6.64 (m, 4H) 6.32 (d, J=5 Hz, 1H), 6.04-6.15 (m, 2H), 
4.65 – 4.72 (m, 2H) 4.28 – 4.58 (m, 4H), 4.20 (d, J=10 Hz, 1H), 3.85 – 3.98 (m, 
2H), 3.23 – 3.43 (m, 2H), 2.94 – 3.24 (m, 11H), 2.63 – 2.71 (dd, 2H), 2.50 – 2.60 
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(m, 4H, looks like dd with overlap), 2.34 – 2.54 (m, 6H), 2.24 – 2.32 (m, 2H), 1.98 
– 2.17 (m, 7H), 1.80 – 1.91 (m, 2H), 1.43 – 1.65 (m, 5H), 0.80 – 0.92 (m, 2H), 
0.51 – 0.61 (m, 4H), 0.11 – 0.18 (m, 4H) ppm. 
13C NMR (CDCl3) 300 MHz:  
 
δ 208.24, 163.49, 152.95, 148.99, 148.62, 148.02, 139.15, 139.04, 138.86, 
133.05, 129.90, 129.67, 123,26, 119.52, 117.62, 105.67, 90.77, 70.30, 68.23, 
68.10, 59.38, 53.76, 52.48,  51.74, 51.30, 50.89, 50.74, 49.61, 49.25, 43.99, 
36.44, 35.00, 31.63, 30.69, 30.02, 27.83, 27.39, 26.27, 26.02, 25.95, 23.38, 9.45, 
4.548, 4.17 ppm.  
ESI-MS: m/z 558 
Discussion of spectral data 
An HPLC analytical method was developed to separate the codrug product from 
NTX and CYT.  Using the method described in Chapter 6, it can be seen in 
Figure 5.3 (A) & (B) that the product gave a clean peak for codrug, and no CYT 
or NTX was detected.  NTXOL was not an issue in this synthesis, and it only 
appears in Figure 5.3 (A) because the method was designed to also separate 
NTXOL in case we pursued a CYT-NTXOL codrug in the future.  The ESI-MS 
spectrum shown in Figure 5.2 also suggests that the product gave a clean mass 
profile with the expected m/z for CYT-NTX.  However, NMR spectral data are 
much more information rich than either the HPLC or the MS data, and it is clear 
from the 1H NMR spectrum of the isolated codrug material that a single CYT-NTX 
codrug was not obtained by this synthesis.  This is particularly obvious in the 
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phenyl region of the spectrum, where complex multiplets emerge due to the 
different magnetic environments of the phenyl protons on the NTX and the CYT 
moieties.  Indeed, the proton spectrum is very complex, and multiple multiplets 
are seen throughout the entire field.  This type of complexity suggests an 
isomeric mixture of products in the CYT-NTX sample, in particular since the CYT 
moiety is an asymmetric secondary amine, and amide-like linkers (such as the 
secondary carbamate in CYT-NTX) have restricted rotation about the carbonyl C-
N bond.  Since there is an opportunity for CYT to attack 3-O-PNP-NTX by a 
variety of vectors, it may be expected that geometric isomerism is possible in the 
product.   
13C NMR spectral analysis also confirms that the material isolated in this 
synthesis cannot be a single isomer of CYT-NTX.  There are 44 individual peaks 
that can be discerned from background noise when the spectrum is expanded 
and the frequencies are assigned (see Figure 5.4 A for a peak-expanded view of 
the spectrum after 30 minute acquisition time and Figure 5.4 B for the 
unexpanded spectrum from overnight acquisition). The molecular formula for 
CYT-NTX is C32H35N3O6, and each of the 32 carbons should be magnetically 
unique.  If one CYT-NTX isomer is described by C32H35N3O6, and another CYT-
NTX isomer is identical except for rotation of the CYT moiety with 11 carbons, it 
is reasonable to assume that C32 + C11 = C43 unique carbons may appear in the 
13C NMR spectrum.  Here we see C44, which may mean the carbonyl carbon is 
also showing magnetic inequivalence.   
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Returning to proton spectra, if one assumes two compounds are present and 
assigns one methylene set of the cyclopropyl peaks the normalized integral value 
of 4.00 for 4 protons (would be 2H for a single isomer) and then analyzes the 
proton data with 500 MHz NMR and Mestrenova software, 70 protons are 
accounted for.  Two isomers of CYT-NTX would have 70 protons.  Therefore, 1H 
NMR data are also consistent with the assumption that there appear to be two 
unique compounds present in the CYT-NTX sample.  Furthermore, the ratio of 
isomers appears to be 1:1.  Solvent peaks were not included in these analyses. 
HPLC analysis showed one peak for the codrug under a variety of conditions 
using the following stationary phases: Zorbax C18, Apollo C18, Kinetex PFP, and 
phenyl.  TLC analyses also indicated a single spot under various conditions.  All 
of the reagents employed in the synthesis also contained chromophores that 
could be detected by the HPLC analytical method that was employed.  Geometric 
isomers can generally be separated by chromatography, although this may not 
be an easy task, since the two structures are very similar.  Attempts to observe 
two peaks for the product utilizing a more selective Cyclobond 2000 chiral 
column also failed.  Since we could not successfully separate CYT-NTX isomers 
for individual study, we decided to pursue the isomeric mixture in our stability and 
PK studies that are detailed in Chapters 6 and 7.  For simplicity, ―CYT-NTX‖ is 
referred to in this dissertation, but the reader should note that CYT-NTX is really 
a mixture of two unique geometric isomers, as evidenced by NMR spectrometry. 
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Scheme 5.1 One-pot synthesis of CYT-NTX via microwave chemistry. 
 
 
 
 
 
 
258 
 
 
 
 
 
Scheme 5.2 Attempted synthesis of N-PNP-BUP carbamate synthon. 
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Scheme 5.3 Attempted synthesis of BUP-NTX via 3-O-PNP-NTX carbonate. 
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Figure 5.1 Codrug structures. 
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Figure 5.2 ESI-MS of 3-O-(-)-cytisine naltrexone (CYT-NTX) carbamate. 
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Figure 5.3 (A) HPLC chromatogram of CYT, CYT-NTX, NTXOL and NTX. (B) 
Clean chromatogram of CYT-NTX after solvent washes with THF and MeOH. 
(C) 1H NMR spectrum of CYT-NTX after solvent washes with THF and MeOH 
(solvent peaks: MeOH δ 1.22, 3.5 ppm; DCM δ 5.3 ppm; CDCl3 δ 7.26 ppm ).  
 
 
 
A 
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Figure 5.4 (A) 13C NMR spectrum of CYT-NTX (expanded view).  (B) 13C NMR 
spectrum of CYT-NTX with overnight acquisition time and no peak 
expansion (CDCl3 triplet δ 77.2 ppm is cut off to emphasize product peaks).   
 
 
 
 
 
A 
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Figure 5.5 GC-MS of the N-PNP-BUP-carbamate synthesis. 
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Figure 5.6 EI-MS of bupropion. 
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Figure 5.7 EI-MS of p-nitrophenol.  
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Figure 5.8 EI-MS of 3-tert-butyl-5-(3-chlorophenyl)-4-methyl-oxazolidin-2-
one.  
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Figure 5.9 EI-MS of p-nitrophenol gemini carbonate.   
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Figure 5.10 ESI-MS of BUP and NTX (failed reflux in THF).  
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Figure 5.11 ESI-MS of NTX-NTX Gemini prodrug, the major product from 
microwave chemistry. 
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Chapter 6 
 
  In vitro stability studies of the prodrugs 
 
6.1 Introduction 
In order to assess the candidacy of our amino acid ester prodrugs for MNTD, 
several stability criteria needed to be met.  For instance, a prodrug intended for 
percutaneous delivery through aqueous microchannels should be able to 
demonstrate adequate stability at skin-relevant pH and temperature over the time 
course of a skin diffusion experiment (t90 ≥ 48 hours @ pH 5.0 and 32°C).  Also, 
prodrugs intended for this purpose should be readily hydrolyzed at physiological 
pH and temperature, or in the presence of human plasma at appropriate body 
temperature (pH 7.4 and 37°C).  Rapid hydrolysis at pH 7.4 with or without 
enzymatic assistance is desired for two reasons.  First, rapid hydrolysis ensures 
that parent drug is systemically available following skin transport.  Second, it has 
been shown that extensive prodrug bioconversion in viable skin facilitates NTX 
and NTXOL transdermal flux enhancements (see Chapter 1 for references).  
Therefore, all of the prodrugs that were synthesized in Chapters 2 & 3 were 
assayed for MNTD candidacy by answering the following stability questions with 
HPLC-UV analyses: 
 Is the prodrug stable enough for skin diffusion studies in 0.3 M acetate 
buffer (pH 5.0 & 32°C) with t90 ≥ 48 hours? 
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 Using 25mM HEPES-buffered Hanks’ balanced salt solution or 50% 
Dulbecco's phosphate–buffered saline (PBS), is prodrug stability at pH 7.4 
and 37°C less than that observed at pH 5.0 and 32°C? 
 Does prodrug stability in 50% human plasma suggest that the prodrug will 
rapidly hydrolyze to parent drug and promoiety in the biophase?  
 
The stability story for CYT-NTX turned out to lead us in a different drug delivery 
direction than MNTD after certain critical data were obtained.  Initial assessment 
of codrug stability at pH 5.0 and 7.4 demonstrated that the codrug was not labile 
to hydrolysis.  Initial qualitative assays of codrug in the presence of 100% human 
plasma also showed no peaks for parent drugs, and no apparent reduction in the 
area of the codrug peak (37 °C x 4 days, data not shown).  Therefore, it was 
determined that CYT-NTX may need first-pass metabolism to hydrolyze the 
secondary carbamate linker in its structure.  Evidence to support that hypothesis 
is presented in Chapter 7.  With these data in hand, we decided to undertake a 
full stability analysis of CYT-NTX in an oral drug delivery paradigm.  Therefore 
CYT-NTX required different analyses than the MNTD prodrug series. 
 
A codrug or prodrug intended for oral delivery must demonstrate stability under a 
broader scope of conditions.  For instance, a compound ingested orally must first 
encounter the environment of the stomach, which can vary in pH from about pH 1 
to 2 in a fasted state.  Additionally, the stomach contains a milieu of enzymes 
that can hydrolyze labile linker moieties.  Following exposure to these conditions, 
273 
 
an orally ingested compound encounters pH 4 to 5 in the beginning of the small 
intestine and pH 7 to 9 in the small intestine and colon.  There are also different 
enzymes present throughout the small intestine and colon.  Expounding even 
further, a compound that is absorbed into the systemic circulation encounters a 
new environment of about pH 7.4 with a new host of widely variegated enzymes 
that can bind a molecule and increase its rate of hydrolysis dramatically.  So it is 
clear that a broad range of stability analyses are necessary to assess the 
candidacy of a compound for oral delivery.  In that regard, we tested CYT-NTX in 
the following in vitro hydrolysis media to determine if this codrug should be 
advanced to in vivo studies in the live Sprague-Dawley (S-D) rat: 
 Chemical buffer systems of pH 1.5, 5.0, 7.4 & 9.0 (37 °C) 
 Simulated Gastric Fluid (SGF, USP, 37 °C) 
 Simulated Intestinal Fluid (SIF, USP, 37 °C) 
 80% rat plasma (37 °C) 
 80% human plasma (37 °C) 
SGF contains pepsin and SIF contains pancreatin.  These features set the 
simulated fluids apart from the chemical buffers that have no enzymatic activity.  
80% human plasma (HP) was used in comparison to 80% rat plasma (RP) to 
investigate any interspecies differences between humans, for which the codrug 
would be intended clinically, and S-D rats, for which in vivo studies would be 
conducted to see if the codrug hydrolyzed in a living animal model.  
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6.2 Kinetics of hydrolysis in aqueous solutions (non-enzymatic) 
Amino acid prodrugs 
Buffer stability studies of the amino acid prodrugs at pH 5.0 and pH 7.4 were 
conducted by Mikolaj Milewski in Audra Stinchcomb’s lab, with the exception of 
6-O-Ile-NTXOL whose stability at pH 7.4 was done by the author in Dr. Crooks’ 
lab.  Therefore, 6-O-Ile-NTXOL stability at pH 7.4 is summarized separately. 
 
Prodrug stability studies in donor (0.3M acetate buffer, pH 5.0) and receiver 
solution (25mM HEPES-buffered Hanks’ balanced salt solution, pH 7.4) were 
initiated by charging a 10ml volume of hydrolysis media thermostated at 32 °C 
(pH 5.0 samples) and 37 °C (pH 7.4 samples) with ≈ 1.0 mg of prodrug.  The 
suspension was then filtered through a 0.45µm nylon syringe filter (Acrodisc® 
Premium 25mm Syringe Filter).  Aliquots were withdrawn, and the filtrates were 
collected over a period of approximately 3 half lives.  Samples were then diluted 
with ACN-water 70:30 (v/v) for HPLC analysis.  All amino acid ester prodrug 
hydrolysis studies showed pseudo-first-order kinetic behavior.  Apparent pseudo-
first-order hydrolysis rate constants (Kapp) were estimated from the slope of the 
log-transformed amount of prodrug remaining in the medium.  All stability studies 
were carried out in duplicate (n=2).  Table 6.2 summarizes the stability data as 
acquired by Milewski (unpublished).   
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6-O-Ile-NTXOL 
A stock solution of 0.75 mg/mL (1.6 mM) prodrug was prepared in DMSO.  A 
stock internal standard (IS) solution of salicylamide (0.076 mg/mL, 0.55 mM) in 
methanol containing 0.04% heptafluorobuyric acid ion pairing agent (HFBA) was 
also prepared.  Reactions were initiated by adding 40.0 µL of the prodrug stock 
solution to 760.0 µL of a pre-warmed (37±0.5 °C) solution of 50% PBS (initial 
reaction concentration of 0.038 mg/mL, 82 µM). The initial reaction concentration 
was within the linear range of the standard curve, and more concentrated 
reactions were impossible due to extensive prodrug precipitation at higher levels.  
Sampling over the course of time was done by the following method.   50.0 µL 
aliquots of the reaction mixture were removed at pre-determined time points. 
50.0 µL of internal standard solution and 50.0 µL of blank 0.04% HFBA in 
methanol were added to the reaction mixture aliquots in low volume inserts, and 
the solutions were vortexed.  Samples were immediately injected on the HPLC 
column and analyzed.  The data are summarized in Table 6.2.  
 
CYT-NTX 
All stability studies of the CYT-NTX codrug were conducted by the author in Dr. 
Crooks’ lab.  The codrug was challenged at 37±0.5 °C in four different pH 
environments (pH 1.5, 5.0, 7.4, & 9.0). Stability studies were conducted using a 
0.2 M hydrochloric acid buffer (pH 1.5); a 0.2 M phosphate buffer  (pH 7.4);  a 0.2 
M phosphate buffer (pH 5.0); and a 0.2 M boric acid and potassium chloride 
buffer (pH 9.0).  Reactions were initiated by adding 5.0 mL of a 1.00 mM stock 
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codrug solution in THF to 5.0 mL of the appropriate thermostated (37±0.5 oC) 
aqueous buffer solution. Aliquots (455.0 µL) were taken at various time intervals, 
mixed with 45.0 µL of 10.0 mM internal standard solution (N-1-
naphthylacetamide in THF) and analyzed by HPLC.  The data are summarized in 
Table 6.3. 
 
6.3 Kinetics of hydrolysis in human plasma and/or rat plasma 
Amino acid prodrugs 
All stability studies of the amino acid prodrugs in enzymatic media were 
conducted by the author in Dr. Crooks’ lab.  Stock solutions of prodrugs were 
prepared in DMSO.  The stock concentrations were 0.75 mg/mL (1.6 mM) 6-O-
Ile-NTXOL, 1.0 mg/mL (2.3 mM) 6-O-Val-NTXOL, and 3.0 mg/mL (7.2 mM) 6-O-
β-Ala-NTXOL in DMSO (see the discussion section for an explanation why the 
same reaction concentrations could not be used).  A stock internal standard (IS) 
solution of salicylamide (0.076 mg/mL, 0.55 mM) in methanol containing 0.04% 
HFBA was also prepared.  Reactions were initiated by adding 40.0 µL of the 
prodrug stock solution to 760.0 µL of a pre-warmed (37±0.5 °C) solution of 50% 
HP in 50% PBS buffer (pH 7.4).  This equates to the following initial reaction 
concentrations:  6-O-Ile-NTXOL = 0.038 mg/mL, 8.2 x 10-5 M;   6-O-Val-NTXOL = 
0.050 mg/mL, 1.1 x 10-4 M; and 6-O-β-ala-NTXOL = 0.15 mg/mL, 3.6 x 10-4 M.  
80% HP was not used, because HP supplies were limited.  Also, it has been 
shown that there is not a significant difference between hydrolysis rate data 
obtained with 50% HP and 80% HP stock solutions when hydrolysis reactions 
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are initiated with drug dissolved in DMSO (Di, Kerns et al. 2005).  This is true for 
final reaction concentrations of DMSO up to 5%, and the reactions in this study 
were 5% DMSO.  The buffer concentration of 50% PBS was used, because 
clouding of the plasma solutions was observed over the course of a stability 
experiment if 80% PBS was used.  Sampling over the course of time was done 
by the following method.   50.0 µL aliquots of a reaction mixture were removed at 
various time points and placed into 1000 µL eppendorf tubes.  50.0 µL of internal 
standard solution was added to the samples, and 300.0 µL of ice cold methanol 
containing 0.04% HFBA was charged to the tubes to precipitate proteins.  The 
mixtures were vortexed for exactly 30 seconds and subsequently centrifuged for 
exactly 10 minutes at 12,000 rpm.  Supernatants were removed into individual 
culture tubes and dried under N2 gas in a bath maintained at 37±0.5 °C.  
Residues were reconstituted in 150.0 µL methanol containing 0.04% HFBA with 
vortexing for exactly 30s and then visually inspected for solid material.  All of the 
samples were clear, and they were immediately transferred to low-volume inserts 
and injected onto the HPLC column for analysis. The data are summarized in 
Table 6.2. 
 
CYT-NTX 
All stability studies of the CYT-NTX codrug in enzymatic media were conducted 
by the author in Dr. Crooks’ lab.  The procedure for CYT-NTX used identical 
sampling and reaction volumes as the prodrugs above.  However, several 
modifications were required.  First, a 2.5 mg/mL (4.5 mM) stock solution of 
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codrug in DMSO was employed.  Second, the extraction solvent was 5% formic 
acid in acetonitrile, because the codrug was insoluble in methanol containing 
HFBA.  Third, protein precipitation was achieved with 600.0 µL of chilled 
extraction solvent rather than 300.0 µL. Finally, the HP and RP reactions were 
run with 80% plasma in 50% PBS buffer (pH 7.4).  The data are summarized in 
Table 6.3. 
 
6.4 Kinetics of hydrolysis in SGF and SIF 
SGF and SIF were prepared by the methods of the USP.  A 2.5 mg/mL (4.5 mM) 
CYT-NTX codrug stock solution was prepared in DMSO.  Reactions were 
initiated by adding 40.0 µL of the prodrug stock solution to 760.0 µL of pre-
warmed (37±0.5 °C) SGF or SIF (reaction concentrations of 2.2 x 10-4 M).  50.0 
µL aliquots of the reaction mixture were removed. 50.0 µL of internal standard 
solution and 50.0 µL of blank 0.04% HFBA in methanol were added to the 
reaction mixture aliquots in low volume inserts, and the solutions were 
homogenized with vortexing.  Samples were immediately injected on the HPLC 
column and analyzed.  The data are summarized in Table 6.3. 
     
6.5 Standard Curves and Data Analysis 
Amino acid prodrugs in 50% HP (and 6-O-Ile-NTXOL in 50% PBS control) 
In the stability studies of amino acid ester prodrugs, salicylamide was used as an 
internal standard (IS).  Stock solutions of prodrugs and a stock solution of IS was 
prepared in methanol containing 0.04% HFBA.  Standard curves with eight 
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different concentration points were generated and analyzed in the stability 
studies.  In the case of HP studies, standards were prepared by spiking 300.0 µL 
of prodrug diluted stock solutions to eppendorf tubes containing 50.0 µL of blank 
50% HP and  50.0 µL of IS solution.  Then the samples were worked up and 
reconstituted as described in Section 6.3.  In the case of the 6-O-Ile-NTXOL 
control study (50%PBS), standards were prepared by dissolving the prodrug in 
methanol containing 0.04% HFBA and making a series of dilutions.  50.0 µL of 
the appropriate diluted stock solution was spiked to 50.0 µL of blank buffer and 
50.0 µL of IS solution.  The calibration curves obtained from standards were 
prepared using quadratic least-squares regression of area-under-the-curve 
(AUC) ratios (AUCprodrug/AUCIS) versus prodrug concentration.  The amount of 
remaining prodrug over the course of time was then determined using the 
standard curves.  The linear ranges and R2 data for the standard curves are 
reported in Table 6.1.   
 
CYT-NTX chemical stability assays 
 In the stability studies of CYT-NTX, two different methods were employed.  N-1-
naphthylacetamide was used as an IS in the CYT-NTX chemical stability studies 
that were initially conducted (Buffers pH 1.5 – 9.0).  Standards for NTX, CYT, 
and CYT-NTX were prepared in solutions with the exact composition of the 
mobile phase since the study involved four different buffers and isocratic HPLC 
mobile phase conditions (details in the next section).   It was also expected that 
the codrug would not degrade.  It turned out that the standard curves were 
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unnecessary since the average AUCcodrug/AUCIS value was robust in all buffers 
tested for 24 hours (One-way ANOVA, p > 0.05). This is an indicator of codrug 
stability, because the concentration of analyte remaining over the course of time 
is determined by inserting the value Y = AUCanalyte/AUCIS into the equation of the 
standard curve least squares regression line.  Since no peaks were observed for 
CYT or NTX in any of these studies, and since average AUCcodrug/AUCIS values 
did not significantly change during stability experiments, it can be concluded that 
the codrug was stable in these media.  The linear ranges and R2 data for the 
standard curves that were generated in the buffer assays are reported in Table 
6.1. 
 
CYT-NTX enzymatic stability assays (Plasma, SGF and SIF) 
 The CYT-NTX stability studies that were performed in enzymatic media used 
salicylamide as an IS and a different HPLC-UV method.  Standard curves were 
not generated in the first run of these studies, because it was possible to check 
stability of the codrug by examining the ratio AUCcodrug/AUCIS over time and 
checking for statistically different ratios during the stability experiment.  If 
changes were observed, standard curves could be generated after the studies. 
Following satisfactory evidence that the codrug did not degrade (n = 1), the 
experiments were repeated for a total of n=3, and the average AUCcodrug/AUCIS 
was examined for statistically significant change (p ≤ 0.05).  In all cases, p > 0.05 
was observed (One-way ANOVA). 
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Determination of half-lives 
All of the amino acid ester prodrugs showed pseudo-first-order kinetic behavior.  
Apparent pseudo-first-order hydrolysis rate constants (Kapp) were calculated from 
the slope of log transformed AUCprodrug/AUCIS as a function of time.  Kapp data 
were converted to half-life values using the equation t1/2 = ln(2)/ Kapp and the 
average half-lives and their standard deviations were determined using Microsoft 
Excel.  All stability studies were carried out in triplicate (n=3) by the author, 
except for those which were conducted in duplicate by Milewski (n=2) as 
described in Section 6.2.  The stability studies conducted by the author 
employed standard curves with salicylamide as internal standard.  Table 6.2 
summarizes the stability data which are reported as t1/2(avg) ± SD. 
 
6.6 HPLC Analysis 
There were multiple HPLC methods utilized to determine the stability of our 
amino acid ester prodrugs and the CYT-NTX codrug.  In particular, developing 
methods that worked for the CYT-NTX codrug and its key analytes proved to be 
challenging.  Milewski utilized a modification of the HPLC method employed by 
Hussain et al., and the details are reported elsewhere (Milewski 2011).  This 
section focuses only on the methods that were developed by the author. 
 
All of the studies employed an Agilent 1100 series HPLC instrument equipped 
with a G1322A Degasser, a G1311A Quat Pump, a G1313A autosampler, and a 
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photodiode array detector.   Agilent software was used to drive the instrument 
and to collect area data for half-life calculations.   
 
CYT-NTX buffer stability assays 
The first method was developed for stability analysis of the CYT-NTX codrug.  
The mobile  phase was A:B = 23:77 (isocratic) where A = THF and B = 0.067% 
HFBA and 0.067% octane sulfonate sodium (base adjusted to pH 4.0 with 
triethylamine).  The flow rate was 0.55 mL/min, and 280 nm UV detection was 
used.  Fig. 6.4(A) shows a representative chromatogram of the method with the 
four analytes clearly marked.  Figure 6.4(B) is an overlaid snapshot of the 
codrug and N-1-naphthylacetamide internal standard at t =24 hours in the four 
different buffers.  No degradation of CYT-NTX was observed in any of the buffers 
tested.  
 
Amino acid prodrug stability studies and CYT-NTX enzymatic stability studies  
These studies utilized the same column and guard column and the same mobile 
phase solutions; however, different gradients had to be employed to separate the 
compounds properly, and to ensure no overlap with matrix peaks.  In every case, 
the stationary phase consisted of a 4 µm Waters Phenyl Column (3.9 x 150 mm) 
attached to a 4 µm Nova-pak® C18  3.9 x 20 mm guard column.  The mobile 
phase in each assay was as follows:  solvent A = aqueous solution of 0.04% 
heptafluorbutryic acid (HFBA); and solvent B = 0.04% HFBA in methanol.  The 
flow rates varied between 0.3 mL/min and 0.5 mL/min for the different prodrugs 
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and the codrug.  The specific details regarding analytes, flow rates and gradient 
programs are shown along with representative chromatograms for each set of 
compounds in Figures 6.1, 6.2, 6.3 and 6.5.   
 
6.7 Discussion 
CYT-NTX demonstrated stability in all of the media tested (Table 6.3).  The peak 
at r.t. = 16.0 - 16.7 min in Figure 6.4 B appeared to represent hydrolysis of the 
codrug at pH 1.5; however, that same peak also appeared in buffer blanks, and it 
was not due to NTX or CYT.   Therefore, CYT-NTX was advanced to in vivo 
studies in the S-D rat to determine if it could be hydrolyzed in a living animal 
model (Chapter 7).  In contrast, each of the amino acid esters tested 
demonstrated pseudo first-order hydrolysis kinetics.  From the data observed, we 
were able to determine which of the compounds was best suited for an MNTD 
paradigm.   
 
pH 5.0 stability to assess MNTD candidacy 
It can be seen in Table 6.2 that the majority of the amino acid ester prodrugs 
were not suitable for MNTD based on our minimum stability criterion that t90 must 
be greater than or equal to the intended time course of a skin diffusion 
experiment (48 hours) at pH 5.0 and 32 °C.  The latter cutoff was established for 
our studies, because it becomes difficult to estimate the extent of bioconversion 
in the viable skin following a diffusion experiment if the prodrug extensively 
degrades by simple chemical means during the experiment.  Also, high levels of 
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hydrolysis before skin transport do not allow a true estimation of drug flux.  In 
total, the results are not too surprising.  The phenolic esters were extremely labile 
as expected, and aliphatic esters outperformed their phenolic counterparts by at 
least an order of magnitude (with the exception of Pro and Ala prodrugs).  Bulky 
side chains on aliphatic ester promoieties (Ile and Val) provided the best recipe 
for success in this series of prodrugs, with β-Ala also showing similar stability 
enhancing results.  These observations are well within the expectations one can 
glean from the review of amino acid prodrugs in Chapter 1.  Overall, the MNTD 
candidates were determined to be 6-O-Ile-NTXOL, 6-O-Val-NTXOL and 6-O-β-
Ala-NTXOL.  Prodrugs that did not meet the minimum criteria were not pursued 
in further stability tests. 
 
pH 7.4 Stability (chemical and enzymatic) to assess prodrug behavior 
Adequate stability at pH 5.0 was not enough to establish our prodrugs as 
appropriate MNTD candidates.  In a prodrug design, rapid degradation under 
physiological conditions is desired, because the prodrug itself is just a delivery 
system for the parent drug.  As such, an ideal prodrug for the MNTD paradigm 
should have pH 5.0 stability as stated in the last section with nearly 
instantaneous hydrolysis at pH 7.4 (enzyme assisted in plasma or in a simple 
chemical buffer).  This is true because rapid skin bioconversion at pH 7.4 is 
expected to greatly enhance flux of the parent drug, and that is the paramount 
objective of an MNTD prodrug design.  Unfortunately, it is very difficult to design 
a prodrug with these ideal characteristics.  Greater rates of hydrolysis can be 
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expected at pH 7.4 compared to pH 5.0, simply because the concentration of 
hydroxide ion in an aqueous system is higher at pH 7.4.  In Table 6.2, it is 
obvious that significant hydrolysis rate enhancements of approximately one order 
of magnitude were observed at pH 7.4 as compared to pH 5.0; however, these 
rates were not rapid enough to ensure enhanced skin transport of NTXOL.  
Therefore, we examined the hydrolysis behaviors of the Ile, Val and β-Ala 
prodrugs in 50% HP to see if further rate enhancements could be expected in 
vivo.   
 
The stability data for our prodrugs that advanced to 50% HP turned out to be 
very interesting.  From the data summarized in Table 6.2, it appears as though a 
critical design feature that increases pH 5.0 stability of α-amino acid ester 
prodrugs of NTXOL (bulky side chains) also renders them susceptible to 
extensive protein binding which slows hydrolysis.  This is evident due to the 
increased plasma stabilities of the Ile and Val prodrugs compared to their 
stabilities in 50% PBS or HEPES buffers (pH 7.4).  On the other hand, the β-Ala 
prodrug did not demonstrate evidence of protein binding, because its rate of 
hydrolysis was significantly increased in plasma to yield a half-life of 2.2 ± 0.1 
hours.  Therefore, 6-O-β-Ala-NTXOL is the lead compound of this series of 
prodrugs. 
 
Although, 6-O-β-Ala-NTXOL is the established lead compound, its half-life is still 
fairly long for an MNTD candidate, and it would be necessary to perform skin 
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diffusion and disposition studies to see if faster rates of bioconversion could be 
achieved in viable skin tissue.  Unfortunately, these studies require fairly large 
amounts of prodrug, and it was not possible to scale-up the procedures 
described in Chapter 3 to afford enough material for the studies.  Further 
optimization of the synthetic strategy for scale-up would be needed.   
 
One inconsistency in the amino acid ester prodrug stability studies should be 
explained.  The hydrolysis reactions were not all run at the same concentration, 
because the 6-O-Ile-NTXOL and 6-O-Val-NTXOL prodrugs demonstrated 
precipitation problems when reactions were run at concentrations equivalent to 
the 6-O-β-Ala-NTXOL prodrug reactions (0.15 mg/mL, 3.6 x 10-4 M).  6-O-Ile-
NTXOL is crystalline in nature, and it precipitates very easily at pH 7.4.  
Therefore, reactions involving 6-O-Ile-NTXOL had to be run at the lowest 
concentration of all the prodrugs (0.038 mg/mL, 8.2 x 10-5 M) to avoid this 
precipitation.  6-O-Val-NTXOL also showed precipitation problems, but it could 
be run at higher reaction concentrations (0.050 mg/mL, 1.1 x 10-4 M).  6-O-β-ala-
NTXOL did not precipitate from plasma media at the concentrations tested, but it 
exhibited less extraction efficiency than the other two prodrugs.  Therefore, it had 
to be run at higher reaction concentrations than either of the other two prodrugs 
(0.15 mg/mL, 3.6 x 10-4 M) in order to obtain a good peak for quantitation over 
the time course of the study.  In the ideal case, comparative stability studies in 
enzymatic media should be carried out at equivalent concentrations to control for 
an unknown enzyme saturation level; however, it was not possible to do this 
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utilizing HPLC-UV under the analysis conditions of this study.  More sensitive LC-
MS or LC-MS/MS procedures would have been required, and the instrument time 
necessary to employ these resources was not available.  Nonetheless, the 
stability data indicate that 6-O-β-Ala-NTXOL had a much faster rate of 
conversion to parent drug than either the Val or the Ile prodrugs, even at greater 
hydrolysis reaction concentrations.  Moreover, the propensity of the Val and Ile 
prodrugs to precipitate at pH 7.4 is not a desirable characteristic for an MNTD 
prodrug.   Thus, it should be noted that at the concentrations used in these 
studies, the prodrugs remained in solution, so the reported rates of hydrolysis 
were not artificially accelerated by precipitation. 
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Table 6.1 Standard curve data for the analytes.  (No standard curves 
generated for plasma, SGF and SIF studies of CYT-NTX since AUCcodrug/AUCIS 
was robust throughout a stability experiment (p > 0.05)). 
 
Analyte Linear Range R2 
6-O-β-Ala-NTXOL 
19 µM – 1.2 mM 0.9999 
6-O-Val-NTXOL 
18 µM – 1.1 mM 0.9998 
6-O-Ile-NTXOL      
(plasma study) 
26 µM – 1.7 mM 0.9999 
6-O-Ile-NTXOL      
(control study) 
20 µM – 5.0 mM 0.9999 
CYT-NTX 
(buffer stability studies) 
56 µM – 0.90 mM 0.9982 
CYT 
(buffer stability studies) 
0.16 mM – 2.6 mM 0.9965 
NTX 
(buffer stability studies) 
92 µM – 1.5 mM 0.9952 
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Table 6.2 Stability of amino acid ester prodrugs of NTX and NTXOL.  Data 
are reported as t1/2(avg) ± SD as determined from two (n=2) or three (n=3) 
independent experiments. 
 
 
Prodrug 
t90 (pH 5.0) 
(n=2) 
t1/2 (pH 7.4) 
(n=2) 
t1/2 (50% HP) 
(n=3) 
6-O-β-Ala-NTXOL 5.6 ± 0.5 d 0.47 ± 0.24 d 2.2 ± 0.1 h 
6-O-Val-NTXOL 5.2 ± 0.2 d 0.48 ± 0.03 d 0.76 ± 0.03 d 
6-O-Ile-NTXOL 14.3 ± 0.3 d 0.88 ± 0.02 d* 1.3 ± 0.1 d 
6-O-Ala-NTXOL 9.9 ± 0.5 h no data no data 
6-O-Pro-NTXOL 5.2 ± 0.7 h no data no data 
6-O-Leu-NTXOL 0.93 ± 0.0 d no data no data 
3-O-Val-NTX 1.5 ± 0.0 h instantaneous no data 
3-O-Ala-NTX 1.3 ± 0.1 min instantaneous no data 
3-O-Leu-NTX 2.7 ± 0.0 min instantaneous no data 
 
*
 6-O-Ile-NTXOL was assayed (n =3) 
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Table 6.3 Stability of CYT-NTX.   
pH 1.5 stable 
pH 5.0 stable 
pH 7.4 stable 
pH 9.0 stable 
SGF stable 
SIF stable 
50% HP stable 
80% RP stable 
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4 µm Waters Phenyl Column (3.9 x 150 mm) + 4 µm Nova-pak® C18 3.9 x 20 mm 
guard column.  Solvent A:  Aqueous solution of 0.04% (HFBA); Solvent B:  
0.04% HFBA in methanol. 
Gradient Elution at 0.5 mL/min: 
Time (min) %A %B 
0 65 35 
0.3 65 35 
10 10 90 
12 10 90 
12.1 65 35 
21 65 35 
 
Figure 6.1 HPLC chromatogram of salicylamide, NTXOL and 6-O-Ile-NTXOL 
(gradient elution). 
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4 µm Waters Phenyl Column (3.9 x 150 mm) + 4 µm Nova-pak® C18 3.9 x 20 mm 
guard column.  Solvent A:  Aqueous solution of 0.04% HFBA; Solvent B:  0.04% 
HFBA in methanol. 
Gradient Elution 0.3 mL/min: 
Time (min) %A %B 
0 65 35 
0.3 65 35 
10 10 90 
12 10 90 
12.1 65 35 
21 65 35 
 
Figure 6.2 HPLC chromatogram of salicylamide, NTXOL and 6-O-Val-NTXOL 
(gradient elution).  
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4 µm Waters Phenyl Column (3.9 x 150 mm) + 4 µm Nova-pak® C18 3.9 x 20 mm 
guard column.  Solvent A:  Aqueous solution of 0.04% HFBA; Solvent B:  0.04% 
HFBA in methanol. 
Gradient Elution at 0.3 mL/min: 
Time (min) %A %B 
0 65 35 
10 65 35 
20 10 90 
21 65 35 
30 65 35 
 
Figure 6.3 HPLC chromatogram of salicylamide, NTXOL and 
6-O-β-Ala-NTXOL (gradient elution). 
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Figure 6.4 (A) HPLC chromatogram of (-)-cytisine, CYT-NTX, NTX and 
N-1-naphthylacetamide (isocratic elution).  (B) Representative HPLC 
Chromatograms of CYT-NTX in buffers at t = 24 hours.  Broad peak at           
r.t. = 16.0 - 16.7 min (pH 1.5) is present in blank buffer. 
A 
B 
pH 1.5 
pH 5.0 
pH 7.4 
pH 9.0 
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4 µm Waters Phenyl Column (3.9 x 150 mm) + 4 µm Nova-pak® C18 3.9 x 20 mm 
guard column.  Solvent A:  Aqueous solution of 0.04% heptafluorbutryic acid 
(HFBA).  Solvent B:  0.04% heptafluorbutryic acid (HFBA) in methanol. 
Gradient Elution at 0.3 mL/min: 
Time (min) %A %B 
0 75 25 
0.3 75 25 
17 10 90 
26 10 90 
27 75 25 
36 75 25 
 
Figure 6.5 HPLC chromatogram of (-)-cytisine, salicylamide, NTX and 
CYT-NTX (gradient elution). 
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Chapter 7 
  Pharmacokinetic Analysis of CYT-NTX in male Sprague-Dawley Rats 
 
The ultimate test of performance for a given codrug candidate resides in its ability 
to behave as an in vivo delivery form of its two constituent drugs.  Therefore, in 
order to investigate the codrug-like behavior of CYT-NTX, male Sprague-Dawley 
(S-D) rats were chosen as an in vivo model.  The data described in this chapter 
were obtained through a collaborative effort.  The author was responsible for the 
synthesis and characterization of CYT-NTX; for participation in the dosing of 
animals and removal/preservation of plasma from blood samples; and for the 
extraction and preparation of plasma samples for PK analysis.  Dr. Zaineb 
Albayati (UK) was responsible for the appropriate treatment of animals; for 
animal surgeries; for the dosing of animals and the removal of blood samples; 
and for the PK analysis of chromatographic data using WinNonlin software.  Dr. 
Manjula Sunkara (UK) is to be credited with the LC-MS/MS method development 
and the collection of analytical data from rat plasma samples.  Special thanks are 
due to Dr. Andrew J. Morris (UK) for allowing the use of his LC-MS/MS resources 
and for allowing Dr. Sunkara’s participation in the study, and to Dr. Philip Breen 
(UAMS) for his review and suggestions regarding the PK study. 
7.1 Animals 
All procedures that involved the use of S-D rats were conducted in accordance 
with the guidelines set forth by the University of Kentucky Institutional Animal 
Care and Use Committee established by the National Institutes of Health’s Guide 
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for the Care and Use of Laboratory Animals (1996).  Male S-D rats weighing 250 
– 300 grams were housed two per cage with ad libitum access to food and water 
in the Division of Laboratory Animal Resources within the College of Pharmacy at 
the University of Kentucky.  Rats were anesthetized with 40 mg/kg pentobarbital 
i.p. and surgically implanted with cannulae in the femoral (blood sampling) and 
jugular (i.v. dosing) veins.  Three to four days post-surgery, rats were observed 
for signs of local infection at surgical sites, for hair yellowing, for the presence of 
blood around the nose or eyes, for indications of lessened appetite, and for signs 
of lessened or absent fecal activity.  Following appropriate evidence of 
successful recovery from surgery, i.v. or p.o dosing was performed and blood 
samples (0.15 mL) were withdrawn over the course of 7 hours at 5, 15, 30 and 
45 min, and 1, 2, 3, 5 and 7 h.  The withdrawn blood was replaced with 
heparinized saline (0.15 mL).  Rats were euthanatized after collecting the last 
plasma sample by administration of an overdose of pentobarbital (150 mg/kg, 
i.v.) via the femoral cannula followed by thoracotomy. 
 
7.2 Objectives 
In an effort to deliver NTX and CYT as an equimolar mixture per os, the CYT-
NTX codrug was prepared by the methods described in Chapter 5. This work 
was designed to investigate the oral bioavailability and plasma pharmacokinetics 
(PKs) of the new CYT-NTX codrug in S-D male rats after a single 1.0 mg/kg 
(1.79 x 103 nmol/kg) i.v. bolus dose or an oral dose of 10.0 mg/kg (1.79 x 104 
nmol/kg). Blood samples were taken up to 7  h as described in Section 7.4.  
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7.3 Methods  
Six (3 rats/group) S-D male rats were dosed 1.0 mg/kg (1.79 x 103 nmol/kg) with 
CYT-NTX codrug, i.v. or 10.0 mg/kg (1.79 x 104 nmol/kg), p.o.  Plasma CYT-NTX 
codrug, NTX, and CYT concentrations were quantitated utilizing an LC-MS/MS 
assay method described below.  Plasma PK parameters were calculated using a 
two-compartment open model for both CYT-NTX codrug and NTX.  CYT was not 
detected in plasma in this study (see Section 7.10). 
 
7.4 CYT-NTX dose preparations 
CYT-NTX codrug was dissolved in a saline solution containing 15% w/v 
concentration of PEG-400 and filtered through a 0.2-μm filter.  The animals were 
administered a 10.0 mg/kg oral dose or a 1.0 mg/kg i.v. dose of CYT-NTX 
codrug.  Blood samples (0.15 mL) were obtained at 5, 15, 30 and 45 min, and 1, 
2, 3, 5 and 7 h after oral dosing and i.v. injection. The withdrawn blood was 
replaced with heparinized saline (0.15 mL) after each blood-draw.  Blood 
samples were centrifuged at 8,000 rpm for 15 min, and plasma was separated, 
frozen immediately on dry ice, and stored at -20 °C prior to analysis. 
 
7.5 Analyte Sample Preparation  
50.0 μL of plasma was transferred to polypropylene tubes to which 50.0 μl of 
working internal standard (salicylamide dissolved in acetonitrile) was added 
followed by treatment with 600.0 µL of a solution of acetonitrile containing 5% 
formic acid.  Vortex mixing was carried out for one minute.  The samples were 
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then centrifuged for 15 min at 8,000 rpm. The supernatant was transferred into 
glass tubes and evaporated to dryness under nitrogen gas at 37 °C.  Following 
drying, the residue was dissolved in 150.0 μl of HPLC mobile phase by vortexing 
for 1 min.  Ten (10.0 μl) of the sample was then injected onto the HPLC column, 
and analytes were quantified by an LC-MS/MS spectrometric analysis.   
 
7.6 LC-MS/MS Analysis 
Standard curves for CYT-NTX, CYT, NTX, and salicylamide were generated by 
preparing stock solutions of these analytes in acetonitrile containing 5% formic 
acid.  Ten standards were prepared by spiking diluted stock solutions to 50.0 µL 
of blank S-D rat plasma and then proceeding with the treatment procedure 
described above.  Standard curves showed good linearity (R2=0.9800 - 0.9988).  
 
An LC-MS/MS method was successfully developed to determine the PK profiles 
of the CYT-NTX codrug, and NTX in rat plasma after a single oral dose of 10.0 
mg/kg (1.79 x 104 nmol/kg) or an i.v. dose of 1.0 mg/kg (1.79 x 103 nmol/kg) of 
the codrug.  CYT was not detected in rat plasma for reasons that are unclear. 
Each of the analytes (including CYT) demonstrated a quantifiable detector 
response at the plasma concentrations that were relevant to this study. See 
Section 7.10 for a discussion on possible reasons why CYT was not observed in 
rat plasma samples.  
 
Analysis of the analytes was carried out using a Shimadzu UFLC system coupled 
to an AB Sciex 4000-Qtrap hybrid linear ion trap triple quadrupole mass 
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spectrometer in multiple reaction monitoring (MRM) mode, operating in the 
positive electrospray ionization mode with optimal ion source settings determined 
by standards of CYT-NTX codrug, CYT and NTX. Salicylamide was used as an 
internal standard.  A curtain gas of 20 psi, an ion spray voltage of 5500 V, an ion 
source gas1/gas2 of 40 psi and a temperature of 550 °C were employed.  MRM 
transitions monitored were as follows: CYT-NTX codrug- m/z 558.2/540.2, m/z 
558.2/217.3; CYT- m/z 191.1/148.2, m/z 191.2/133.1; NTX-m/z 342.1/324.1, m/z 
342.1/270.1; and for salicylamide, m/z 138.0/121.1, m/z 138.0/65.1.  CYT-NTX 
codrug, CYT, NTX and salicylamide were separated using a Kinetex PFP, 2.6 
um, 100 X 4.60 mm column (from Phenomenex). The mobile phase consisted of 
water with 0.04% heptafluorobutyric acid as solvent A and methanol with 0.04% 
heptaflorobutyric acid as solvent B. Separation of CYT-NTX codrug, CYT, NTX 
and salicylamide was achieved using a gradient of 20 % solvent B in the first 
minute, followed by an increase to 100% solvent B in the next 5 minutes. 100% 
solvent B was maintained for the last four minutes and equilibrated back to initial 
conditions over 3 minutes. The flow rate was 0.5 mL/min with a column 
temperature of 30 ⁰C. The sample injection volume was 10.0 µL.  The optimal ion 
source settings for each MRM transition are summarized in Table 7.1.  Figs. 
7.4A and 7.4B show the LC-MS/MS chromatograms and the extracted ion 
chromatograms for the 4 analytes using the analytical methodology described 
above.   
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7.7 Plasma Pharmacokinetics  
 
Individual CYT-NTX codrug and NTX plasma concentration-time profiles after i.v. 
bolus administration were best fitted by a two-compartment open model and first 
order elimination (Phoenix WinNonlin, Professional, version 6.2, Pharsight, 
Mountain View, CA) with inverse-variance weighing, and the goodness of fit was 
determined by the AIC (Akaike criteria), SC (Schwartz criteria), and WSSR 
(weighted sum of square of residuals). The lower the AIC, SC, and WSSR the 
more appropriate is the selected model.  PK parameters were calculated with the 
Gauss–Newton minimization method (Yamaoka, Nakagawa et al. 1978, Ludden, 
Beal et al. 1994) and a weighting factor as 1/Y2.  The following exponential 
expression was used;  
 
Equation 7.1.  Cp = Ae
-αt + Be-βt                                                                                                          
 
where Cp is the plasma concentration of CYT-NTX codrug or NTX; A and B are 
pre-exponential constants, α and β are the distribution rate constant and the 
elimination rate constant, respectively, and t is time.  The PK parameters 
including elimination half-life t1/2, volume of distribution Vd, area under the curve 
from 0 to infinity (AUC0-inf), and total body clearance (CLtot), were estimated using 
the computer program described above.   
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Following oral administration, data were analyzed by the two-compartment open 
model and first order absorption to determine peak concentration (Cmax), the time 
to reach maximum plasma concentration (tmax), and area under the curve from 0 
to infinity (AUC0-inf).  Plasma concentration (Cp) is described by an equation with 
three exponential terms: 
 
Equation 7.2.  Cp = Ae
-αt + Be-βt + Ce-ka
t , where C = - (A+B)     
                                                                                    
Cp is the plasma concentration of CYT-NTX codrug or NTX; A, B and C are pre-
exponential constants; ka, α and β are the absorption rate constant, the 
distribution rate constant and the elimination rate constant, respectively; and t is 
time.  PK parameters including absorption half-life t1/2(a), elimination half-life t1/2, 
and AUC0-inf were estimated using the computer program described above. 
 
Absolute bioavailability of the codrug was determined using Equation 7.3: 
Equation 7.3.  F% = [(AUCp.o. x Dosei.v.) / (AUCi.v. x Dosep.o)] x 100% 
where AUCp.o., AUCi.v., Dosep.o., and Dosei.v. represent the AUC0-inf and 
corresponding doses of the codrug, respectively. 
 
The fraction of orally administered co-drug appearing as NTX in the portal 
circulation (fa) was determined by Equation 7.4.  
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Equation 7.4.   
. . . .
. . . .
p o i v
a
i v p o
AUC Dose
f
AUC Dose
  
In the above expression, the different values of AUC(0-inf) for NTX obtained by the 
two different dosing routes of codrug are a measure of NTX release and 
absorption across the gastrointestinal barrier from orally administered codrug. 
However, the parameter fa does not include any decrease in NTX appearing in 
the systemic circulation due to first pass elimination.  This equation is a 
rearrangement of Equation 89 reported by Houston et al (Houston 1981). 
7.8 Results  
An LC-MS/MS method has been successfully applied to the PK study of the 
CYT-NTX codrug.  The codrug hydrolyzed to release NTX in the live S-D rat after 
administration of a single oral dose of 10.0 mg/kg (1.79 x 104 nmol/kg) or a 1.0 
mg/kg (1.79 x 103 nmol/kg) i.v dose.  Figure 7.1 is a plot of the mean plasma 
concentration versus time profile of the codrug, and NTX released from the 
codrug, by the p.o. route of administration, while Figure 7. 2 is a plot of the mean 
plasma concentration versus time profile of the codrug, and NTX released from 
the codrug, by the i.v. route.  Figure 7.3 shows an overlay of the mean plasma 
levels of NTX as a function of time which were observed following p.o. and i.v. 
dosing of the codrug. The carbamate linker of the CYT-NTX codrug apparently 
cleaves in vivo to produce NTX; however, the presence of constituent CYT was 
not observed at any time point.   Thus, only NTX was observed as a hydrolysis 
product of the CYT-NTX codrug.  Determination of the fate of released CYT in 
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the rat would require further study; however, some possible explanations for why 
we did not detect CYT are offered in Section 7.10. 
 
7.9 Pharmacokinetic Properties 
Oral administration of the codrug in S-D rats resulted in NTX delivery with a peak 
plasma concentration of 6.8 ± 0.9 nmol/L which was reached within 1.08 ± 0.36 
hours.  The value of fa(NTX) calculated using Equation 7.4 was 0.13 (13%).  The 
areas under the plasma concentration-time curves (AUC0-inf) for codrug and 
released NTX after oral and i.v. dosing were as follows: 26.9 ± 2.8, 34.8 ± 15.9 
hr•nmol/L (p.o.); and 237 ± 103, 27.0 ± 0.6 hr•nmol/L (i.v.), respectively.  The 
codrug is very lipophilic in nature, and this is reflected in its large volume of 
distribution of 17.7 ± 9.2 L/kg and its rapid clearance of 0.126 ± 0.1 L/min/kg 
which were observed following bolus administration.  The solubility properties of 
the codrug also support these data (soluble in benzene and DCM, but very poorly 
soluble in THF, alcohols or neutral water).  The PK parameters are summarized 
in Table7. 2.      
 
7.10 Discussion   
The cytisine-naltrexone (CYT-NTX) codrug was designed as a drug delivery 
system in which the end goal was to achieve equimolar release of the two 
separate therapeutic agents, CYT and NTX, in the biophase. The CYT-NTX 
codrug exhibited desirable in vitro stability characteristics for an oral drug delivery 
candidate (Chapter 6).  Indeed, there was no evidence of degradation of the 
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compound to its constituent drugs over the course of 24 hours in chemical 
buffers adjusted to pH 1.0, 5.0, 7.4, and 9.0 (n=3).  Likewise, the codrug was 
stable over a 24 hour time course in 80% rat plasma, 80% human plasma, and in 
simulated gastric fluid and simulated intestinal fluid that had been prepared by 
the methods of the USP (n=3).  Having established the codrug as a stable entity 
for oral delivery, our next goals were as follows: (1) to determine if the codrug 
would hydrolyze in vivo in the S-D rat; and (2) to investigate the PK profile of the 
codrug and/or its released constituent drugs (CYT and NTX).   
 
The CYT-NTX codrug was shown to hydrolyze in the rat to release NTX, but CYT 
was not detected. The hydrolysis is not complete, as intact codrug can be seen 
along with NTX at all time points regardless of the route of administration (Figs. 
7.1 & 7.2). Therefore, these data show a prolonged release of NTX from the 
codrug over time. The release of NTX and CYT from the codrug should occur in 
an equimolar ratio according to the codrug structure; however, CYT was not 
observed in the plasma at any time point.  We suspect that CYT may not have 
been observed for one of the following reasons:  (1) a pre-hydrolysis metabolic 
event may have chemically modified the CYT moiety before carbamate cleavage 
occurred; (2) CYT may have been metabolized or eliminated immediately after 
hydrolysis; (3) the CYT plasma level may have dropped below the limit of 
quantitation of our LC-MS/MS assay due to substantial loss of CYT by 
biotransformation and/or sequestration into an unknown tissue compartment; or 
(4) it is possible that the ester side of the carbamate linker of CYT-NTX cleaves 
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readily in vivo to release NTX while the amide side remains intact as a carbamic 
acid intermediate following release of NTX.  Also, it is noteworthy that in New 
Zealand rabbits, CYT has a short in vivo half-life of 0.86 ± 0.17 hours and an oral 
bioavailability of 32.18% (Astroug, H., et al. 2010).  Nonetheless, the CYT-NTX 
codrug hydrolyzes in vivo, because measurable levels of NTX were observed in 
all of the rats, regardless of the route of administration.  
 
A two-compartment model adequately describes the PK of oral CYT-NTX codrug 
and its released NTX.  It can be shown that at any time point after the Cmax of 9.7 
± 1.4 nmol/L at tmax of 0.74 ± 0.04 hr, the codrug is present at a lower 
concentration than NTX, Fig. 7.1.  Absorption of the codrug appears to be very 
rapid (t1/2(a)
 = 0.30 ± 0.04 hr).  Also, fast linker cleavage to release NTX occurs, 
because NTX was detected in plasma within 5 min after oral dosing, and it 
reached a Cmax of 6.8± 0.9 nmol/L with a tmax of 1.08 ± 0.36 hr.   
 
A two-compartment model also describes i.v. dosing of the codrug and its 
release of NTX (Fig. 7.2). Peak plasma levels of released NTX (Cmax = 9.6 ± 2.8 
nmol/L) were detected within 5 min, indicating rapid cleavage of the codrug.  In 
contrast to oral dosing, plasma codrug concentrations were significantly higher 
than NTX levels at all time points resulting in AUC(0-inf) values of 237 ± 103 
hr•nmol/L (codrug) and 27.0 ± 0.6  hr•nmol/L (NTX) (Fig. 7.2 and Table 7.2).  
Therefore, it appears as though first-pass metabolism contributes significantly to 
the hydrolysis of the codrug in vivo.    
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7.11 Bioavailability of CYT-NTX and fraction of NTX absorbed  
Use of Equation 7.3 with the data obtained from the individual oral delivery 
experiments resulted in an average Apparent F value of 1.02 ± 0.1%.  This small 
value is partly due to fast first pass metabolism of orally administered codrug.  
Also, some of the very early codrug concentration points occurred before blood 
was sampled for codrug levels, and these concentrations were not able to be 
included in the calculation of AUC.  Moreover, it is important to note that 
calculation of the bioavailability of the codrug is not straight forward due to rapid 
hydrolysis in vivo.  Since the intravenously administered codrug also undergoes 
hydrolysis, a true bioavailability estimate cannot be made by comparison of AUC 
data of the codrug alone.  AUC data for the codrug and NTX can be summed and 
entered into Equation 7.3 in the form 
  
F% = [Σ(AUCcodrug,NTX(p.o.)) x dose(i.v.)] / [Σ(AUCcodrug,NTX(i.v.)) x dose(p.o.)] x 100% 
 
In this way, an oral bioavailability estimate of the codrug that includes the 
released NTX can be obtained.  However, in the case of this study, any 
contributions that are made by CYT cannot be added into the summed AUC 
expression for total bioavailability.  Nonetheless, the average estimated total 
bioavailability of codrug based on summed AUC data of CYT-NTX and NTX from 
the individual rats is 2.53 ± 0.82%.   
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Another feature of codrug bioavailability must be mentioned.  In the design of a 
codrug, it is desirable for plasma levels of constituent drugs to far exceed the 
plasma levels of the codrug.  In the perfect case, codrug bioavailability of zero 
with therapeutic delivery of the constituent drugs would be observed.  This is 
because the codrug would be functioning as a ―chemical‖ delivery system, and 
only the constituent drugs would be delivered to the systemic circulation.  Oral 
administration of CYT-NTX in S-D rats showed that the codrug did achieve 
higher plasma levels of NTX compared to CYT-NTX at every time point after tmax, 
while intravenous administration resulted in higher plasma levels of codrug over 
a seven hour time course.        
 
As determined by Equation 7.4, oral administration of the codrug resulted in 
fa(NTX) = 0.13 (13%) compared to iv administration.  This fa value is indicative of 
the conversion of codrug to NTX. In comparison, the fraction of administered 
codrug that was converted to NTX after intravenous administration was 
approximately 0.11 (11%) (AUCNTX(i.v.)/AUCcodrug(i.v.) = 27/237 hr•nmol/L) . These 
are reasonable available fractions of NTX by either route.  However, oral delivery 
has the advantage that at every time point after tmax, the codrug is present in 
lower concentration than NTX (Fig. 7.1).  The opposite is true after i.v. 
administration (Fig. 7.2).  As previously mentioned, it is not desirable for codrug 
levels to exceed constituent drug levels in vivo.  The ratio of AUCcodrug to AUCNTX 
following oral codrug administration is 0.77 (77%), and the reciprocal ratio is 1.29 
(129%).  This value that is greater than unity simply indicates that the process is 
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NTX elimination rate limited and has no ramifications for comparative 
bioavailability between NTX and codrug.  
  
It was observed in Chapter 6 that plasma hydrolysis of the codrug does not 
occur in 80% phosphate-buffered S-D rat plasma within 24 hours. Therefore, 
these observations suggest that hydrolysis of the codrug is taking place in tissue 
compartments other than plasma, and that first-pass bioconversion likely plays a 
role in the hydrolysis of the codrug.  Disposition and tissue homogenate studies 
would be required to determine which tissues host the enzymes that participate 
in the bioconversion.  Nonetheless, the current body of work demonstrates that 
the CYT-NTX codrug is stable for oral formulation purposes, and that it is 
hydrolyzed to yield quantifiable NTX levels in the S-D rat.  
7.12 Conclusions  
In this study, oral administration of the CYT-NTX codrug resulted in NTX delivery 
with prolonged exposure (AUC) and an fa value of approximately 0.13 (13%) 
compared to i.v.  The mean plasma concentration versus time profiles for NTX 
indicate that the codrug performs best by the oral route, because intravenous 
administration results in higher levels of codrug compared to NTX at all time 
points, while oral delivery achieves significantly higher levels of NTX compared to 
codrug after about 45 minutes.  The fate of CYT was not determined in this study, 
since it could not be detected/quantitated in rat plasma after i.v. or oral 
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administration of the codrug; however, CYT-NTX may hold promise as a potential 
lead compound for further design optimization and development.   
7.13 Future Directions 
The CYT-NTX and NTX plasma levels measured in this study were low due to 
the large volume of distribution and rapid clearance of CYT-NTX.  Inasmuch, 
optimization of the codrug structure will likely be necessary to observe better oral 
absorption and higher free drug levels in rat plasma following oral and 
intravenous administration, respectively.  Regarding CYT-NTX itself, drug 
disposition studies should be conducted in order to investigate the areas where 
the drug distributes, and to determine whether or not deposition occurs in tissues 
such as fat.  The latter is highly likely with a volume of distribution of 17.7 L/kg. 
Brain exposure studies could also reveal more information about the degree of 
exposure of CYT-NTX in the CNS.  Most importantly, it needs to be known what 
is happening to the CYT moiety in the rodent model, since no claim can be made 
that CYT-NTX is an effective codrug without such knowledge.  Some attractive 
ideas to pursue in the future would include linkers between CYT and NTX to 
change the physiochemical properties toward greater hydrophilicity.  For 
instance, short polyethylene glycol linkers may lower the volume of distribution of 
the codrug and increase its solubility and oral absorption; however, they would 
also change the stability properties of the codrug in the GI tract.   
With regard to bioavailability measurements of constituent CYT and NTX, bolus 
doses of CYT and NTX alone should be administered to the S-D rat to make 
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more appropriate bioavailability estimates of the constituent drugs released from 
the codrug in vivo (after the fate of CYT is sorted out).  Also, these data could be 
greatly enhanced by a greater power of n = 8 – 10 animals per group, because it 
is obvious that there was substantial variability in our plasma concentration data.  
This is to be expected with an n = 3 animal study.  However, we were interested 
in obtaining preliminary evidence that CYT-NTX can be hydrolyzed in the S-D rat, 
and our data clearly show this to be the case.  CYT-NTX can therefore be 
considered a lead compound for further study and development, but not as an 
effective delivery system of CYT and NTX under the present observations.   
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Table 7.1 Optimal ion source settings for each MRM transition 
 
 Q1 Q3 
Time 
(msec) 
DP 
(volts) 
CE 
(volts) 
CXP 
(volts) 
CYT 191.126 148.2 200 36 33 8 
 191.126 133.1 200 36 41 6 
CYT-NTX 
codrug 558.213 540.2 200 121 43 14 
 558.213 217.3 200 121 61 12 
 558.213 350.2 200 121 51 8 
 558.213 235.2 200 121 55 14 
 558.213 431.2 200 121 47 10 
 558.213 486.3 200 121 49 12 
NTX 342.123 324.1 200 96 31 16 
 342.123 270.1 200 96 37 16 
salicylamide 137.997 121.1 200 101 23 6 
 137.997 65.1 200 101 37 10 
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Table 7.2 Two-compartmental pharmacokinetic parameters of NTX after 
administration to male rats of 1.0 mg/kg (1.79 x 103 nmol/kg) CYT-NTX 
codrug i.v. or 10.0 mg/kg (1.79 x 104 nmol/kg ) p.o.  Data are represented as 
mean ± SEM, n =3 of CYT-NTX codrug for each route (p.o. and i.v.). 
 
PK Parameter Codrug (i.v.) Codrug (p.o.) NTX (i.v.) NTX (p.o.) 
Dose (nmol/kg) 1.79 x 103 1.79 x 104 1.79 x 103 1.79 x 104 
Cmax (nmol/L) − 9.7±1.4 9.6±2.8 6.8±0.9 
t max (hr) − 0.74±0.04 − 1.08±0.36 
t1/2 (hr) 1.32±0.63 2.60±1.05 2.50±0.05 2.72±2.43 
t 1/2(a) (hr) − 0.30 ± 0.04 − − 
AUC(0-inf) 
(hr•nmol/L) 
237±103 26.9±2.8 27.0±0.6 34.8±15.9 
Vd (L/kg) 17.7±9.2 − − − 
CLtot (L/min/kg) 0.126±0.1 − − − 
Apparent F% 100 1.02 ± 0.1 − − 
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Figure 7.1 Plot of mean plasma concentration vs. time of the CYT-NTX 
codrug and NTX released from the codrug after a single oral dose of 1.79 x 
104 nmol/kg. Results are the mean of 3 rats ± SEM. 
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Figure 7.2  Plot of mean plasma concentration vs. time of the CYT-NTX 
codrug and NTX released from the codrug after a single intravenous dose 
of 1.79 x 103 nmol/kg. Results are the mean of 3 rats ± SEM. 
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Figure 7.3 Plot of mean plasma concentration vs. time of NTX released from 
CYT-NTX codrug after oral and i.v. administration. Results are the mean of 3 
rats ± SEM. 
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Figure 7.4A LC-MS/MS chromatogram of (-)-cytisine, salicylamide, NTX and 
the CYT-NTX codrug. 
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Figure 7.4B LC-MS/MS extracted ion chromatograms of (-)-cytisine, 
salicylamide, NTX and the CYT-NTX codrug. 
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Chapter 8 
Summary 
 
There exists an ongoing need for new medications that can provide efficacy in 
the treatment of alcohol abuse and nicotine addiction with minimal side effects.  
This project was designed to address two specific populations of drug-addicted 
individuals.  The first target population was those individuals who abuse alcohol, 
but do not smoke cigarettes as well.  The second target population was the group 
of individuals who smoke cigarettes and abuse alcohol simultaneously.  For 
those who abuse alcohol but do not smoke, NTX is often a medication that is 
prescribed.  However, NTX is not without its limitations, as it exhibits poor 
bioavailability and gastrointestinal side effects in addition to dose-dependent 
hepatotoxicity.  In particular, patients who would need higher levels of NTX to 
achieve relief from craving, and who are also already hepatocompromised from 
their drug abuse behaviors, would be excluded from therapeutic outcomes of 
NTX oral dosage forms.  Transdermal delivery is an attractive alternative to the 
oral route of drug administration; however, NTX does not possess the necessary 
physiochemical properties that would allow it to be dosed efficaciously by the 
percutaneous route.  To solve this problem, it was envisioned that highly water 
soluble prodrugs of NTX or its active metabolite 6-β-naltrexol (NTXOL) could 
possibly serve as dosage forms for microneedle-enhanced transdermal delivery 
(MNTD).  Accordingly, we designed synthetic strategies to afford phenolic amino 
acid esters of NTX using carbodiimide coupling techniques and BOC protecting 
groups.  Deprotection of BOC from the prodrugs required multiple studies to find 
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conditions that preserved the ester linker moiety, and 4N HCl in dioxane proved 
to be the reagent of choice.  Unfortunately, the phenolic prodrugs of NTX were 
triaged early in our stability studies due to rapid degradation at skin-relevant pHs.  
In subsequent efforts to stay with the popular amino acid prodrug theme, we 
designed regioselective synthetic strategies to afford aliphatic amino acid ester 
prodrugs of NTXOL.  The chemistry was much more difficult to achieve our goal 
in the 6-O-NTXOL prodrugs series, due to design limitations that required 
orthogonal protecting groups and fairly unconventional deblocking strategies in 
synthetic procedures.  For instance, problems arose when BOC methodology 
was applied to the 6-O-NTXOL series of prodrugs due to hygroscopic end 
products that could not be isolated in pure form.  Likewise, solid phase peptide 
synthesis strategies failed to afford our desired prodrugs.  Eventually, a 
combination of Fmoc and Allyl protecting groups proved to be the route to 
success in our synthesis efforts, although some of the most hydrophilic prodrugs 
suffered from apparent degradation during purification by column 
chromatography.  Nonetheless, of the six 6-O-NTXOL amino acid prodrugs that 
were synthesized and tested, three of the compounds proved to be stable 
enough in pH 5.0 donor solution for further evaluation at pH 7.4 (enzymatic and 
non-enzymatic conditions).  6-O-Ile-NTXOL had the best pH 5.0 stability, but it 
was also very stable at pH 7.4, and showed evidence of protein binding in 
plasma with a longer half-life under conditions of enzymatic challenge as 
compared to blank buffer.  The Ile prodrug was also crystalline in nature, and it 
easily crystallized out from solution at pH 7.4.  6-O-Val-NTXOL had similar 
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stability at pH 5.0 and pH 7.4 compared to 6-O-β-Ala-NTXOL, but the Val 
prodrug was also prone to precipitation at pH 7.4, and it too showed evidence of 
protein binding in plasma stability studies due to an increased half-life compared 
to that observed in blank buffer.  In contrast, 6-O-β-Ala-NTXOL was established 
as the lead compound amongst the three MNTD candidates due to its faster rate 
of hydrolysis in human plasma.  However, further skin diffusion and disposition 
studies would be needed to assess its rate of bioconversion and microchannel 
transport in skin.  Unfortunately, MNTD analyses require multi-gram amounts of 
prodrug, and scale-up efforts to afford enough 6-O-β-Ala-NTXOL were 
unsuccessful.  Thus, the 6-O-NTXOL amino acid esters were so difficult to 
synthesize that they were disqualified from further development.  Indeed, scale-
up problems are well known in the pharmaceutical industry, and they are often 
the reason for the termination of many promising clinical candidates. 
In order to treat the second target population of individuals who abuse alcohol 
and smoke cigarettes simultaneously, a dual therapeutic strategy was indicated.  
This is true because consumption of either alcohol or tobacco alone serves as a 
cue for abuse of the other (comorbidity).  In the case of patients belonging to this 
population, we envisioned that an oral codrug of NTX conjugated to (-)-cytisine (a 
smoking cessation agent used in Europe) could be a plausible therapeutic agent 
to approach the treatment of both addictions with a single drug molecule (i.e. a 
codrug).   
In order to justify a codrug design, it should not be feasible to simply prepare a 
dosage form that contains a physical mixture of the two constituent drugs.  Our 
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decision to prepare the CYT-NTX codrug as an oral drug delivery candidate was 
based on three critical design features.  First, CYT and NTX are both known to 
exhibit poor oral bioavailability.  Second, the pharmacokinetics of CYT and NTX 
are not amenable to dosing the two drugs as a physical mixture.  Third, the 
therapeutic windows of CYT and NTX overlap.  For instance, NTX dosed at 50-
100 mg/day with a 5-40% bioavailability corresponds to 7-118 µmol/day while 
CYT dosed at 9 mg/day with 32.18% bioavailability corresponds to a 14.8 
µmol/day dose.  Therefore, we decided to pursue the CYT-NTX codrug design. 
 The CYT-NTX codrug was afforded in good yield using a novel and facile one-
pot microwave chemistry procedure.  The carbamate linker was found to be 
stable over the time course of 24 h in buffer systems held at pH 1.5, 5.0, 7.4 and 
9.0, and in 80% rat plasma, 80% human plasma, simulated gastric fluid and 
simulated intestinal fluid.  Such stability studies are conducted in the 
pharmaceutical industry to assay drug candidates for stability in the 
gastrointestinal tract.  Thus, our in vitro stability work provided evidence that 
CYT-NTX would be expected to survive the rigors of oral dosing in a living 
animal.   
In order to determine in vivo performance of CYT-NTX, we chose the adult male 
Sprague-Dawley rat as an animal model.  Six (3 rats/group) S-D rats were dosed 
i.v. with 1.0 mg/kg CYT-NTX codrug, or 10.0 mg/kg, p.o.  Plasma CYT-NTX 
codrug, NTX and CYT concentrations were quantitated with a sensitive LC-
MS/MS method.  The plasma PK parameters of CYT-NTX and NTX were 
calculated using a two-compartment open model. The oral route of administration 
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resulted in greater plasma levels of NTX than those observed following 
intravenous administration. Comparatively, the fraction of intravenously 
administered codrug that was converted to NTX was 11%, while the fraction of 
orally administered codrug converted to NTX was 13%.  Furthermore, the oral 
delivery profile showed higher mean plasma levels of NTX compared to codrug 
at all time points after tmax(codrug), while i.v. administration resulted in higher 
plasma levels of codrug compared to NTX at all time points up to the 7 hour end 
point of the study.  Oral administration of the CYT-NTX codrug also resulted in 
rapid absorption and distribution (5 min) of the codrug, and NTX was released 
from codrug with a peak plasma concentration of 6.8 ± 0.9 nM reached at 
1.08±0.36 hours.  Unfortunately, plasma CYT was not detected at any time point 
for reasons that remain unclear.  We suspect that elimination or metabolism 
events may have prevented our detection and quantitation of CYT, or the drug 
may have evaded detection under our assay conditions.  The latter point is highly 
unlikely, because a one-to-one molar release of CYT from the codrug at the 
plasma concentrations we detected in our PK study would be well within the 
robust detection range of CYT based on our standard curves.  This is especially 
true in the early time points of the Cp-t curve that represents iv administration of 
the codrug (Figure 7.2). Otherwise, CYT plasma levels may have dropped below 
the limit of quantitation of our LC-MS/MS assay due to substantial loss of CYT by 
biotransformation and/or sequestration into an unknown tissue compartment, or it 
is also possible that the ester side of the carbamate linker of CYT-NTX cleaves 
readily in vivo to release NTX while the amide side remains intact as a carbamic 
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acid intermediate following release of NTX.  As mentioned previously, CYT has a 
short half-life in vivo, and CYT derivatives have also been designed, because 
CYT is known to have poor bioavailability (Canu Boido and Sparatore 1999, 
Tasso, Canu Boido et al. 2009).  Whatever the case, it appears that CYT-NTX is 
stable under the conditions that are necessary for oral delivery, and the codrug 
absorbs and distributes rapidly.  Once in the biophase, it appears that the 
hydrolysis is more efficient by the oral route, which suggests that hepatic 
metabolism is involved.  Indeed, in vitro experiments revealed that the codrug is 
stable in rat plasma over a time course of 24 hours.  Overall, CYT-NTX may 
show promise for further development.  However, determination of the fate of 
CYT in vivo would be necessary to make any claim that the codrug can function 
as a promising clinical candidate for the treatment of comorbid alcohol and 
tobacco abuse, and it is quite likely that CYT-NTX needs further structural 
optimization to achieve therapeutic delivery of both CYT and NTX in an animal 
model or a human patient.    
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